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Abstract 
Alterations to metabolic pathways, in particular post-translational modification, are a 
recognised hallmark of diseases such as autoimmunity, inflammation and cancer, and 
potentially provide a source of altered self antigens that can stimulate immune responses. 
Most notably, phosphorylated peptides have emerged as a group of tumour associated 
antigens which can be presented by MHC molecules and recognised by T-cells, and therefore 
represent promising candidates for future cancer immunotherapy strategies. However, how 
antigen phosphorylation impacts upon antigen presentation and recognition remains 
unclear. During this study I demonstrated that the phosphate moiety of phosphopeptides 
bearing the canonical P4 phosphorylation is more structurally diverse in its binding mode 
than previously thought. Strikingly, two epitopes exhibited a major conformational change 
upon addition of the phosphate moiety, effectively creating “conformational neoantigens”. 
This occurred through a similar mechanism for each epitope, whereby the presence of the 
phosphate moiety raised the position of the P4 Serine, allowing phosphate-mediated 
contacts with MHC residues and distorting the conformation of the central epitope region 
most critical for T- cell receptor recognition. Finally, I found that recognition of 
phosphopeptides can be both phosphate-dependent and epitope-specific at the level of the 
T-cell receptor. Therefore, this study shows that phosphorylation can have a profound and 
diverse effect on antigen binding, epitope identity and T-cell receptor recognition.  In 
summary, my studies suggest that phosphopeptides are not only tumour associated but also 
highly antigenically distinct, establishing them as attractive candidates for cancer 
immunotherapy strategies. 
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1 Introduction 
1.1 Cancer and the immune system 
1.1.1 Tumour biology 
Although death rates for some cancers have fallen in recent years, cancer remains a leading 
cause of death worldwide and is projected to increase by 45% between 2007-2030 (WHO, 
2010). 
Tumour development in humans is thought to involve a multistep process of genetic 
alterations originating from defects in DNA repair mechanisms (Kinzler and Vogelstein 1996; 
Jiricny and Marra 2003; Peltomaki 2003), thus helping to drive the progression of normal 
cells into highly malignant cancers. These multiple genetic changes range from single 
nucleotide point deletions to chromosome complement disruption (Kinzler and Vogelstein 
1996) and can be due to hereditary defects or induced through chemical carcinogens, UV 
exposure or other external factors. Due to the decreased functionality of DNA repair 
mechanisms these cells often exhibit an increased mutation rate in pathways which are 
thought to be crucial to cancer formation, survival and metastasis. Hanahan & Weinberg 
(Hanahan and Weinberg 2000) describe in their seminal paper six pathways cancers exploit 
in order to survive; self sufficiency in growth signals, insensitivity to anti-growth signals, 
tissue invasion and metastasis, sustained angiogenesis, limitless replicative potential and 
evasion of apoptotic signals. Since the publication of this article in 2000, other attributes 
have been added to the list (Figure 1.1) (Hanahan and Weinberg 2011), most notably, the 
ability of tumour cells to evade host immune responses (Dunn, Old et al. 2004). 
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Figure 1.1 Hallmarks of cancer 
 
In order for tumours to grow and survive, tumour cells must first exploit several of these 
pathways. Figure adapted from (Hanahan and Weinberg 2011)  
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1.1.2 Evidence for tumour suppression by the immune system 
It was first hypothesised by Ehrlich in 1909 that the immune system plays a role in 
recognising and eliminating tumour formation (Ehrlich 1909). However it was not until the 
1950’s that Burnet and Thomas proposed the theory of immunosurveillance in which the 
small, continual accumulation of nascent tumour cells possessing detrimental genetic 
alterations are recognised and destroyed by the host immune system (Burnet 1957; Thomas 
1959). However, for the tumour to grow to an observable clinical grade the tumour must 
evade the host cancer immunosurveillance mechanisms through a process termed cancer 
immunoediting (Figure 1.2) (Dunn, Bruce et al. 2002; Dunn, Old et al. 2004). Dunn et al 
proposed that during immunoediting the cancer cell population undergoes Darwinian 
evolution in order to survive. The first stage of immunoediting consists of the “elimination” 
phase mentioned above, in which immunosurveillance mechanisms destroy the majority of 
arising pre-cancerous cells. This however applies selective pressures upon the arising tumour 
cells and the second stage, “equilibrium”, is reached where the selective pressures of the 
immune response have preferentially selected arising tumour cells with decreased 
immunogenicity and enhanced survival factors. These surviving cells, with increased genetic 
instability and survival advantages lead to the final stage of “tumour escape”. 
Numerous studies in both mouse and human models provide evidence for 
immunosurveillance mechanisms acting to control tumour cell growth. Although early 
mouse models failed to prove the existence of tumour immunosurveillance (Gorer and Kaliss 
1959; Stutman 1974), which lead to the immunosurveillance hypothesis falling out of favour, 
it was not until the development of knockout mouse models that the theory of 
immunosurveillance could be formally proved.  
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Figure 1.2 Cancer Immunoediting 
 
Cancer Immunoediting is thought to involve three phases. Firstly, nascent tumour cells (red 
rectangular cells) arising from normal cells (large grey rectangles) are recognised and 
eliminated by cells of the innate and adaptive immune response (circles). This is followed by 
a period of equilibrium in which some tumour cells, through genetic instability, become 
resistant to immune recognition and elimination (orange, blue and pink rectangles). This is 
followed by the third phase of tumour escape in which the cells able to persist during the 
equilibrium phase outgrow to form a tumour mass capable of suppressing the immune 
response directly and through recruitment of suppressor cells such as CD4+CD25+ regulatory 
T-cells. This figure was modified from (Strausberg 2005).  
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In particular the Interferon-γ receptor (IFN-γR) knockout mouse was found to be 10-20 times 
more susceptible to tumour induction by chemical carcinogenesis (Kaplan, Shankaran et al. 
1998). Also, over-expression of a dominant-negative mutant IFN-γR α subunit in sarcomas 
completely ablated tumour sensitivity to IFN-γ and following transplantation into naive 
syngeneic hosts displayed increased tumourigenisis and reduced immunogenicity (Dighe, 
Richards et al. 1994). These results demonstrate that IFN-γ, a key product of many immune 
responses, is a critical component of tumour control by the host. Further studies using other 
mouse models, such as perforin knockout and RAG-2 knockout mice (van den Broek, Kägi et 
al. 1996; Shankaran, Ikeda et al. 2001), provided additional evidence to support the 
immunosurveillance theory. The most striking of these showed that chemically induced 
tumours generated in RAG-2 immune-deficient mice are strongly immunogenic and were 
able to be killed upon transplantation to a WT immune-competent host. However, tumours 
generated in the same manner in WT immune-competent hosts are weakly immunogenic 
and were not able to be controlled upon transplantation (Shankaran, Ikeda et al. 2001). This 
provided direct evidence for immunoediting, where highly immunogenic tumour cells arising 
in the immune-competent host are eliminated by the immune response early in the 
tumourigenisis process, thus leaving a subset of weakly immunogenic tumour cells to persist. 
The evidence for immune control of tumour growth in human models comes firstly from 
studies in immunocompromised hosts; including organ transplant patients who are receiving 
immunosuppressive drugs and human immunodeficiency virus (HIV) positive patients. 
Following solid organ transplantation, patients have a 4-fold increased risk of developing 
cancer (Adami, Gabel et al. 2003). Although many of these tumours are virally associated 
and may arise due to the lack of anti-viral immune responses rather than anti-tumour 
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responses, increased relative risk ratios have been observed for a range of tumours with no 
apparent link to viral infection (Sheil 1986; Penn 1996). Secondly there is a large body of 
evidence which demonstrates that in immunocompetent patients the presence of tumour 
infiltrating lymphocytes (TILs) can correlate with increased survival in many tumour settings 
(Clemente, Mihm et al. 1996; Ropponen, Eskelinen et al. 1997; Schumacher, Haensch et al. 
2001; Zhang, Conejo-Garcia et al. 2003; Galon, Costes et al. 2006). Although these data 
clearly show that the immune system can act to curtail tumour growth, there is also 
evidence in some tumour settings which shows the presence of TIL infiltration can result in 
poor prognosis (Kataki, Scheid et al. 2002). Potentially this highlights another aspect of the 
tumour immune-editing hypothesis, in that cancer cell survival may in some cases involve 
not simply overcoming but even utilising the immune response and this will be discussed in 
greater detail in section 1.4.2. 
1.2 Vertebrate Immunity 
The vertebrate immune system consists of complex cellular networks that have evolved to 
defend the host against a wide array of pathogens and has been implicated in host 
protection from tumourogenesis (Dunn, Bruce et al. 2002; Kim, Emi et al. 2007; Swann and 
Smyth 2007). These processes are commonly separated into two categories; the innate 
immune response and the adaptive immune response. The innate response to an antigen 
occurs early and does not involve processing of antigen. Cells of the innate immune system 
express pattern recognition receptors (PRRs), which allow them to recognise pathogen-
encoded and damage associated molecules (pathogen-associated molecular patterns, 
PAMPs and damage-associated molecular paterns, DAMPs) directly (Bianchi 2007; Sancho, 
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Joffre et al. 2009). The innate response therefore does not require prior contact with the 
pathogen and subsequent encounters with the same antigen do not lead to increased 
activation of the innate response. In contrast, the adaptive response requires processing and 
presentation of antigen by antigen presenting cells (APC), which initiate the clonal expansion 
of antigen specific lymphocytes in response to pathogen challenge. As a consequence, the 
adaptive immune response is slower to initiate than the innate response, but allows the 
generation of “immunological memory” through survival of clonally expanded antigen 
specific lymphocyte populations (Gowans and Uhr 1966; Zinkernagel, Bachmann et al. 1996; 
Zinkernagel 2002). Together the innate and adaptive immune responses allow the immune 
system to respond quickly to an antigen but also establish long-lasting pathogen specific 
memory. 
Unlike cells of the innate immune system, which carry multiple germline encoded receptors 
that can recognise a wide array of pathogen determinants, the lymphocytes of the adaptive 
immune system, B-cells and T-cell, bare only a single specificity of antigen receptor, namely 
the B-cell receptor (BCR) and the T-cell receptor respectively, whose structure belongs to the 
immunoglobulin super family. The specificity of lymphocyte antigen receptors is diverse and 
is reliant upon a unique ability of lymphocyte cells to rearrange the genes encoding its 
antigen receptor. The antigen receptor consists of multiple inherited gene segments which 
are able to undergo somatic gene rearrangement to produce a distinct combination of 
segments for each antigen receptor (Nemazee 2006). The diversity in the receptor repertoire 
is further enhanced due to events that introduce variations during the rearrangement of 
each segment such as N-nucleotide addition (Cabaniols, Fazilleau et al. 2001) and in B-cells 
somatic hypermutation (Teng and Papavasiliou 2007). This diversity is most apparent in the 
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complimentary determinant regions 1-3 (CDR1-3) (Wu and Kabat 1970) produced during VDJ 
and VJ recombination. However this quasi-random generation of lymphocyte antigen 
receptors, which collectively express a wide array of antigen specificities, could inevitably 
lead to the generation of an auto-reactive lymphocyte population. This problem is addressed 
to a large extent during lymphocyte development, where clones which are potentially self-
reactive are eliminated from the repertoire by clonal deletion (Blackman, Kappler et al. 
1990; Rajewsky 1996), thus allowing the expansion of self-tolerant lymphocyte populations 
(Figure 1.3). Therefore the diversity of lymphocyte receptors generated is extensive, 
although only a small proportion of naïve lymphocytes finally progress past the selection 
process and develop into matured lymphocytes.  
B-cells and the antibodies they produce are able to recognise and bind to free antigen 
whereas in contrast, T-cells are known to recognise antigen in the context of MHC molecules 
(Zinkernagel and Doherty 1974; Zinkernagel and Doherty 1974) and therefore require 
antigen processing. The selection process that determines further T-cell development 
involves a fine balance between the initial positive selection of T-cells which recognise 
presented self-molecules, followed by negative selection of those that recognise self with a 
high affinity (Strasser, Puthalakath et al. 2007). Thus each receptor surviving into the mature 
repertoire is functional but at the same time potentially auto-reactive T-cell populations are 
eliminated.  The survival of lymphocytes is thought to be mediated by signalling through the 
antigen receptor and co-receptors (Blackman, Kappler et al. 1990; Cantrell 2002; Pobezinsky, 
Angelov et al. 2012), and that these signals are provided by other cells in the lymphoid 
organs (Anderson and Takahama 2012). Lymphocytes that fail to receive signals undergo a 
form of programmed cell death called apoptosis. 
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Figure 1.3 Clonal Selection Theory 
 
A multitude of lymphocytes with different antigen specificities arise from a single precursor. 
Self-reactive lymphocytes are deleted in the thymus during negative selection leaving a pool 
of mature naïve lymphocytes. Upon antigen recognition and in the presence of secondary 
signalling on activated antigen presenting cells, the antigen specific lymphocytes proliferate 
and differentiate to form a clonal pool of effector and memory cells. Figure taken from 
Immunobiology (Janeway, Travers et al. 2005). 
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Alternatively, those that do receive appropriate signals are then able to mature into naïve 
lymphocytes. In the case of T-cells, the proliferation of an antigen specific populations of 
naive lymphocytes relies upon interaction with presented molecules, co-stimulation and 
cytokine stimulation which is facilitated by APC present in the draining lymphoid tissue 
(Curtsinger, Johnson et al. 2003). Following antigen removal most of the activated antigen 
specific cells undergo apoptosis. However, a small proportion remains after antigen removal 
and there is strong evidence to suggest these form the basis of immunological memory (Gray 
2002; Zinkernagel 2002; Fazilleau, McHeyzer-Williams et al. 2007).    
The generation of effective immunity to pathogens requires coordination between the 
innate and adaptive immune responses. One major link between the two responses is 
provided by a group of cells that are collectively termed ‘professional antigen presenting 
cells’ (APC). An important class of APC is the dendritic cell (Liu 2001). Dendritic cells (DC) are 
thought to exist in peripheral tissues in what is termed an immature state, where they 
continuously “sample” the surrounding environment by endocytosis and pinocytosis 
(Guermonprez, Valladeau et al. 2002; Lutz and Schuler 2002). In this immature state they 
show low expression of MHC molecules at their surface and lack co-stimulatory molecule 
expression, but have an increased ability to phagocytose pathogens (Banchereau and 
Steinman 1998; Lutz and Schuler 2002). Immature DC also express high levels of the Toll-like 
receptor family and other PRRs on their surface, which have evolved to detect PAMPs 
present on a wide array of pathogens (Akira and Hemmi 2003) and DAMPs associated with 
cellular stress and necrosis (Bianchi 2007; Sancho, Joffre et al. 2009). During infection, DCs 
become activated and migrate into the lymphatics and eventually to the local lymph tissue. 
During this process the DC receives maturation signals that enable the up-regulation of MHC 
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class I and II molecules, allowing presentation of phagocytosed antigen (Lutz and Schuler 
2002). In addition, they also show up-regulation of co-stimulatory molecules such as CD86, 
CD40, and adhesion molecules and chemokines, which collectively explain their potent 
ability to stimulate naïve T-cell responses (Banchereau and Steinman 1998; Lutz and Schuler 
2002).   
Once in the draining lymph node, DC are highly efficient at presenting antigen to naïve T-
cells circulating through the lymphatic system, namely CD4+ T-cells via MHC class II 
complexes and/or CD8+ T-cells via MHC class I complexes.  Successful priming of a response 
involves binding of the TCR to cognate antigen displayed by MHC molecules on the DC 
surface, along with co-stimulatory signals from DC to T-cell (Curtsinger, Johnson et al. 2003).  
Chief amongst these are the costimulatory B7 family molecules expressed on the DC surface, 
which are recognised by CD28 on the T cell surface (Carreno and Collins 2002). 
Subsequently, increases in adhesion molecule expression, cytokine production, and up 
regulation of CD40 ligand, which binds to CD40 on APC and transmits activating signals to 
the T-cell, help sustain T-cell signalling and drive clonal expansion and differentiation 
(Guermonprez, Valladeau et al. 2002).   
CD4+ T-cells play key immune-regulatory roles and can profoundly influence any subsequent 
responses to a given pathogen. Their differentiation is relatively complex but subsets of 
functionally distinct CD4+ T-cells can be separated on the basis of the cytokines they 
produce into Th1, Th2 or the more recently recognized regulatory-T-cell (Treg) and Th17 cell 
lineages. The Th1 lineage produces IL-2 and IFN-γ, and favours the cell-mediated immune 
response by activating macrophages and stimulating the CD8+ T cell response, thus enabling 
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elimination of intracellular pathogens (Szabo, Sullivan et al. 2003). In contrast, Th2 CD4+ T-
cells produce IL-4, IL-13 and IL-10, and are involved in co-ordination of the B-cell humoral 
response (Paul and Zhu 2010). Since Th1 cytokines can inhibit Th2 differentiation and vice-
versa, CD4+ T cell responses have the potential to become polarised (Neurath, Finotto et al. 
2002; Romagnani 2004). The factors affecting Th1/Th2 polarisation are not entirely clear, but 
include the nature of the cytokines induced by a pathogen, the costimulatory signals from 
APC and the nature of the peptide-MHC ligand (Akira, Takeda et al. 2001). Since Th1/Th2 
bias is thought to be evident relatively early in the immune response (Rothenberg, Moore et 
al. 2008), production of particular cytokines by cells of the innate immune system is thought 
to be relevant (Romagnani 2004). A more recent identification of a novel subset of IL-17 
producing CD4+ T-cells has been defined as Th17 cells (Stockinger and Veldhoen 2007). The 
Th17 subset has been shown to directly mediate inflammation and play an important role in 
many autoimmune diseases (Furuzawa-Carballeda, Vargas-Rojas et al. 2007). 
Understanding how adaptive immune responses are generated is of key importance in 
establishing how durable immunity to specific antigens is elicited, and how these processes 
might be harnessed therapeutically. In particular, stimulation of class I MHC-restricted T cell 
responses forms the basis of many vaccination and cancer immunotherapy strategies, and 
understanding the key interactions that determine the ability of a given antigen to be 
processed and presented to CD8+ T-cells is likely to have a major impact on the design of 
such therapies. 
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1.3 Antigen Presentation 
1.3.1 Proteasomal degradation of cytosolic antigens 
MHC class I molecules bind short peptide fragments, that are from pathogen-derived or self-
molecules, enabling stable expression on the cell surface and presentation of such antigen to 
CD8+ T-cells (Bjorkman, Saper et al. 1987). Class I molecule presentation can occur via two 
routes; processing of intra cellular antigens (Townsend and Bodmer 1989), either self or 
pathogen derived, or secondly, through cross presentation of exogenous antigens. For the 
moment I will focus on the endogenous antigen processing pathway and will focus on cross 
presentation in section 1.3.6. For intracellular antigens to be presented they must first be 
processed into small fragments, since class I molecules typically bind peptide fragments of 8-
10 amino acids in length. This consists of two processes; ATP- dependent ubiqutination and 
unfolding, and ATP-independent degradation of the polypeptide chain. 
The proteasome, an abundantly expressed ATP-dependent protease present in the cytosol 
and nucleus, plays a major role in degrading intracellular proteins (Peters, Franke et al. 
1994), including those destined for presentation by class I MHC molecules. Each proteasome 
consists of a 20S core proteosome formed from multiple α and β protein subunits that stack 
in four heptameric rings to form a hollow cylinder (Figure 1.4). At each end of the 20S 
cylinder, the PA700 (19S) complex acts as a cap, and contains subunits that have ATPase 
activity and help to unfold the proteins to be digested, as well as those involved in 
recognition of proteins targeted for destruction (Peters, Franke et al. 1994). The 19S caps 
therefore act as regulated “gates” controlling entrance of the polypeptide chain to the 
proteolytic core of the proteosome.  
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Figure 1.4 The proteasome 
 
 
The proteasome consists of a central 20S subunit comprised of α and β proteins stacked in a 
heptameric ring structure. The entry of protein chains into the 20S core is regulated by 19S 
which forms a cap structure at either end of the S20 proteasome. Figure taken from (Adams 
2004). 
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Once the polypeptide chain is within the proteolytic core of 20S, the chain is degraded by 
different endopeptidases, aminopeptidases and carboxypeptidases in an ATP-independent 
fashion. The 3-15 amino acid peptide chains then diffuse out of the proteosome into the 
cytosol. Unlike conventional proteases, the function of this mechanism allows the protein 
substrate to remain bound until all of it is converted into short fragments. 
The proteasome can exist in two forms, the ‘constitutive’ proteasome is expressed in all 
mammalian cells, and the ‘immunoproteosome’, which contains three distinct IFN-γ-
inducible subunits, LMP2, LMP7 and PA28, and is mainly expressed during infection in cells 
stimulated with inflammatory cytokines such as IFN-γ (Griffin, Nandi et al. 1998). 
Replacement of constitutive subunits with LMP2 and LMP7 alters the activity of the 
proteasome, such that increased cleavage is observed after hydrophobic residues, favouring 
production of peptides suitable for both TAP transport and MHC binding (Rivett and Hearn 
2004). In addition, incorporation of the PA28 ring structure at either end of the 20S 
proteasome is thought to increase efflux of peptides from the proteasome, potentially 
allowing antigenic peptides that might otherwise be cleaved to escape further processing 
(Wang and Maldonado 2006). Due to this it has also been found that the 
immunoproteosome is highly important for generating a variety of immune responses (Van 
den Eynde and Morel 2001; Strehl, Seifert et al. 2005).   
In most cases, the proteins that proteasomes act on are targeted for destruction by covalent 
attachment of the small protein ubiquitin (Hershko and Ciechanover 1998). Ubiquitin can 
exist free in the cell or covalently linked to a large number of intracellular proteins, the 
majority of which are ultimately destined for proteasomal destruction. Ubiquitin is prepared 
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for conjugation by the ATP-dependent ubiquitin-activating enzyme E1, which activates the 
ubiquitin and transfers it to one of a number of E2 ubiquitin-conjugating enzymes. The E2 
enzymes act in conjunction with E3 accessory proteins to form E2-E3 ubiquitin ligases, 
whereby the E3 moiety recognises specific degradation signals in protein substrates, and the 
E2 protein ultimately attaches a polyubiquitin chain to specific Lysine residues in the target 
protein (Hershko and Ciechanover 1998). This polyubiquitin attachment is then recognised 
by subunits of the PA700 proteasome complex which targets the protein for proteolytic 
degradation (Pickart 1997). The complexity of the ubiquitin system is emphasised by the 
existence of multiple (>30) distinct E2 enzymes and hundreds of different E3 proteins that 
complex with specific E2 enzymes. The system therefore consists of multiple distinct 
proteolytic pathways, which share the E1 enzyme and the proteasome but differ in the 
composition of their ubiquitin ligases, allowing recognition of different degradation signals 
(Pickart 1997; Pickart 2001) and consequently targeting of distinct subsets of intracellular 
proteins for destruction.  
The nature of the degradation signals that influence which proteins are targeted for 
proteasomal destruction and how these are regulated is highly relevant when considering 
which proteins serve as substrates for the class I MHC processing pathway. Newly 
synthesised proteins can be substrates for class I MHC peptide production due to the 
production of defective ribosomal products (DRiPs) which can contain large patches of 
abnormally exposed hydrophobic residues that act as signals for destruction of the protein 
(Yewdell, Antón et al. 1996; Minami, Hayakawa et al. 2010). These can usually be rectified by 
chaperone proteins that aid in the correct refolding of the protein, however, if these are 
unable to repair the misfolded protein then the protein is ultimately eliminated, avoiding 
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formation of protein aggregates. Regulated destruction of protein can also occur through 
targeted phosphorylation events at specific sites on a protein which unmask a normally 
hidden degradation signal (Hao, Oehlmann et al. 2007). The main mechanism by which cells 
recognise these abnormal degradation signals are through the multiple E3 molecules that 
facilitate protein entry into the ubiquitin mediated-proteasomal degradation pathway. Once 
the poly-peptide has been cleaved the peptide fragment is able to be transported into the 
endoplasmic reticulum (ER) by the transporter associated with antigen processing (TAP). 
1.3.2 TAP transport 
Class I MHC molecules typically present peptides derived from cytosolic proteins. However, 
the peptide-binding domains of nascent class I MHC proteins are never exposed to the 
cytosol, and instead face the lumen of the ER. Therefore, in order for peptide antigens to 
enter the ER and be loaded onto class I MHC molecules, they must first be transported 
across the ER membrane. This is facilitated by TAP, which carries out ATP-dependent peptide 
transport (Abele and Tampe 2004). TAP is a member of the ABC transporter family of 
proteins and is a heterodimer formed from two MHC-encoded proteins, TAP-1 and TAP-2 
(Reits, Griekspoor et al. 2000). The heterodimer consists of 3 structural domains; the pore 
domain, the peptide binding domain and finally the ATP-binding domain. The pore domain is 
~50Å in diameter and therefore restricts the length of peptides able to enter and be 
transported across the ER membrane (8-16 amino acids). Binding of peptide to the peptide 
binding domain is somewhat sequence-dependent, favouring hydrophobic residues at the 
COOH terminal end of the peptide antigen (van Endert, Riganelli et al. 1995). These features 
favour transport of peptides suitable for binding to class I MHC molecules. Binding of 
peptide to TAP results in a conformational change in the TAP molecule and may act as the 
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switch for ATP hydrolysis.  ATP is bound to TAP at the third domain; the Nucleotide Binding 
Domain. The exact mechanism of peptide transport across TAP and the ER membrane is still 
not fully understood; however a mechanism has been proposed but not yet proven 
experimentally (Figure 1.5) (Abele and Tampe 2004; Procko, O'Mara et al. 2009). 
1.3.3 Antigen processing in the endoplasmic reticulum 
Assembly of class I MHC molecules in the endoplasmic reticulum (ER) depends on 
association of the class I MHC heavy chain with β2-microglobulin and peptide (Purcell and 
Elliott 2008; Lee, Park et al. 2009). This in turn is dependent on the further proteolytic 
processing of the ER peptide pool, and on a series of chaperone-mediated events on the 
lumenal face of the ER membrane that, assuming appropriate peptides are present, 
ultimately result in stable assembly of the class I MHC molecule (Elliott and Williams 2005). 
Stable association with peptide results in release of class I MHC to the cell surface, whereas 
unstable association with class I MHC proteins, results in retention in the ER. 
Subsequent to transport of proteasomally generated peptides to the ER via TAP, various 
aminopeptidases associated with the ER are involved in additional cleavage and trimming of 
the peptide antigens present. A key aminopeptidase implicated in the final proteolytic 
processing of peptides presented on MHC class I molecules is the ER-associated 
aminopeptidase 1 (ERAP1) (Chang, Momburg et al. 2005). ERAP1 has been found to trim N-
extended precursor peptides but spares peptides ~ 9 amino acids, the length that optimally 
binds to MHC class I.  In this sense, ERAP1 acts as a ‘molecular ruler’, binding to peptide 
substrates of 9-16 amino acids in length and accurately trimming them to a length of 9 
amino acids but no less (Chang, Momburg et al. 2005).  
 
 
Figure 1.5 TAP transport of peptides 
 
TAP consists of two transmembrane domains (TMD) and two nucleotide binding domains (NBD). TAP resides in a peptide receptive 
conformation bound to two molecules of ATP. Upon peptide binding the structure of TAP alters to allow the peptide into the ER. During 
the alteration of TAP’s conformation the ATP molecules are hydrolysed to ADP which subsequently is lost from the TAP molecule. This 
causes the TAP molecule to take up new ATP molecules and revert to the peptide receptive conformation and thus starting the cycle 
again. Figure taken from (Abele and Tampe 2004). 
1
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In addition, the ERAP1 molecule possesses substrate specificity in that peptides with 
hydrophobic C-termini are able to bind to ERAP1 whereas peptides with charged C-termini 
do not bind, therefore favouring the appropriate trimming of peptides with C-terminal 
residues suitable for binding class I MHC molecules (Kochan, Krojer et al. 2011). 
Aminopeptidases such as ERAP-1 therefore have profound effects on the repertoire of 
peptides generated for class I MHC loading.   
Newly expressed class I MHC heavy chains initially associate with the ER chaperone calnexin, 
which catalyses association with β2-microglobulin. Subsequently, the heavy chain:β2-
microglobulin complexes associate with a number of other proteins that are involved class I 
MHC stabilisation and loading, and are collectively termed the peptide loading complex 
(PLC), which contains the proteins tapasin, ERp57 and calreticulin (Elliott and Williams 2005). 
The function of this complex is to maintain the class I MHC molecule in a peptide-receptive 
conformation and retain it in close proximity to peptides transported into the ER lumen by 
TAP. A key member of the complex is Tapasin, which is required for class I antigen 
presentation and aids the stability of class I molecules. To date, three functions of Tapasin 
have been discovered, emphasising its vital role in the folding of class I MHC molecules. 
Firstly, the tapasin molecule stabilises the TAP heterodimer and so promotes peptide 
transport into the ER. Secondly, it links the TAP molecules to the MHC molecules and so is 
structurally integral to the PLC. Thirdly, it plays a role in the loading of peptide antigens onto 
the MHC (Sadasivan, Lehner et al. 1996; Elliott and Williams 2005). ERp57 is a thiol-
oxidoreductase involved in ensuring correct folding of newly formed MHC heavy chain along 
with calreticulin. The ERp57 protein is also thought to be involved in facilitating 
conformational flexibility of the class I binding cleft to assist in peptide binding (Purcell and 
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Elliott 2008). However, cells defective in either tapasin or calreticulin show defects in class I 
MHC assembly and express class I MHC molecules at the surface that contain suboptimal low 
affinity peptides. Consequently, the PLC complex is thought to facilitate a key peptide-
editing function, allowing the exchange of low affinity peptides bound to the class I MHC 
molecule for those of higher affinity. 
1.3.4 Class I MHC structure 
Class I MHC molecules consist of a type I transmembrane heavy chain comprising a α1-α2 
peptide-binding platform and a membrane-proximal α3 domain, which associates non-
covalently with the β2-microglobulin light chain and bound peptide (Bjorkman, Saper et al. 
1987; Madden 1995). The α3 and β2-microglobulin domains, located proximal to the cell 
membrane, share (relative amino-acid sequence and intra-chain disulphide bridge) 
homology to immunoglobulin constant regions (Peterson, Cunningham et al. 1972; 
Bjorkman, Saper et al. 1987).  The highly polymorphic α1 and α2 domains, located distal to 
the cell membrane, associate together as an “intra-chain dimer” to form a distinctive 
peptide-binding platform oriented away from the presenting cell at the membrane-distal 
end of the molecule, and supported by the membrane-proximal α3 and β2-microglobulin 
domains.   
Within the α1-α2 platform, the peptide binding site is located in a groove situated between 
two α-helices positioned on top of an eight-stranded antiparallel β sheet. The antigen 
binding site of HLA-A2 is approx 25Å long and 10Å wide (Bjorkman, Saper et al. 1987), 
enclosed at either end by bulky amino acid side chains that are conserved in almost all class I 
MHC molecules. Early structures of class I MHC molecules noted electron density un-
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attributable to HLA-A2 heavy chain along this groove and it was hypothesised that this 
represented a mixture of bound peptides (Madden, Garboczi et al. 1993).  
Subsequent structures of class I MHC molecules in the presence of individual peptide species 
has clearly defined the molecular mechanisms governing class I MHC antigen presentation. 
The peptide occupies an extended conformation along the groove, with variations in length 
accommodated over the central region of the antigen. The enclosed nature of the groove 
explains why the length of peptides bound to MHC class I molecules generally falls into a 
limited range, from ~8-14 amino acids long. The interactions that bind the peptide within the 
groove of the HLA-A2 molecule occur in defined pocket regions termed A-F (Saper, Bjorkman 
et al. 1991) (Figure 1.6). Interactions to the amino and carboxyl termini involve conserved 
amino acid residues and involve Pocket A and Pocket F, respectively. Pockets B and F play 
critical roles in accommodating primary anchor residues. Pocket B is located adjacent to 
pocket A and protrudes under the α1 domain helix, reaching the backbone of the α1 domain 
β-sheet. The opening of pocket B is composed of entirely polar side chains, however the 
inner surface is completely hydrophobic, explaining the presence of Leu as the primary 
anchor at position 2. In addition, the hydrophobic Pocket F permits interaction with the 
hydrophobic C-terminal primary anchor residue, which is oriented downwards to the β-sheet 
floor of the groove (Saper, Bjorkman et al. 1991). 
These studies have defined the key structural requirements for peptide-MHC binding. 
Importantly, the structures emphasise that peptide is critical to the structural integrity of the 
complex (Madden 1995), forming interactions with the α1 and α2 helix and the β-sheet floor 
forming the base of the peptide-binding groove. 
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Figure 1.6 Pockets of the MHC-class I binding groove 
 
Interactions to the amino and carboxyl termini involve conserved amino acid residues and 
involve Pocket A and Pocket F, respectively. Pocket B is involved in P2 anchor residue binding 
as is the F pocket for PC anchor residues. Pockets D, C and E are not thought to play as 
prominent a role in peptide binding as pockets A, B and F. 
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In addition, the strikingly high number of polymorphic residues in class I MHC genes map to 
residues oriented into the groove, or protruding from the surface of the alpha helices 
(Bjorkman, Saper et al. 1987). Consequently, allelic differences between MHC molecules give 
rise to distinct peptide-binding and TCR-binding properties. 
1.3.5 MHC-peptide binding and complex stability 
Since class I MHC molecules are highly unstable in the absence of antigen, the affinity of 
peptides for the class I MHC molecule plays an important role in determining presentation 
and stability at the cell surface, and can profoundly affect immunogenicity (Micheletti, 
Bazzaro et al. 1999; Skokos, Shakhar et al. 2007). Below a certain threshold affinity, peptides 
are likely to be out-competed by others that possess a higher binding affinity for the MHC 
molecule in question, which will be presented at the cell surface at a greater level than their 
low affinity counterparts. Peptide binding affinity, typically in the nanomolar range for 
immunogenic peptides, relies upon several factors. The optimal length of peptides bound to 
class I MHC molecules is between 8-10 amino-acids in length, however larger peptides have 
been shown to bind (Parker, Bednarek et al. 1992).  For a peptide to bind to class I MHC, it 
must have a free N-terminal amino group and a free C-terminal carboxylic acid group, 
suggesting interactions with the N and C termini form important contacts to the MHC 
molecule. Analysis of peptides eluted from class I MHC molecules indicated thousands of 
peptides are able to bind each allele, and highlighted this promiscuous binding is dependent 
on the presence of key primary anchor residues (Engelhard 1994). For HLA-A2, primary 
anchor residues are located at positions 2 and 9, where Leucine and Valine are preferred 
respectively. The nature of the primary anchor residues has been shown to have a dramatic 
impact upon the affinity of a peptide for MHC (Parker, Bednarek et al. 1992; Madden, 
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Garboczi et al. 1993). Not surprisingly, anchor modification is commonly employed in 
peptide vaccine design to improve the efficacy of the particular peptide antigen in 
generating an immune response (Irvine, Parkhurst et al. 1999; Borbulevych, Baxter et al. 
2005). In addition, secondary anchor residues, which can be located at various points along 
the peptide chain, can also modify the affinity of a given peptide for MHC.  
1.3.6 Cross Presentation 
Cross-presentation is defined as the mechanisms by which exogenous antigens gain access 
to the MHC class I processing pathway for presentation to cytotoxic CD8+ T-cells.  
Professional APCs are the principle cells capable of cross-presenting extracellular antigen on 
MHC class I. During this process the APC acquires antigen from the surrounding environment 
through endocytic mechanisms, most notably phagocytosis and macropinocytosis. The 
internalised antigen can then be processed by at least two different mechanisms (Cresswell, 
Ackerman et al. 2005; Rock and Shen 2005). One method is by antigen escape from the 
phagosome, thereby entering the usual cytosol-proteasome degradation pathway for MHC 
class I antigens, however, at present the exact mechanisms of antigen escape are unclear. 
Secondly the phagosome can fuse with the endosome, thus allowing phagocytosed antigen 
to be degraded by endosomal proteases (particularly cathepsin S (Shen, Sigal et al. 2004)) 
and binding to MHC class I molecules within the endocytic compartment itself. Depending 
upon the nature of the antigen, one or both of these pathways can contribute to cross-
presentation in vivo (Rock and Shen 2005). The result of cross-presentation can also have a 
profound effect on the activation or tolerance of an immune response towards a particular 
antigen, depending upon other factors such as “danger signals” and the presence of co-
stimulatory molecules (Kurts, Kosaka et al. 1997). The concept of cross-presentation is 
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important when formulating potential vaccination strategies because the ability of an 
antigen to be cross-presented can determine the success of a vaccination in generating CD8+ 
T-cell responses. 
1.4 Immunotherapy  
1.4.1 Immunotherapy strategies 
Standard treatments for many malignancies involve surgical resection, chemotherapy and/or 
radiotherapy, however these are subject to numerous side effects, are frequently unable to 
provide a lasting protection against cancer and for some malignancies these methods prove 
ineffective. To solve this, many different immunotherapy stratergies have been devised 
exploiting different aspects of the immune system, all with varying degrees of success. So far 
Stem Cell Transplantation (SCT) has proved to have powerful anti-tumour effects through 
allo-reactive responses, as evidenced by the graft versus leukaemia effect (Riddell, Berger et 
al. 2003). Antibody therapy has also proved very successful in the clinic, with several 
antibody treatments available for the treatment of different malignancies (Scott 1998; Los, 
Roodhart et al. 2007). However, these treatments can often have drastic side effects (e.g. 
graft versus host disease) and in the case of antibody therapy are very expensive and do not 
form a lasting memory response, therefore relying on a prolonged treatment period. It is 
therefore desirable to further investigate the possibility of a cellular based treatment for 
malignancy by harnessing the patient’s own immune system. To date, adoptive transfer of 
MHC matched donor cells into patients treated with radiotherapy has been the most 
successful treatment for blood borne malignancies but has little effect upon solid 
malignancies (Dudley, Wunderlich et al. 2002; Dudley and Rosenberg 2003). Other methods 
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involving in vitro priming of autologous T-cells with various tumour antigens have had 
varying degrees of success depending upon the tumour antigen targeted, method of T-cell 
priming and method of T-cell administration to the patient. Studies by Rosenberg et al have 
shown promising results of ex vivo antigen primed T-cell reactivity against tumours when re-
administered back to the patients (Dudley, Wunderlich et al. 2002). In spite of this, the cell 
numbers used, man hours and the cost of this method would be unsuitable for most clinics 
around the world. TCR gene transfer of TCRs specific for tumour associated antigens is also 
the focus of much interest as the transfer of these TCRs into a recipients T-cells can result in 
circumventing the problems of central tolerance against tumour antigen (Stanislawski, Voss 
et al. 2001).    
As well as T-cell vaccines, DC vaccines are also of key interest (Figdor, de Vries et al. 2004; 
Melief and Van der Burg 2008) as a successful vaccine would be able to prime a host 
response in vivo, therefore reducing time and cost in generating antigen specific T-cells, and 
could potentially lead to a strong lasting memory response involving multiple arms of the 
immune system. There are many methods with which to prime tumour specific dendritic 
cell-induced responses used in the literature; such as DNA delivery using virus or gene gun 
approaches (Scheerlinck, Casey et al. 2001), tumour cell lysate (Gatza and Okada 2002), 
recombinant protein and exosome delivery (Siguo Hao 2007). Another important variable in 
DC vaccination is the maturation state of the dendritic cell and the method by which it is 
matured (Gilboa 2007). Finally, the site and method of administration can also play a key 
role in the induction of immune responses. For example the site of administration either 
intra lymphatic, intra dermal or intravenous, and the addition of cytokines all have a key role 
in the migration and type of immune response generated (Morse, Coleman et al. 1999; 
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Morel and Turner 2010). To date, Sipuleucel-T (Provenge) is the only cellular based 
treatment for solid malignancy which has FDA approval for use in the clinic. It is currently 
used for the treatment of patients with prostate cancer and has been shown to increase the 
median survival of patients with metastatic prostate cancer by 4.1 months (Kantoff, Higano 
et al. 2010). The personalised treatment consists of harvesting PBMC from a patient through 
leukapheresis, followed by incubation of the dendritic cells with a fusion peptide, consisting 
of the prostatic acid phosphatase (PAP) antigen and granulocyte-macrophage colony 
stimulating factor (GM-CSF). The activated dendritic cells are then infused back into the 
patient to facilitate an immune response against PAP expressing tumour cells. Finally, BCG 
vaccination for the treatment of bladder cancer has been shown to be clinically effective 
(Biot, Rentsch et al. 2012), however the precise immunological mechanisms of this effect are 
still largely unknown. 
1.4.2 Challenges facing immunotherapy 
Clearly due to the immunosuppressive environment and poor immunogenicity exhibited by 
many tumours (Foss 2002; Zou 2005) there remain many challenges facing future 
immunotherapy strategies.  
Although various immunotherapies have shown some benefit to patients enrolled on clinical 
trials (Dudley, Wunderlich et al. 2002; Kantoff, Higano et al. 2010), these responses have 
typically been modest and short lived, highlighting the fact there is still no cell based 
vaccination that provides complete regression in the majority of cases.  This is not only due 
to each individual’s tumour being slightly different to that of another, at various stages of 
tumour progression and altered antigen display, but also because the survival and 
progression of malignancy involves complex “evolutionary” processes which tailor the 
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microenvironment and immune response to evade destruction and aid in tumour formation 
and metastasis. For solid tumours to grow past a certain size of around 2mm3 the tumour 
must form blood vessels to supply oxygen and nutrient-rich blood to the tumour. This 
process involves many cytokines and growth factors such as vascular endothelial growth 
factor (VEGF) produced by the tumour (Gabrilovich, Chen et al. 1996). These molecules have 
been shown to have a potentially negative impact upon immune responses by down 
regulating the activation of dendritic cells, thus inhibiting the activation of antigen specific T-
cells (Gabrilovich, Chen et al. 1996). Loss of MHC molecules is also a common T-cell 
subversion mechanism of malignant cells (Bubeník 2004) as cells that do not possess MHC 
are unable to be targeted by T-cells. However, this would usually result in the targeted 
destruction of the cell by NK-cells, which rely upon a balance between activatory and 
inhibitory signals for their activation (Di Santo 2006). The tumour may exploit this by down-
regulation of activatory ligand such as MICA and MICB on the cell surface of the tumour and 
also through production of inhibitory cytokines (Khong and Restifo 2002). This therefore 
provides immunity to NK-cell attack due to MHC loss and protection against T-cell targeting.  
Subversion of the immune response can also occur through the tumour’s expression of so 
called “death receptors” such as FasL (Hahne, Rimoldi et al. 1996) and TRAIL (Radoja and 
Frey 2000) which upon binding counterpart receptors upon T-cells, activate programmed cell 
death pathways within the T-cells leading to T-cell elimination. 
Also the role of the tumour microenvironment and surrounding cell populations can also 
negatively impact upon immunotherapy strategies. Key cellular components of this 
immunosuppressive environment include T-reg (Beyer and Schultze 2006) and Monocyte 
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derived suppressor cells (MDSC) (Lesokhin, Hohl et al. 2012), both of which are able to 
suppress anti-tumour responses and also aid the growth of the tumour. 
Hence there are multiple challenges that need to be considered when designing any 
potential immunotherapy. However, one key aspect of immunotherapy approaches 
frequently relies upon the targeting of specific antigens expressed by the tumour. However 
these antigens are often self-antigens and so the majority of potential tumour reactive T-
cells are either deleted from the repertoire, have very low affinity or have become anergic 
due to peripheral tolerance mechanisms (Zheng, Gao et al. 2002; Mapara and Sykes 2004). 
One potential approach to a successful immunotherapy strategy therefore involves targeting 
tumour specific antigen by moderate/high affinity T-cells present within the repertoire. 
Potential tumour specific antigen targets for immunotherapy include; tumour associated 
viral antigens (Restifo, Dudley et al. 2012), cancer testis antigens (CTAgs), which are usually 
expressed only in immuneprivileged sites (such as the testes) but commonly overexpressed 
by certain tumours (Scanlan, Gure et al. 2002) and antigens which are altered during 
tumourogenesis, either through mutation or over-expression (Wang, Zhou et al. 2002). Most 
importantly these antigens must not be presented within the thymus, thus allowing reactive 
T-cells to evade central tolerance. However, given that some of the methods used to target 
these antigens, such as TCR gene transfer, can generate potent anti-tumour effects but can 
also elicit strong auto-immune effects if the TCR reactivity were not specific for tumour 
antigen (Bendle, Linnemann et al. 2010). A second consideration for the selection of optimal 
tumour associated antigens for immunotherapy strategies would be the functional 
importance of these antigens in maintaining the tumour phenotype and survival, which in 
the case of CTAgs is poorly understood. 
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1.5 Targeting post-translationally modified antigens as novel 
tumour antigens for immunotherapy 
1.5.1 Types of post-translational modification 
One potential approach to address the issues outlined above is to focus immunotherapeutic 
strategies on tumour associated antigens inherently linked to tumour phenotype in some 
way. Targeting metabolic changes that occur upon tumourigenisis would be one possible 
axis for such approaches. Clearly, signalling pathways are well recognised to be altered in 
cancer cells, with alterations in kinase pathways highlighted as being particularly relevant 
(Greenman, Stephens et al. 2007). This raises the question of whether post-translational 
modification, and especially phosphorylation, might provide a means to specifically target 
cancer cells. Clearly a wide range of post-translational modifications occurs in cells including; 
glycosylation, citrinulation, acetylation and phosphorylation. However, phosphorylation of 
cellular proteins is one of the most wide spread, in addition, kinase pathways are also 
altered/upregulated in cancer and are a hallmark of malignant transformation (Vogelstein 
and Kinzler 2004; Greenman, Stephens et al. 2007). Targeting kinases themselves has proved 
promising for some cancers (Baselga 2011; Gherardi, Birchmeier et al. 2012) and raises the 
question of whether the altered phosphoproteome in cancer cells gives rise to an 
immunological signature of tumourigenisis, and one that may be targeted therapeutically. 
1.5.2 Phosphorylation 
The pool of phosphoproteins that could potentially provide a source of class I MHC epitopes 
is large. Firstly, up to a third of cellular proteins are phosphorylated (Alberts, Johnson et al. 
2002). Secondly, the majority of these take place in the cytosol, the key site where proteins 
are degraded for class I MHC presentation by the proteasome. Finally, phosphorylation is 
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known to play an important role in the regulated destruction of certain cellular proteins 
(Harper 2002; Hao, Oehlmann et al. 2007). The source of phosphorylated antigen for class I 
MHC presentation can arise from a number of different cellular processes and can be from 
functional proteins that have been targeted for degradation in order to limit their activity or 
from a large pool of miss-folded/abnormalities that may occur during post translational 
modifications, such as aberrant phosphorylation. This highlights the potential for 
phosphorylation to provide antigens for presentation by MHC class I molecules to the 
immune system. Since many viral proteins are also phosphorylated during an infection, it is 
conceivable that these may also be presented by class I MHC molecules. Therefore, 
mechanistically how phosphorylated proteins might be processed and presented on MHC 
molecules is an important area of study in order to fully understand the repertoire of 
antigens that are available for immune recognition. Phosphorylated proteins therefore 
provide a potential source of antigens for class I and II MHC presentation that are 
functionally linked to the transformation process and might prove tumour selective. 
1.5.3 Presentation of phosphopeptide antigens 
Within the last decade it has become clear that post translationally modified proteins, 
including phosphoproteins, can enter the class I presentation pathway, ultimately giving rise 
to phosphopeptides that can be presented on class I molecules at the surface of cells, for 
recognition by the immune system. The first study to demonstrate natural phosphopeptide 
presentation on class I MHC (Hogan, Eisinger et al. 1998) involved sequencing of peptides 
eluted from class I molecules by mass spectrometry, and revealed presentation of a single 
phosphopeptide by HLA-A68.2 on the surface of a lung tumour cell line. However this study 
did not study the further effects of phosphorylation in antigen binding and T-cell recognition. 
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In 2000 Zarling et al used mass spectrometry to identify the presence of phosphopeptides on 
a range of MHC class I alleles (Zarling, Ficarro et al. 2000). By using various EBV transformed 
LCL cell lines, each expressing a different class I MHC allele, it was demonstrated that each 
class I MHC allele could present a varying degree of phosphopeptides and interestingly 
found that HLA-B alleles present a wider range of phosphopeptides than HLA-A alleles. The 
authors proposed that this is likely to reflect the common structural features shared by MHC 
binding motifs and phosphokinase motifs. Presentation of phosphopeptides was also shown 
to be completely TAP dependent and therefore many of these peptides were likely to 
originate from processed proteins in the cytosol. The selective recognition of 
phosphopeptide by mouse CTL was also demonstrated, which I shall go on to discuss further 
in section 1.5.4. This study therefore provided the first comprehensive insight into how 
posttranslational effects such as phosphorylation might play an important role in antigen 
presentation and immune recognition. However the study did not fully resolve the structural 
aspects of how these phosphopeptides might bind to class I MHC molecules. 
To further characterise the binding mode and sequence repertoire of phosphopeptide 
antigens presented by class I MHC molecules in a cancer background, Zarling et al in 2006 
published results that identified a common motif of phosphopeptides presented by HLA-
A*0201 in various cancer cell lines (Zarling, Polefrone et al. 2006). 36 phosphopeptides were 
found to be presented by HLA-A*02001 (HLA-A2) on one or more of the 4 cell lines tested, 
each containing a single phosphoserine (pSer) or phosphothreonine (pThr). Of these 9-13 
amino acid phosphopeptides, 68% contained a pSer or pThr at P4. In addition, 62% of the 
phosphopeptides contained a charged amino acid residue at the P1 position (Arg or Lys). 
However, of the peptides that contained pSer at P4, 50% also contained a positively charged 
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amino acid at P1. Finally, 41% of the phosphopeptides contained subdominant anchor 
residues (Met, Ile, Val or Gln rather than the optimal Leu) at P2 compared to only 23-24% of 
non-phosphorylated peptides. Therefore a distinct canonical HLA-A2 binding 
phosphopeptide motif had been determined, which contained a phosphorylation at P4, a 
positively charged residue at P1 and could tolerate a higher frequency of subdominant 
anchor residues compared to non-phosphorylated peptides. 
The molecular basis of canonical phosphopeptide presentation by HLA-A2 was first 
investigated by Mohammed et al, who compared the structure of four canonical 
phosphopeptide/HLA-A2 complexes determined by x-ray crystallography (Mohammed, 
Cobbold et al. 2008). The four peptides were canonical phosphopeptides in that they all 
contained a P4 phosphorylation and a charged P1 residue. The group included one nonamer 
and three decamers. The overall mode in which phosphopeptides bind to the HLA-A2 
molecule was found to be similar to that of non-phosphorylated peptides in that the 
stabilising interactions usually observed between the peptide termini and the A and F 
pockets of the HLA-A2 groove are conserved for all peptides. The anchor residues at P2 and 
the carboxy-terminus were also orientated similarly to most previous HLA-A2 structures. In 
all four phosphopeptides, the phosphate at P4 was structurally conserved in that the 
phosphate head group was orientated upwards and towards the N-termini P1 position. The 
highly conserved orientation of the phosphate head group allows for a variety of stabilising 
interactions between the phosphate, P1 residue and residues of the HLA-A2 peptide binding 
groove. HLA-A2/phosphopeptide binding assays confirmed that the phosphate can have a 
profound effect upon MHC binding affinity. Finally, the study suggested that 
phosphorylation might affect overall peptide conformation itself. These data therefore not 
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only suggest that phoshopeptides can bind with altered affinities compared to their non-
phosphorylated counterparts, due to the ability to tolerate poor anchor residues, but also 
that the phosphate could potentially play a key role in antigen presentation to TCR; not only 
through direct interaction with the solvent exposed phosphate but also through possible 
conformational change upon addition of the phosphate moiety. 
A second study by Petersen et al was the first to directly compare the structures of HLA-A2 
associated phosphorylated epitopes and non-phosphorylated counterparts (Petersen, 
Wurzbacher et al. 2009). The study compared one canonical epitope, RVASPTSGV (RVAS), 
and two non-canonical epitopes, GLLGSPVRA (GLLGS) and YLDpSGIHSGA (YLDS), in their 
phosphorylated and non-phosphorylated forms. Most strikingly the study demonstrated that 
for these epitopes phosphorylation has very little effect upon overall antigen conformation. 
This highlights that discrimination of these antigens by phosphopeptide specific T-cells is 
likely to rely solely on direct binding of the TCR with the phosphate moiety. 
1.5.4 T-cell recognition of post-translational modified antigens 
In addition to how phosphopeptides are presented by MHC molecules, which is still 
relatively poorly understood, our understanding of how they are recognised by the TCR is 
another area worthy of investigation. Of relevance, mice immunised with phosphopeptide 
pulsed DC generated from bone marrow stem cells are able to prime phosphopeptide 
specific T-cells in vivo, and expand CD8+ T-cell populations able to recognise peptide pulsed 
cells in a phosphate-dependent and epitope-specific manner in vitro (Zarling, Ficarro et al. 
2000). More recently a study reported that phosphopeptide-specific T cells generated in a 
similar manner kill human tumour cell lines presenting phosphopeptide antigen (Zarling, 
Polefrone et al. 2006).   
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These studies provide somewhat limited insight into how T-cells are likely to recognise class I 
MHC-restricted phosphopeptides. Although they indicate that phosphopeptides can survive 
in vitro cross-presentation, confirmed by pulsing exogenous antigen onto DC and using these 
cells to prime T-cell responses, both studies use phosphopeptides from a human source to 
generate T-cells from mice. Thus the lack of central and peripheral tolerance in this scenario 
suggests this is in effect similar to immunising with foreign antigen. Therefore, the 
experimental system used in these studies is likely to be very different to priming of natural 
responses to phosphopeptide antigens, or of therapeutic vaccination strategies in a human 
setting. Despite these caveats, these two studies provide clear evidence that tumour cells 
presenting phosphopeptides can in principle be recognised by T-cells in a manner that is 
both phosphate-dependent and epitope-specific.  
Collectively, these results along with structural studies of phosphopeptide-HLA-A2 
complexes have generated some hypotheses as to how phosphate-specific recognition might 
take place. In the case of antigens such as RVAS, discrimination of phosphopeptide epitopes 
by phosphopeptide specific T-cells may rely solely upon direct TCR interaction with the 
phosphate moiety, due to similar conformations. In summary, the full impact of 
phosphorylation on antigen structure and discrimination by the TCR remains unclear. 
1.5.5 Phosphopeptides as novel tumour antigens for immunotherapy 
As mentioned previously, many of the abnormalities in cancer also occur in posttranslational 
modification events and targeted activation/deactivation of cell signalling pathways 
(Greenman, Stephens et al. 2007). Of these, phosphorylation is of key importance. These 
modifications are able to be presented by MHC class I molecules on the surface of tumour 
cell lines and have the potential to be recognised by T-cells in a phosphate as well as epitope 
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specific manner (Zarling, Ficarro et al. 2000; Zarling, Polefrone et al. 2006). These therefore 
represent a novel and qualitatively distinct set of tumour associated antigens that are linked 
to the transformation process. Although the presence of phosphopeptide/MHC complexes 
has been shown, the immunological relevance to cancer therapy in a human setting has not 
and questions in this area still remain.   
Despite these issues, phosphopeptides are arguably promising targets for future 
immunotherapy approaches. However, to fully comprehend the mechanisms of presentation 
and the responses generated by phosphoantigens, a molecular understanding of their 
presentation and recognition is important. By understanding the structural basis of 
phosphopeptide presentation, such as the effects of phosphate position on MHC 
stabilisation, peptide conformation and TCR recognition, may in the future provide the 
ability to predict how a phosphorylated antigen might function as a potential target for 
cancer therapy.  Just as the determination of primary anchor residues for class I MHC 
molecules helped improve the design of new vaccines for both viral and cancer therapy, so 
might the knowledge generated by studying the structure of phosphoantigen presentation 
and recognition help improve future vaccine design. 
1.6 Aims 
Clearly there remain many unresolved questions regarding phosphopeptide presentation 
and recognition. This study aims to directly address some of these issues by determining the 
effect of phosphorylation on epitope binding and overall conformation, and also, whether 
epitope specific recognition, which is clearly highly dependent upon the phosphate at a 
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cellular level, is innate to the TCR. These issues were examined through X-ray 
crystallographic and biophysical analysis methods. 
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2 Methods 
2.1 Molecular Cloning Techniques 
2.1.1 Plasmids 
pET23a vectors (Novagen) were used for transformation and inducible expression of 
proteins to high-levels in the form of E. coli inclusion bodies. HLA-A2 and HLA-B7 heavy 
chains (encompassing α1, α2 and α3 domains), β2-microglobulin (β2M) and LILRB1 encoding 
pET23a plasmids had previously been generated in the Willcox laboratory prior to the 
commencement of my PhD. Constructs enabling biotinylation of HLA-A2 heavy chain were 
also previously produced by cloning the HLA-A2 heavy chain region into the JMB002 
biotinylation construct (generated by Jonathan M. Boulter and based on the pGMT7 vector). 
Human CD8α constructs (Geneservices 100005953 ORF plasmid) were sub-cloned into 
pET23a vectors as described (Gao, Gerth et al. 1998). For characterisation of the 
phosphopeptide specific T-cell receptor (TCR) binding, constructs of the IRS2, IRS2BK and 
CDC25B αβ TCR clones were kindly donated by Angela L. Zarling (University of Virginia, USA) 
and utilised as template for sub-cloning into TOPO-TA, pMT/BiP/V5-His-A (Drosophila 
expression vector) and pMT/Bip/V5-BirA-His (Novagen). The hygromycin-encoding co-
transfection plasmid, pCoHygro, was obtained from Novagen.      
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2.1.2 Bacterial cell culture 
DH5α (Invitrogen), TOP10 (Invitrogen) or BL-21 (Novagen) E. coli cells were cultured in Luria 
Bertani (LB) media (10g Bactotryptophan, 10g NaCl and 5g Yeast extract per litre of 18 Ohm 
milli-Q water) or low salt LB (10g Bactotryptophan and 5g Yeast extract per litre). LB agar 
plates were prepared by adding 15g of agar powder to a litre of LB. All media was autoclaved 
prior to use. Ampicillin was added to the culture media (following autoclaving and cooling to 
50°C) at a final concentration of 100μg/ml. LB agar plates were stored at 4°C. 
2.1.3 Preparation of chemically competent bacteria 
Stocks of chemically competent E. coli DH5α (Invitrogen) or BL-21 (Novagen) cells were 
produced by streaking for single colonies onto LB agar plates containing no antibiotic and 
incubating at 37°C for 16 hours. A single colony was then selected and inoculated into a 5ml 
starter culture of LB media with no antibiotic and grown at 37°C, 180rpm until slightly 
cloudy. This was then diluted into 100ml of fresh LB media and incubated at 37°C as above. 
Once the cells had reached an OD600 of 0.4-0.6 the culture was spun at 4000rpm in a Sorval 
RC 5C plus, using the SS-34 rotor for 15 minutes at 4°C. The resulting supernatant was 
removed and the pellet re-suspended in 20ml of pre-chilled TFB1 (30mM Potassium acetate, 
50mM Manganese chloride, 100mM Potassium chloride, 10mM Calcium chloride, 15% v/v 
glycerol). A second round of centrifugation was then performed as described above. 
Following this the supernatant was removed before re-suspending the pellet in 4ml of pre-
chilled TFB2 (10mM Sodium-MOPS pH 7.0, 75mM Calcium chloride, 10mM Potassium 
chloride, 15% v/v glycerol). The cell suspension was rapidly divided into 200μl aliquots and 
flash frozen in liquid nitrogen. Chemically competent bacterial cells were stored at -80°C 
prior to use. 
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2.1.4 Bacterial transformation with plasmid DNA 
50-100μl of chemically competent E. coli cells was thawed on ice. Typically, 0.5-1.0μg of 
plasmid DNA was then added and the cells and incubated for 30 minutes on ice. The cells 
were then heat shocked at 42°C for 90 seconds, 500μl SOC media (20g Bactotryptophan, 
0.5g NaCl, 5g Yeast extract, 2.5Mm KCl, 10mM MgCl2 and 20mM glucose per litre of 18 Ohm 
milli-Q water) added and incubated at 37°C with shaking at 180rpm for 1 hour.  Following 
incubation, 150μl of the cells were subsequently plated out onto LB/Amp plates and 
incubated at 37°C for no more than 16 hours. 
2.1.5 Insect S2 cell culture and transfection with plasmid DNA 
Non-transfected Parental S2 cells (Invitrogen) were cultured in complete growth media 
consisting of; Schneiders Drosophila medium (Lonza), 1.8g/L L-Glutamine and 10% FCS 
(Geneflow). For transfection of parental S2 cells with plasmid DNA, 3ml of cells were plated 
out into a single well of a 6 well plate (Iwaki) at a density of 1x106 cells/ml. These were then 
grown until the cell density reached 2-4x106 cells/ml, which was typically after 36 hours. The 
Invitrogen Calcium Phosphate transfection kit was used for all transfections. Firstly Solution 
A (240mM CaCl2, 9.5μg plasmid DNA, 0.5μg pCoHygro plasmid DNA, sterile H2O to final 
volume of 150μl) was slowly mixed with 150μl of Solution B (2X HBS) and incubated at room 
temperature for 30-40 minutes. The resultant mixture was then added drop wise to the cells 
and incubated for 24 hours at 27°C. Media was then removed and the wells washed twice 
with fresh media. Each wash was pooled and the cells pelleted at 100xg for 10 minutes. Cells 
were re-suspended in 3ml fresh complete growth media, returned to the same well and 
incubated at 27°C for 2 days. Finally the cells were harvested and transferred to selective 
media (complete growth media containing 300μg/ml hygromycin B (Roche)) which was 
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replaced every 4-5 days. After 12-14 days cells were transferred to T25 flasks (Iwaki) in 5-6ml 
selective media. 
2.1.6 Isolation of plasmid DNA 
Plasmids were transformed into either DH5α or TOP10 (Invitrogen) E. coli cells as mentioned 
above. After 16 hours of incubation at 37°C a single colony was picked from the plate and 
transferred to 5ml of LB media containing 100μg/ml Ampicilin. The cultures were incubated 
overnight at 37°C, with vigorous shaking at 180 rmp. The cells were then pelleted using a 
1.5ml tube in consecutive 5 minute spins at 17,000 g using a bench top centrifuge. The 
supernatant was discarded after each spin. Once all cells were pelleted, plasmid DNA was 
then purified from the cell pellet using QIAprep Spin Miniprep Kit (QIAGEN) using the 
manufacturer’s instructions and reagents. Briefly; this involved re-suspending the cell pellet,  
lysing  the cells  with an alkaline buffer containing sodium hydroxide, neutralisation in high 
salt conditions and finally centrifugation (13,000 g for 10 minutes) through silica matrix 
causing adsorption and separation of DNA from lysate. Following this the matrix was washed 
using an ethanol-based solution, and DNA was then eluted with 50μl PCR clean dH2O. DNA 
stocks were   stored at -20°C. 
2.1.7 Polymerase chain reaction 
Typically, 50μl reactions were performed containing; <0.1μg DNA (0.5-1μl from a QIAprep 
spin Miniprep sample), 20pmol of each forward and reverse primer, 10mM dNTPs, 5μl of 
relevant 10X stock enzyme buffer, 1μl PFU Ultra or Expand DNA polymerase enzyme and 
made to a final volume of 50μl with PCR clean dH2O. Reactions were carried out using a 2720 
thermocycler (Applied Biosystems). The program used for individual reactions varied, 
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however a typical example consisted of; 95°C for 2 minutes, 95°C for 45 seconds, 65°C for 1 
minute, 72°C for 5 minutes followed by 24 cycles of 95°C for 45 seconds, 65°C for 1 minute, 
72°C for 5 minutes. PCR products were then analysed by agarose gel electrophoresis. 
2.1.8 Agarose gel electrophoresis 
Agarose gels were made by adding 0.8-1.0% (w/v) agarose powder to TBE buffer (89mM Tris 
base, 89mM boric acid, 2mM EDTA) and heating to dissolve the agarose. Before cooling, 
ethidium bromide solution was mixed to a final concentration of ~0.5μg/ml with the agarose 
before pouring. A 10X loading buffer consisting of 16g sucrose, 0.25% (w/v) Bromophenol 
Blue, 40ml dH2O was used in the preparation of all samples. Agarose gels were immersed in 
TBE buffer before samples were loaded and gels ran at 80V. The size of DNA fragments were 
assessed by comparing their migration to a 100 base pair marker ladder (Roche). The ladder 
bands are sized 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 
1500 and 2642 base pairs. Gels were examined and recorded under UV light using a Syngene 
InGenius image capture system. 
2.1.9 Gel purification of DNA 
Digested plasmid and insert DNA were visualised under UV light. Bands were excised from 
the agarose gel and subsequently purified using the QIAquick gel extraction kit following the 
manufacturer’s guidelines. Briefly, agarose bands were dissolved at 50°C in buffer QG (this 
buffer provides the appropriate pH for optimal DNA binding to the silica membrane), DNA is 
then bound to a silica matrix and washed with further buffer QG to remove residual 
impurities followed by a final wash with buffer PE containing ethanol to remove salts. DNA 
was then eluted from the matrix using 50μl PCR clean dH2O.    
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2.1.10 Restriction enzyme DNA digests and DNA ligation 
The restriction enzymes XbaI, BglII and XhoI (Roche) and the appropriate buffers were used 
to digest insert and vectors in preparation for cloning and also for verification of successful 
cloning. Restriction digests were performed for 2 hours at 37°C. To prevent re-circularisation 
of cut vectors following restriction enzyme digest, 1μl of alkaline phosphatase (NEB) was 
added and incubated for 1 hour at 37°C. Following agarose gel purification of the insert and 
vector, DNA ligation was conducted overnight using T4 DNA ligase and the appropriate DNA 
ligase buffer, as per manufacturer’s instructions (NEB). 
2.1.11 DNA sequencing 
DNA sequencing reactions were performed by the Functional Genomics service, University of 
Birmingham, utilising the ABI BigDye Terminator v3.0 reaction and an ABI 3730 Sequencer. 
2.2 General Protein Techniques 
2.2.1 S2 insect cell protein expression 
Transfected S2 cells were sub-cultured into 500ml Erlenmyer flasks (Corning) at a cell density 
of 1.2x106 cells/ml in 125ml of selective media supplemented with  0.05% Pluronic F-68 
surfactant (Gibco) and incubated for 5 days at 27°C with constant shaking at 80rpm. 
Following this cells were transferred into 250ml complete growth media plus 0.05% Pluronic 
F-68 surfactant in 1L Erlenmyer flasks at a cell density of 1.2x106 cells/ml. Upon cells 
reaching a cell density of 3-5x106 cells/ml (typically 3 days), the cells were induced by 
addition of 500μM copper sulphate (CuSO4). The cells were then incubated for a further 5 
days before harvesting of the supernatant by centrifugation at 100g for 20 minutes followed 
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by 5000 rpm for 20 minutes in a Beckman Coulter Avanti 5-26xp centrifuge using the JLA8.1 
rotor.  
2.2.2 Ni-NTA column purification of His tagged proteins 
Proteins generated in the S2 insect cell expression systems contained a C-terminal His tag 
allowing purification of expressed proteins supernatant. One litre of supernatant was first 
dialysed overnight in 10L of phosphate buffered saline (PBS) (Oxoid) before addition to a Ni-
NTA column overnight at 4°C. The column was then moved to room temperature and 
washed with 300-500ml of 10mM Imidazole in PBS to remove unbound proteins. Elution of 
His-tagged proteins was performed with 250mM Imidazole in PBS. Eluted protein was buffer 
exchanged using a PD-10 column into 5mM Tris pH 8, 150mM NaCl before storing at -20°C.     
2.2.3 E.coli protein expression 
BL-21 E. coli cells (Novagen) were transformed with plasmid DNA as described above. After 
16 hour incubation on antibiotic plates a single colony was selected and transferred to 10ml 
of LB containing 100μg/ml ampicillin.  The cells were then incubated at 37°C with vigorous 
shaking at 180 rpm for ~3 hours or until the media turned cloudy. The starter culture was 
then used to inoculate 2 litres of LB-ampicillin media (ampicillin at final concentration of 
100μg/ml) using 5ml of the starter culture per litre. This was further incubated as above. As 
the optical density increased, 1ml samples were removed and the OD600 was measured 
against an LB media blank. Upon reaching the desired OD range of 0.4-0.6 the cultures were 
induced with 1M IPTG to a final concentration of 0.5mM and incubated under the same 
conditions for 4 hours. After this period the cultures were incubated at 6°C, with reduced 
shaking of 100 rpm. 
46 
 
2.2.4 Inclusion body purification 
Inclusion bodies were harvested from post induction protein expression cultures. The cells 
were pelleted at 6000 rpm for 20 minutes at 4°C (Beckman Coulter Avanti 5-26xp centrifuge 
using the JLA8.1 rotor), supernatant discarded and the cells re-suspended in 50ml ice-cold 
PBS. The cells were then sonicated for five 45 second bursts at 50% duty cycle, using a 
Misonix Sonicator and a standard 12mm probe. The cells were then centrifuged at 13500 
rpm in a Sorval RC5C plus using the SS-34 rotor at 4°C for 15 minutes. The supernatant was 
discarded and the inclusion body homogenised in Triton wash buffer (50mM Tris-HCl, 0.5% 
Triton-X100, 200Mm NaCl, 10Mm EDTA, 0.1% (w/v) Sodium Azide, 2mM DTT, pH 8.0) so that 
cell debris and membrane components were removed, before being pelleted again as above. 
This wash step was repeated two additional times. Following the third wash with Triton 
wash buffer, the pellet was re-suspended and homogenised in wash buffer containing no 
Triton-X100 (50mM Tris-HCl, 1mM EDTA, 0.1% (w/v) Sodium Azide, 2 mM DTT, pH 8.0) so as 
to remove detergent and salt from the inclusion bodies. The purified inclusion bodies were 
then finally pelleted as above and solubilised in a denaturant urea solution consisting of; 8M 
Urea, 50mM MES pH 6.5, 10mM EDTA and 2mM DTT or for CD8αα inclusion bodies; 
adjustment of pH to 8.0 along with addition of 500mM NaCl and 10% Glycerol. Inclusion 
bodies were then incubated overnight at 4°C on a rocking platform. Insoluble material was 
separated from the soluble inclusion bodies by centrifugation at 15000 rpm for 30 minutes 
at 4°C (Sorval). Supernatant was harvested into 1ml aliquots and stored at -80°C. Purity and 
concentration was assessed by SDS-PAGE and Bradford-Dye binding assay respectively. 
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2.2.5 SDS-PAGE  
SDS-PAGE separating gels of 15% acrylamide or 12.5% acrylamide consisted of; 4.9ml SDS 
solution (115ml deionised water, 125ml 1.5M Tris pH8.8 and 5ml 10% SDS), 5ml 30% 
acrylamide, 100μl 10% APS and 4μl TEMED for the 15% solution and 5.74ml SDS solution 
(78.5ml deionised water, 62.5ml 1.5M Tris pH 8.8 and 2.5ml 10% SDS), 4.16ml 30% 
acrylamide, 100μl 10% APS and 4μl TEMED for the 12.5% gels. This was then transferred to a 
1mm BIORAD gel cassette. 1ml of Isopropanol was added in order to level the gel. Stacking 
gels consisted of; 3.2 ml SDS solution (136ml deionised water, 25ml 1M Tris pH6.8 and 2ml 
10% SDS), 0.67ml 30% acrylamide, 40μl 10% APS and 4μl TEMED. The stacking gel was then 
added to the top of the dried separating gel and a 1.0mm comb inserted. 
Samples were prepared by mixing ~1-20μl of protein with 2-4μl of 5x loading buffer (made 
by mixing 5ml 1M Tris pH 6.8, 3g SDS, 1g bromophenol blue, 100μl 2M DTT in a final volume 
of  25ml with deionised water) and making up to a final volume of 10-20μl with deionised 
water. Samples were then boiled at 90°C for 10 minutes before loading onto the SDS-PAGE 
gel. 
SDS-PAGE running buffer was made up of 75g Tris base, 470g glycine and 25g SDS and made 
up to 2.5L with deionised water. SDS-PAGE was carried out using a Bio-Rad SDS-PAGE 
apparatus that was set to 100 volts for 10 minutes through the stacking gel and then 
increased to 180 volts for electrophoresis in the separating gel. SDS-PAGE gels were stained 
for 30 minutes with Coomassie Blue (1.25g Coomassie Brilliant Blue R250, 250ml methanol 
and 50ml acetic acid) and destained overnight with destain solution (300ml water, 150ml 
methanol and 50ml acetic acid). 
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2.2.6 Quantification of protein 
For solubilised inclusion body preparations an approximation of protein concentration in 
each sample was determined by a Bradford dye binding assay. 1ml of Bio-Rad Protein Assay 
Dye Reagent Concentrate was added to 4ml milli-Q water to make a working stock solution. 
An aliquot of the protein sample was taken and diluted 1:10 in 8M urea. This was then mixed 
with the working stock dye solution in a 1:200 mix. The absorption was then measured at 
595nm using an 8M urea control sample as a blank. The concentration of protein was 
calculated on the basis that 1μg of Bovine Serum Albumin has an absorbance of ~0.05 at 
595nm. 
For refolded complexes, accurate determination of the protein concentration was 
performed by measuring the absorbance of a 1:50 protein:buffer solution at 280nm. The 
extinction coefficients for each complex were determined using the following equation:  
                         
  
 
Where W is the number of tryptophan residues, Y is the number of tyrosine residues, S is the 
number of disulphide bonds and Mr is the molecular weight of the protein. Absorbance 
readings at 280nm were then divided by the extinction coefficient to provide protein 
concentrations in mg/ml. The extinction coefficient for HLA-A2 and HLA-B7 complexes was 
determined to be 1.5. The TCRs, LILRB1 and CD8αα were determined to have an extinction 
coefficient of 1.5, 2.2 and 1.3 respectively. 
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2.2.7 Protein refolding 
HLA-A2 complexes containing single phosphopeptides were produced for crystallisation 
trials  using dilution refolding protocols described by Garboczi et al (Garboczi, Hung et al. 
1992), allowing renaturation of β2M and HLA-A2 heavy chain with incorporation of the 
desired synthetic phosphopeptide.  Refolding buffers (100mM Tris pH 8.0, 2mM EDTA, 0.4M 
L-arginine, 0.5mM oxidised glutathione, 0.5mM reduced glutathione and 0.1mM PMSF) were 
maintained at 4°C with constant stirring. 10mg of denatured β2M was added to the 500ml 
refold solution by taking a third of the β2M solution and mixing with ~20ml of the refold 
buffer in a 25ml universal. The diluted β2M was then added back to the main refold buffer 
solution slowly in a drop wise fashion and this procedure repeated for the other two thirds 
of the β2M. Adding the protein in this pulsed fashion is thought to aid in the correct folding 
of the protein by decreasing the total concentration of denatured protein present at one 
time, and is likely to increase the efficiency of renaturation. The refold was then left for at 
least 30 minutes. 2mg of the relevant synthetic phosphopeptides/peptides (Sigma, EZBiolabs 
and Genescript) were then added to the refold mix. At the same time 10mg of HLA-A2 heavy 
chain was added to the refold in the same fashion as the β2M. The refold was then left for 
more than 4 hours before subsequent additions of 10mg HLA-A2 heavy chain. The total 
amount of HLA-A2 heavy chain added to each refold was 50mg. The refold mixes were 
concentrated down to ~10ml using Amicon stirred cells that were pressurised using gaseous 
nitrogen. Samples were then centrifuged at 670 g for 5 minutes and filtered using a 0.45μm 
syringe filter (Sartorius) to remove any precipitated/aggregated protein before loading onto 
a Pharmacia 26/60 Superdex 200 size exclusion chromatography column (GE Healthcare). 
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Refolding of β2M alone was carried out using the same refold conditions as HLA-A2 
complexes. To the 500ml refold 5 x 10mg pulses of β2M were added over 3 days before 
loading onto a Pharmacia 26/60 Superdex 200 size exclusion chromatography column 
Refolding of HLA-B7 complexes was similar to HLA-A2 complexes, however different 
amounts of 12mg, 15mg and 4mg o β2M, MHC heavy chain and peptide respectively were 
used. The β2M used in these refolds was also pre refolded and purified by size exclusion then 
concentrated to 15-20mg/ml before adding the 12mg directly to the refold mix. The heavy 
chain was initially  diluted to 1mg/ml in 1M urea before addition to the refold and was 
added in 3 x 5mg amounts 24 hours apart over three days. The refold mix was incubated   at 
4°C for 2 weeks with constant stirring before purification by size exclusion chromatography 
as described above followed by anion exchange using a Resource Q anion exchange column 
(GE Healthcare). 
The renaturation of LILRB1 was performed in a similar manner to β2M. However before 
refolding commenced the refold buffer was pH adjusted to pH 8.3. 
CD8αα refolding was performed in a 500ml refold buffer containing; 200mM Tris pH 8, 
10mM EDTA pH 8, 1M L-Arginine, 6.5mM cysteamine, 3.7mM cystamine and 0.1mM PMSF. 
Prior to addition to the refold buffer 20mg of inclusion body was incubated for 30 minutes in 
15ml of a reducing and denaturing buffer (6M Guanidine-HCl, 50mM Tris-HCL pH 8, 10mM 
EDTA pH 8, 100mM NaCl,  10mM DTT). A total of 60mg CD8α was added to the refold over 3 
days then left for 48 hours before purification by  size exclusion (26/60 S200) and cation 
exchange (Resource S; GE Healthcare) chromatography. 
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2.2.8 Size exclusion chromatography 
Size exclusion  chromatography was performed with a Pharmacia 26/60 Superdex 200 
column in 20mM Tris pH 8, 50 mM NaCl (5mM NaCl if loading onto Resource Q or Resource S 
columns following size exclusion), using the Pharmacia AKTA FPLC system. Samples were 
loaded in volumes of 5-10ml with a pre-washed super-loop (10ml), and the flow rate was set 
to 3ml/minute. Fractions were collected and concentrated by centrifugation using an 
Amicon Ultra (Millipore) at 670 g until the volume reached ~250μl. The concentrate was 
then transferred to a microcon centrifugal filter units with 10 KDa cutoff membranes 
(Millipore) and centrifuged at 4,100 g in a bench top centrifuge until the volume reached 
~100μl. 
2.2.9 Anion and Cation exchange chromatography 
Anion and cation exchange chromatography was performed using 6ml Resource Q and 
Resource S columns, respectively with a flow rate of 4ml/minute. Columns were pre-
equilibrated with low salt buffer (Buffer A), typically 5mM NaCl. Once protein was loaded a 
gradient of either 50% or 100% of a high salt buffer containing 1M NaCl (Buffer B) was run 
over 10-15 column volumes. Fractions were collected every 0.5ml and concentrated as 
above. 
2.2.10 Western blotting 
Western blotting was conducted by wet transfer electroblotting of proteins (including pre-
stained markers, NEB) from 12.5% SDS-PAGE gels to PDVF (Polyvinylidene Fluoride) 
membranes in the presence of Transfer Buffer (25mM Tris-HCL pH 8, 192mM glycine, 10% 
methanol), followed by a wash in TBS-T (100mM Tris-HCL pH7.5, 150mM NaCl, 0.1% Tween 
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20) and overnight blocking at 4°C in TBS-T plus 5% powdered milk. Probing with anti-His 
antibody (Invitrogen), made up at a dilution of 1:1000 in TBS-T plus 5% milk, was performed 
for 1 hour at room temperature with agitation. This was followed by three 10 minute washes 
with TBS-T and incubation with goat anti-mouse-HRP-conjugated secondary antibody at a 
dilution of 1:10,000 in TBS-T for 1 hour at room temperature. Blots were then washed three 
times in TBS-T before enhanced Chemiluminescence detection was performed using the 
Geneflow ECL Kit. Exposure of Kodak Scientific Imaging film (Kodak) was performed in a 
darkroom using an intensifier cassette and a developer machine (Kodak).   
2.2.11 3C cleavage of T-cell receptors 
Cleavage of purified αβ T-cell receptors, containing a 3C cleavage site following the C-
terminal cysteine of each chain, was performed using HRV 3C protease enzyme (Novagen) at 
a concentration of 1U/100μg protein. The cleavage reaction was incubated overnight at 4°C 
and then either analysed directly by 12.5% SDS-PAGE or cleaved T-cell receptors purified by 
addition of 200μl Ni-NTA beads, overnight incubation at 4°C with constant mixing and the 
supernatant harvested.    
2.2.12 Biotinylation of protein complexes 
Protein complexes were buffer exchanged using PD-10 columns into Biotinylation buffer 
(100mM TRIS pH 8, 20mM NaCl, 5mM MgCl2 and 0.1mM PMSF). Biotinylation reactions were 
carried out by addition of 0.5mM d-Biotin, 5mM ATP, BirA enzyme and a 1X protease 
inhibitor cocktail (Sigma), then incubated in the dark at room temperature overnight.  
 
53 
 
2.3 Surface Plasmon Resonance 
SPR binding studies were performed at 25°C using a BIAcore™ 3000 (BIAcore AB) using HBS-
EP as running buffer (10mM HEPES pH 7.4, 150mM NaCl, 3.4mM EDTA, 0.005% surfactant 
P20). For immobilisation of His-tagged proteins, Ni-NTA chip surfaces were first regenerated 
to remove metal ions that may have been present in previously used reagents by addition of 
Regeneration solution (10mM HEPES pH 8.4, 150mM NaCl, 350mM EDTA, 0.005% surfactant 
P20) followed by a one minute injection of Nickel solution (500μM NiCl2 in running buffer).  
Streptavidin (Sigma) was covalently coupled to CM5 sensor chips (BIAcore AB) via primary 
amines using the Amine Coupling Kit (BIAcore AB). Streptavidin was dissolved in 10mM 
sodium acetate pH 5.5 and injected over the sensor chip at 0.5mg/ml during coupling. 
Analytes were kept on ice and centrifuged at 17,000 g in a bench top centrifuge prior to use 
in order to remove aggregated proteins. Analytes were serially injected over all four flow 
cells at a flow rate of 10μl/minute. For test injections, 10μl was injected (60 second contact 
time). Data were collected at 10Hz. Data analysis was performed using BIAeval software 
(BIAcore AB) and Origin Pro 8 graphing and statistical analysis software (OriginLab 
Corporation). 
2.4 Overview of X-ray crystallography 
2.4.1 Crystal generation 
Crystallisation is achieved by slowly increasing the protein concentration to the point at 
which the protein molecules are forced to interact with one another in an ordered manner. 
This is termed the supersaturated state and may further develop into a crystalline or an 
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amorphous state. Crystal growth can be separated into three phases termed nucleation, 
growth and cessation. During the nucleation phase the formation of well ordered aggregates 
occurs. This is followed by the growth phase whereby protein molecules are recruited to the 
growing face of the crystal to form large well ordered crystals. The final stage is cessation in 
which the growth of the crystal halts due to reduced levels of free protein molecules in the 
solution or through incorporation of impurities within the crystal itself. The conditions 
affecting the stages of crystal growth are often represented in a phase diagram (Figure 2.1). 
This can be separated into two zones; the unsaturated zone, where crystal growth does not 
occur, and the saturated zone, which facilitates crystal growth and is located above the 
solubility curve. The saturation zone can be further divided into three regions. The clear or 
metastable region is where crystal growth can occur but not the initial crystal formation. The 
nucleation zone is the phase in which molecules interact with one another and precipitate 
into ordered crystalline structures. The third phase is the precipitation stage in which protein 
molecules interact with one another to form an amorphous precipitant. 
The overall aim in the generation of crystals for X-ray crystallographic analysis is to identify a 
crystallisation condition in which the saturation point is just within the nucleation zone and 
above the metastable zone. This facilitates a slow and reduced crystal formation with less 
crystal defects in comparison to a more saturated solution, which typically results in rapid 
formation of many nucleation sites resulting in the formation of small and often defective 
crystals. As the crystals grow the saturation levels drop to the metastable phase, in which 
nucleus initiation will cease and the stable growth of the few nucleations present will 
increase the size of existing crystals. 
 
 
Figure 2.1 Two dimensional crystallisation phase diagram 
 
Conditions below the solubility curve are under-saturated and will be unable to support crystal growth. Saturation levels above the 
solubility curve can be separated into three distinct zones; metastable, nucleation and precipitation. The nucleation phase can support 
nucleation and crystal growth. In the metastable zone crystal growth is only maintained for existing nucleation sites. The precipitation 
zone is the point at which the protein forms amorphous aggregates.  
5
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Several factors, including pH, salt concentration, protein concentration and precipitant 
concentration can have a profound effect upon nucleation and crystal growth by reducing 
the solubility of a protein and causing the solution to enter a supersaturated state. Another 
crucial factor in determining the ability of a protein to nucleate and crystal growth to occur is 
the method by which the protein crystallisation takes place. Many methods are used to 
facilitate the crystallisation of proteins (vapour diffusion, batch methods, and equilibrium 
dialysis), all of which aim to bring the protein solution to a supersaturated state. However, 
easily the most common method is the hanging drop vapour diffusion method which is also 
the method employed in this study. 
 The vapour diffusion method involves making “sitting” or “hanging” drops that usually 
contain equal amounts of protein solution (0.1-3μl), equilibrated over a reservoir solution 
that contains the crystallisation agents (pH buffer, salt and precipitant). In this study the 
hanging drop method was used and therefore will be discussed here in greater detail. The 
two solutions (protein solution and crystallisation solution) are mixed on a coverslip (1μl+1μl 
drops and above) or a viewdrop 2 96-well plate seal (100nl+100nl drops). The coverslip or 
plate seal is then inverted so that the drop hangs downwards over a corresponding reservoir 
solution (Figure 2.2). Differences in precipitant concentration between the drop and 
reservoir cause a gradient resulting in water vapour diffusing out of the drop, such that the 
concentration of crystallisation reagents in the drop gradually approaches that of the 
reservoir solution and the protein concentration also increases. Ultimately, these changes in 
the drop commonly lead to supersaturation of the protein and possible crystal formation. 
 
57 
 
Figure 2.2 Diagram of the hanging drop vapour diffusion method 
 
 
Equal volumes of protein and crystallisation reagent are suspended on a coverslip above a 
well containing crystallisation reagent. The well is sealed to form an enclosed system. 
Differences in precipitant concentration between the drop and the reservoir solution allows 
water to diffuse out of the drop by a process called vapour diffusion until equilibrium is 
achieved. During this process the protein concentration within the drop slowly increases 
leading to enhanced protein-protein interactions that can either be specific (crystal 
formation) or non-specific (aggregate formation). The formation of ordered protein-protein 
interactions and crystal nucleation can be dependent upon several factors including protein 
purity, crystallisation reagent conditions and protein concentration. 
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2.4.2 X-ray diffraction 
Once optimal crystal formation has been achieved, peptide–HLA-A2 complex crystals were 
soaked in reservoir buffer containing increasing concentrations (5%, 10% and 15% (v/v)) of 
ethylene glycol or glycerol as cryoprotectants before being ‘flash-cooled’ at 100K in a stream 
of nitrogen gas (Oxford Cryosystems). X-ray data were collected to a resolution of 1.6–2.7Å 
on an in house MicroMax 007HF microfocus rotating anode X-ray generator (Rigaku) with a 
Saturn charge-coupled device detector. This results in the typical X-ray diffraction pattern, 
which represents the reflections of each atom within an asymmetric unit of the crystal. 
2.4.3 Data processing, model building and refinement 
Following X-ray diffraction, each data set was integrated, scaled and merged with programs 
of the XDS suite (Kabsch 1993). Peptide-MHC complex structures were determined by 
molecular replacement with MOLREP (Collaborative Computational Project No 4 1994) using 
as the search model a previously determined HLA-A2 structure with peptide residues 
omitted to eliminate model bias. The LILRB1/HLA-A2-RQA_Vnp complex structure was 
solved by molecular replacement with crystallography and nuclear magnetic resonance 
system (CNS) (Brunger, Adams et al. 1998) using LILRB1/HLA-A2 as the search model (PDB 
code; Willcox et al 2003).  
In each case, the molecular-replacement calculations yielded unambiguous rotation and 
translation function solutions. The molecular models were refined with CNS (Brunger, Adams 
et al. 1998) and  REFMAC5 (Murshudov, Vagin et al. 1997). The progress of refinement was 
verified by monitoring of the variation of the Rfree value (Brunger 1992) calculated from an 
independent set of reflections (5%), which were set aside for cross-validation purposes. The 
59 
 
models were subjected to several rounds of alternating simulated annealing and positional 
refinement followed by isotropic B factor refinement. Examination of the resulting electron-
density maps showed unbiased features in the electron density (full sequence of each 
peptide), which confirmed the validity of the molecular replacement solution. All model 
manipulations were performed with COOT (Emsley and Cowtan 2004). Once the R factor 
values were below 30%, water molecules were included in the models if they appeared in Fo 
– Fc (observed structure factor – calculated structure factor) maps contoured at over 3σ and 
were within hydrogen-bonding distance to chemically acceptable groups. These water 
molecules were added in successive steps and were included in the subsequent refinement 
cycles.  
2.4.4 Structural Verification, Analysis and Figure creation 
The quality of the final refined models was verified with PROCHECK (Collaborative 
Computational Project No 4 1994) and WHATCHECK (Hooft, Vriend et al. 1996). Structural 
figures were produced with Pymol (http://www.pymol.org), with molecular surfaces 
generated using DELPhI (Rocchia, Alexov et al. 2001; Rocchia, Sridharan et al. 2002). 
Structural analysis was performed using Contact (Collaborative Computational Project No 4 
1994). 
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3 Structural plasticity of phosphopeptide 
binding to HLA-A2 
3.1 Background 
It has been previously shown that phosphorylation can alter the binding of naturally 
occurring HLA-A2 restricted phosphopeptide epitopes (Mohammed, Cobbold et al. 2008; 
Petersen, Wurzbacher et al. 2009) through the introduction of additional contacts between 
the phosphate moiety, the peptide and residues of the surrounding MHC. Mohammed et al  
also demonstrated that of the 37 HLA-A2-restricted phosphopeptides identified directly 
from cell lines by mass spectrometry  (Zarling, Polefrone et al. 2006), 62% consisted of 
epitopes that possessed a positively charged residue (Arg or Lys) at position one (P1) and 
68% a single phosphorylation at position four (P4). Collectively, these epitopes were 
described as possessing a canonical phosphopeptide motif. This was also commonly 
associated with sub-optimal anchor residues. The remaining peptides which do not possess a 
positively charged residue and a P4 phosphorylation were defined as having a non-canonical 
phosphopeptide motif. Within the canonical phosphopeptide repertoire the phosphate 
moiety was shown to form key stabilising interactions with the Arg residue at P1 of the 
peptide, Arg65 and Lys66 of the MHC and also numerous indirect contacts with surrounding 
residues of the peptide main chain and MHC. The study also highlighted that this binding 
mode seemed to be highly conserved between the four canonical HLA-A2-phosphopeptides 
complex structures studied (Mohammed, Cobbold et al. 2008). 
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These studies left several questions unresolved. Firstly, of the 37 HLA-A2 restricted 
phosphopeptide epitopes described by Zarling et al only a very small number of epitopes 
have been extensively studied to date and it is therefore unclear how representative these 
structural features are of the entire group. Secondly, the degree of structural plasticity 
exhibited by the phosphate moiety between different epitopes and the exact impact this 
would have on the binding energetics, which vary from quite extreme phosphate dependent 
binding to no dependence on phosphate, is undefined. In this chapter these questions were 
specifically addressed by determining the binding affinities of a range of canonical 
phosphopeptide/non-phosphopeptide epitope pairs using established peptide-MHC binding 
assays together with structural studies of each phosphopeptide/HLA-A2 complex with X-ray 
crystallography. Conceivably these issues could have major effects upon antigen 
presentation under different metabolic conditions and on T-cell recognition. 
3.2 HLA-A2-phosphopeptide complex production 
In order to generate soluble HLA-A2-phosphopeptide complexes for use in structural studies 
two separate pET23a vectors incorporating either the HLA-A2 heavy chain or the β2M - 
domain were generated prior to this study (Mohammed, Cobbold et al. 2008). Full 
expression was performed in E. coli BL21 (DE3) cells and inclusion bodies purified then 
solubilised in 8M urea (Figure 3.1). The purity of HLA-A2 heavy chain and β2M were deemed 
sufficient for further in vitro dilution refolding of HLA-A2-phosphoeptide complexes. For this 
study canonical phosphopeptide epitopes were selected  from the  Zarling et al list of HLA-
A2 presented phosphopeptides (Zarling, Polefrone et al. 2006) whose HLA-A2-peptide 
complex structure are yet to be determined. HLA-A2-phosphopeptide complexes were  
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Figure 3.1 SDS-PAGE analysis of purified HLA-A2 and β2M inclusion bodies 
 
Purified HLA-A2 and β2M- inclusion bodies were solubilised in 8M Urea and 1µl analysed by 
SDS-PAGE. Molecular weight markers (M) were analysed beside HLA-A2 (Lane 1) and β2M- 
(Lane 2) to assess protein size and purity. Yields of HLA-A2 and β2M typically reached 
200mg/L.
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generated by standard in vitro dilution refolding conditions (Garboczi, Hung et al. 1992) and 
subsequently purified by size exclusion chromatography. The yield and purity of each 
purified HLA-A2-phosphopeptide complex was sufficient for crystallisation screening trials as 
demonstrated by a large single peak eluting at 215ml (corresponding to a molecular weight 
of 45kDa) on the S200 size exclusion elution profile (Figure 3.2) and by subsequent analysis 
with SDS-PAGE (Figure 3.3).  
3.3 Crystallisation of HLA-A2-phosphopeptide complexes 
Purified HLA-A2-phosphopeptide complexes were concentrated to 9-15mg/ml before use in 
various sparse matrix based commercial crystallisation screens. Each screen contained 96 
unique conditions and was set up on a small scale (100nl+100nl drops) via the hanging drop 
vapour diffusion method, using a Mosquito nanolitre crystallisation robot (Mohammed, 
Cobbold et al. 2008). Each well, containing 100μl of crystallisation reagent reservoir, was 
then sealed and allowed to equilibrate at 23°C. After 3 days, crystallisation trials were 
inspected manually using a Leica MZI6 microscope in order to identify conditions that 
yielded microcrystals. The success of crystallisation for each HLA-A2-phos complex varied 
(Table 3.1). Interestingly, the most preliminary hits were identified for the HLA-A2-RQIpS 
complex with 48/96 (50%) conditions tested yielding crystals. In contrast, HLA-A2-RLQpS and 
HLA-A2-RLSpS both yielded far fewer conditions. The conditions that yielded the most 
promising crystals, in terms of morphology and size, were further optimised on a large scale 
to grow diffraction-grade crystals (Table 3.1 and Figure 3.4). 
 
  
 
 
Figure 3.2 Size exclusion chromatography purification of a typical HLA-A2-Phosphopeptide complex 
 
 
Refolded HLA-A2-phosphopeptide complexes were purified by S200 size exclusion chromatography. The molecular weight of HLA-A2-
phosphoeptide complex is ~45kDa and thus elutes from the column at around 215ml. Free β2M, which has a molecular weight of 
~11.8kDa, elutes from the column at around 255ml. The third peak at around 270ml consists of low molecular weight refold buffer 
components. 
6
4 
65 
 
Figure 3.3 SDS-PAGE analysis of refolded HLA-A2-phosphopeptide complex 
following purification by size exclusion chromatography 
 
The purity of renatured and gel filtrated HLA-A2-phosphopeptide complex was assessed by 
SDS-PAGE. The analysis shown above is a representative of all HLA-A2-phosphopeptide 
complexes. Molecular Weight markers (M) were analysed alongside HLA-A2-phosphopeptide 
complexes (Lane 1). The HLA-A2 heavy chain and β2M are indicated by the 33kDa and 11kDa 
arrows respectively. 
 
 
 
Table 3.1 Crystallisation conditions for HLA-A2-phosphopeptide complexes 
Epitope 
Sequence 
Source Protein Protein 
Concentration 
(mg/ml) 
Total 
Number of 
‘Hits’ 
Final Optimised Condition 
RLQpSTSERL Mitochondrial escape 1-like 1 11 1/96 0.2M Sodium Formate, 20% (w/v) PEG3350 
RLSpSPLHFV ORF17, chromosome 2 11 1/96 0.2M Sodium Formate, 20% (w/v) PEG3350 
RQIpSQDVKL Adenosine monophosphate deaminase 2 11 48/96 8% (v/v) Tacsimate pH 8, 20% (w/v) PEG3350 
RTFpSPTYGL β-synemin/Desmuslin 7.2 4/576 
0.1M BisTris Propane pH 7.5, 0.02M Sodium/Potassium 
Phosphate, 20% (w/v) PEG 3350 
RTLpSHISEA FLJ13725 12.2 6/288 0.1M Bicine pH 9, 20% (w/v) PEG 6000 
 
The number of conditions which produced initial crystals for each complex is documented along with the number of separate conditions 
tested. The final condition used to grow crystals for X-ray diffraction experiments is also shown for each complex as well as the protein 
concentration at which this was achieved. 
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Figure 3.4 HLA-A2-phosphopeptide complex crystals used for X-ray diffraction 
 
Crystals of HLA-A2-RTLpS (A), HLA-A2-RTFpS (B), HLA-A2-RQIpS (C), HLA-A2-RLSpS (D), HLA-
A2-RLQpS (E) and HLA-A2-PKD2p (F) were grown to sufficient size and quality for X-ray 
diffraction experiments using the hanging drop vapour diffusion technique. Crystals were 
typically produced in 1µl+1µl hanging drops and appeared after 48 hours at 23°C. The size of 
crystals generated typically reached 100µmx100µm. 
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3.4  Data collection and processing 
Prior to data collection HLA-A2-phosphopeptide complex crystals were soaked in reservoir 
solution supplemented with increasing concentrations of ethylene glycol (5, 10, 15 and 20%) 
prior to flash cooling in liquid nitrogen (Mohammed, Cobbold et al. 2008). Data collection 
was performed under the supervision of Dr Fiyaz Mohammed using the ‘in house’ Rigaku 
Micro-Max 007HF rotating anode X-ray generator with a Saturn CCD detector (University of 
Birmingham Macromolecular X-ray Facility). X-ray data were collected (Figure 3.5) to 1.7Å 
for HLA-A2-RQIpS, 1.8Å for HLA-A2-RTFpS, 1.9Å for HLA-A2-RTLpS, 1.8Å for HLA-A2-RLSpS 
and 2.1Å for HLA-A2-RLQpS under a constant nitrogen gas steam at 100K. The crystals 
typically belonged to the orthorhombic space group C2. Diffraction data sets were 
integrated, scaled and merged using programs of the XDS suite (Kabsch 1993).  The relevant 
unit cell parameters and data processing statistics are listed in Table 3.2. All phosphopeptide 
crystals provided high resolution data which was easily processed, as demonstrated by the 
favourable Rmerge values for each complex, thus allowing each complex to be taken forward 
for further structure solution. 
3.5 HLA-A2-phosphopeptide complex structure solution 
Initial phase information for each HLA-A2-phosphopeptide complex was determined by 
molecular replacement using MOLREP (Murshudov, Vagin et al. 1997) a component of the 
CCP4 suite (CCP4 1994). The phasing model consisted of  an HLA-A2 complex (PDB ID code 
1HHG) (Madden, Garboczi et al. 1993), but with the antigenic peptide residues and water 
molecules omitted so as to eliminate model bias. In each case, the molecular-replacement 
calculations yielded unambiguous rotation (rotation angles θ1, θ2 and θ3) and translation  
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 Figure 3.5 Typical example of HLA-A2-phosphopeptide X-ray diffraction pattern 
 
 
A 0.5° oscillation image of the HLA-A2-RTLpS crystal complex, which diffracted X-rays to 
1.9Å, was collected using an in house Micro-Max 007HF rotating anode X-ray generator 
(Rigaku) using a Saturn CCD detector (University of Birmingham Macromolecular X-ray 
Facility). The pink rings represent resolution shells (Å). This image was typical of diffraction 
data collected for each HLA-A2-phosphopeptide complex crystal.  
 
 
 
Table 3.2 Data processing statistics for HLA-A2-phosphopeptide complexes 
 HLA-A2-RLQpS HLA-A2-RLSpS HLA-A2-RQIpS HLA-A2-RTFpS HLA-A2-RTLpS 
Space Group C2 C2 C2 C2 C2 
Unit Cell Length (Å) 
Unit Cell Angles (°) 
a=110.8,b=54.1,c=75.6 
α=90, β=120.4, γ=90 
a=118.7,b=53.5,c=74.9 
α=90, β=104.8, γ=90 
a=118.0,b=54.2,c=75.1 
α=90, β=104.9, γ=90 
a=120.1,b=54.3,c=74.8 
α=90, β=104.6, γ=90 
a=117.4,b=54.8,c=75.4 
α=90, β=104.5, γ=90 
Resolution (Å) 20-2.1 20-1.8 20-1.7 20-1.8 20-1.9 
Observed 
Reflections 
606386 (184123) 687316 (43473) 334999 (48808) 424744 (35684) 327869 (27616) 
Unique Reflections 25449 (8229) 40570 (5048) 46573 (10750) 43093 (6172) 36088 (4747) 
Multiplicity 23.8(22.4) 16.9 (8.6) 7.2 (4.5) 9.9 (5.8) 9.1 (5.8) 
Completeness (%) 98.9 (97.8) 95.8 (80.2) 91.9 (75.4) 99.1 (95.7) 98.1 (92.2) 
Rmerge (%) 11.6 (42.2) 5.2 (68.7) 3.4 (32.8) 5.7 (76.9) 4.2 (45.2) 
I/σ(I) 27.4 (9.3) 40.76 (3.06) 34.0 (4.7) 26.5 (2.4) 34.6 (4.3) 
 
Data processing was performed for each HLA-A2-phosphopeptide complex using programs of the XDS suite. The values in parentheses 
represent data processing statistics in the highest resolution shell. 
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(translation vectors x, y and z) function solutions as demonstrated by peak RF-function and 
monitor scores respectively (Values for each complex are documented in Appendix A-E). The 
molecular replacement solutions for each HLA-A2-phosphopeptide complex were easily 
generated due to the fact that the phasing model used was highly similar (100% identity, 
excluding the peptide epitope) to the HLA-A2-phoshopeptide complexes. 
3.6 HLA-A2-phosphopeptide structure refinement 
The molecular models were refined with CNS (Brunger 1992) and REFMAC5 (Murshudov, 
Vagin et al. 1997). The progress of refinement was verified by monitoring of the variation of 
the Rfree value (Brunger 1992) calculated from an independent set of reflections, which were 
set aside for cross-validation purposes. The models were subjected to several rounds of 
alternating simulated annealing and positional refinement followed by isotropic B factor 
refinement. Examination of the resulting electron-density maps showed unbiased features in 
the electron density (full sequence of each peptide), which confirmed the validity of the 
molecular replacement solution (Figure 3.6). All model manipulations were performed with 
COOT (Emsley and Cowtan 2004). Once the R factor values dropped  below 30%, water 
molecules were included in the models if they appeared in Fo–Fc maps (observed structure 
factor – calculated structure factor) contoured at over 3σ and were within hydrogen-bonding 
distance to chemically acceptable groups. These water molecules were added in successive 
steps and were included in the subsequent refinement cycles.  The final refinement statistics 
for each HLA-A2-phosphopeptide complex structure are summarised in Table 3.3. Due to the 
crystals diffracting to a high resolution and low Rmerge values following data processing, the 
resulting Fo-Fc and 2Fo-Fc maps yielded well defined electron density thus aiding in the 
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Figure 3.6 Unbiased features of electron density maps 
 
The electron density map (grey mesh contoured to 1σ) of HLA-A2-RLQpS is shown following 
molecular replacement and an initial round of refinement. (A) Sticks represent the peptide 
from the phase model 1HHG (Madden, Garboczi et al. 1993) used in the molecular 
replacement calculations. The 1HHG derived peptide does not fit into the electron density 
map, indicating that there is no model bias in the calculated electron density maps. (B) The 
RLQpS peptide fits snugly into the electron density further emphasising the lack of model 
bias. 
 
 
Table 3.3 Refinement Statistics for HLA-A2-phosphopeptide complexes 
 HLA-A2-RLQpS HLA-A2-RLSpS HLA-A2-RQIpS HLA-A2-RTFpS HLA-A2-RTLpS 
Resolution (Å) 20-2.1 20-1.8 20-1.7 20-1.8 20-1.9 
Ref. in working set 24223 38539 44256 40913 34292 
Ref. in test set 1226 2031 2317 2159 1792 
RCryst (%) 19.05 19.53 21.70 21.43 22.13 
RFree (%) 23.00 22.12 23.52 23.34 24.25 
Num. of protein atoms 3155 3179 3156 3145 3103 
Average B-Factor 
Chain A – 20.14 
Chain B – 23.11 
Chain A – 20.34 
Chain B – 21.25 
Chain A – 20.74 
Chain B – 20.50 
Chain A – 20.19 
Chain B – 22.97 
Chain A – 25.71 
Chain B – 23.64 
Number of water mol. 343 440 395 303 224 
RMS Bond Length (Å) 
RMS Bond Angle (°) 
0.014 
1.384 
0.015 
1.533 
0.007 
0.987 
0.006 
0.985 
0.038 
2.590 
Ramachandran Plot 
Allowed (%) 
Generously Allowed (%) 
Disallowed (%) 
 
99.7 
0.3 
0 
 
99.7 
0.3 
0 
 
99.7 
0.3 
0 
 
99.4 
0.3 
0.3 
 
99.4 
0.3 
0.3 
 
Final refinement statistics for each HLA-A2-phosphopeptide complex were generated following several rounds of alternating simulated 
annealing and positional refinement followed by isotropic B factor refinement and model building. 
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 process of model building and refinement of each of the complexes. The quality of the final 
refined models was verified with PROCHECK (CCP4 1994) and WHATCHECK (Hooft, Vriend et 
al. 1996), which demonstrated in most cases that non-glycine residues were absent from the 
disallowed regions of the Ramachandran plot, although one residue (Ser195) was present in 
the disallowed region in HLA-A2-RTLpS and HLA-A2-RTFpS complexes, the residue was in 
well-defined electron density and was situated within a solvent exposed loop region 
therefore this residue was deemed to be in the correct position for these two structures 
(Figure 3.7). Most residues were well defined in all structures, except for a few solvent-
exposed side chains indicating the flexibility of these residues. Hydrogen bonding, 
hydrophobic and van der Waals interactions were analyzed with CONTACT (CCP4 1994). The 
structural analysis of each HLA-A2-phosphopeptide complex was performed with COOT and 
the CCP4 software suite (CCP4 1994). All structural figures were produced using PYMOL 
(Schrodinger 2010).  
3.7 Overall structure of HLA-A2-phosphopeptide complexes 
The overall structure of each HLA-A2-phosphopeptide complex is similar, both to each other 
and to previously solved structures of non-phosphorylated HLA-A2 complexes, with a typical 
overall RMSD of 0.8 (Figure 3.8 A-E). As expected, each complex is comprised of an α1-α2 
peptide binding platform and an α3 membrane-proximal domain non-covalently associated 
with the β2M-light chain and the bound peptide. 
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Figure 3.7 Ramachandran plot for HLA-A2-RLQpS complex 
 
A Ramachandran plot for HLA-A2-RLQpS complex which demonstrates that non-glycine 
residues were absent from the disallowed regions indicating that the model is of high 
quality. 
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Figure 3.8 Overall structures of HLA-A2-phosphopeptide complexes 
 
The overall complex structure for HLA-A2-RLQpS (A), HLA-A2-RLSpS (B), HLA-A2-RQIpS (C), 
HLA-A2-RTFpS (D) and HLA-A2-RTLpS (E) are shown in ribbon representation.  The A2 heavy 
chain is depicted in grey whereas β2M is shown in light blue. Each peptide is shown in stick 
representation, with carbon (green), oxygen (red), nitrogen (blue) and phosphate (orange).  
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Analysis of each phosphopeptide epitope revealed unambiguous electron density for each 
epitope (Figure 3.9). The phosphate in each complex is orientated in a broadly similar way to 
other canonical phosphopeptides in that the phosphate is upward facing, solvent exposed 
and is orientated towards the P1 side chain position and is therefore in an extremely 
prominent position potentially available for recognition by TCRs (Figures 3.8, 3.9 and 3.10).  
The basic mode of peptide binding for each epitope is also similar to that of non-
phosphorylated peptides and previously determined phosphopeptides in that each peptide 
adopts an extended structure in the antigen binding groove. Each peptide maintains 
stabilising interactions between their N and C terminus and HLA-A2 residues as for non-
phosphorylated peptides. In addition to this, the anchor residues at position 2 (P2) and the 
C-terminus (PC) are orientated in a broadly similar orientation to previous HLA-A2-
phosphopeptide structures (Mohammed, Cobbold et al. 2008), in that they point  downward 
into the B and F pockets, respectively (Figure 3.10). 
3.8 Analysis of canonical phosphopeptide binding mode 
Having shown that the overall structure of the HLA-A2-phosphopeptide complexes in this 
study matched previously determined phosphorylated and non-phosphorylated epitopes 
bound to HLA-A2, the role of the phosphate group in binding to MHC was examined for each 
epitope. Previous results have demonstrated that for each epitope the phosphate moiety 
adopts a conserved orientation and mediates intra-molecular peptide contacts to the P1 Arg 
residue as well as  hydrogen-bonding interactions with the α1 helical residues Arg65 and 
Lys66 (Mohammed, Cobbold et al. 2008). 
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Figure 3.9 Individual phosphopeptide epitope structures 
 
Individual phosphopeptide epitope structures of RLQpS (A), RLSpS (B), RQIpS (C), RTFpS (D) 
and RTLpS (E). Each epitope is superimposed onto a 2Fo-Fc electron density map contoured 
to 1σ (grey wire). 
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Figure 3.10 Orthogonal view of peptide binding groove 
 
View of α1α2 peptide binding platform of; HLA-A2-RLQpS (A), HLA-A2-RLSpS (B), HLA-A2-
RQIpS (C), HLA-A2-RTFpS (D) and HLA-A2-RTLpS (E). Molecular surfaces of α1α2 peptide 
binding platforms (grey) overlay ribbon representation of the α1α2 regions (dark blue). 
Phosphopeptides are shown in stick representation 
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However, due to this study focusing on only a small number of canonical phosphopeptides, it 
was still unclear whether this is representative of the whole group or to what extent there is 
structural plasticity within the binding mode of the canonical phosphopeptide repertoire. 
Upon expanding the number of phosphopeptide epitope structures determined it was 
revealed that while some epitopes fall into the category  previously  described by 
Mohammed et al, others showed differences in this phosphate mediated binding implying 
there is a degree of plasticity in the canonical phosphopeptide repertoire as a whole (Figure 
3.11). The RQIpS epitope is representative of an epitope in which the phosphate adopts a 
highly similar binding mode to those described by Mohammed et al (Figure 3.12 A). 
However, the most striking plasticity in phosphate moiety binding was observed for RTFpS in 
which the phosphate group is orientated away from Arg65 and positioned more towards the 
α2 helix of the MHC peptide binding groove compared to other phosphopeptide epitopes, 
resulting in the loss of a direct hydrogen-bonding interaction with Arg65 (Figure 3.12 B). 
Despite this re-orientation away from Arg65, the phosphate moiety mediates compensatory 
interactions with the hydroxyl group of Thr163, located on the α2 helix, through a network 
of water mediated hydrogen bonds. A second epitope, RLSpS, also demonstrated plasticity 
features with regards to the phosphate binding mode, albeit not as pronounced as RTFpS. In 
this case the reorientation of the phosphate moiety resulted in the loss of a direct 
interaction with Arg65 and like RTFpS, an indirect interaction with Arg65 was observed 
through water mediated hydrogen bonds (Figure 3.12 C). Also similarly to RTFpS, the subtle 
reorientation of the phosphate moiety of RLSpS allowed compensatory interactions with the 
hydroxyl moiety of Thr163 via a network of water mediated hydrogen bonds (Figure 3.12 C). 
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Figure 3.11 Plasticity of the canonical phosphopeptide binding mode 
 
Phosphopeptide structures were superimposed onto one another to determine any 
difference in the phosphate binding mode. The side (A) and orthogonal (B) representations 
of RLQpS (cyan), RLSpS (pink), RQIpS (yellow), RTFpS (blue), RTLpS (green) and PKD2 (red) are 
shown. PKD2 represents an epitope which displays the same structural conformation as 
other epitopes previously described (Mohammed, Cobbold et al. 2008). 
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Figure 3.12 Phosphate mediated contacts 
 
Phosphate mediated contacts of HLA-A2-RQIpS (A), HLA-A2-RTFpS (B) and HLA-A2-RLSpS (C). 
The α1 and α2 helices (grey) along with water molecules (red spheres) and interacting side 
chains of the MHC are shown. Red dash lines indicate hydrogen bond interactions. 
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A key observation of the HLA-A2 phosphopeptide antigen repertoire is that the presence of 
subdominant anchor residues is overrepresented within the group and this supports the 
hypothesis that contacts between the phosphate and MHC are able to compensate for 
suboptimal interactions of P2 anchor residues with surrounding residues of the B and F 
binding pockets of the MHC. Previous work by Mohammed et al highlighted the binding 
interactions of four subdominant anchor residue containing phosphopeptides to HLA-A2; 
namely KMDpS, RTYpS, RQApS_M and RQApS (PKD2) (Mohammed, Cobbold et al. 2008). 
This study showed that in the presence of phosphate mediated contacts, the toleration of 
subdominant anchor residues leads to structurally sub-optimal interactions with the MHC, 
including fewer or unusual binding interactions which may result in compensatory 
conformational rearrangement of B-pocket residues. The interactions between each P2 
anchor residue and amino acids that line the B pocket of MHC was determined for RLQpS, 
RLSpS, RTFpS, RTLpS and RQIpS to evaluate how this correlates with peptide-MHC binding 
affinity. The dominant P2 anchor leucine of RLQpS and RLSpS fills the B-pocket optimally, 
thus facilitating numerous hydrophobic and van der Waals interactions with surrounding 
residues Phe 9, Met 45 and Val 67 (Figure 3.13 A-B and Table 3.4) similar to those described 
by previous structures (Madden, Garboczi et al. 1993; Madden 1995; Mohammed, Cobbold 
et al. 2008). In contrast, the threonine of RTFpS and RTLpS although orientated in a similar 
direction to P2 leucine forms considerably fewer interactions with the residues Phe 9, Met 
45 and Val 67 of the B-pocket due to its smaller side chain (Figure 3.13 C-D and Table 3.4).  
Finally, the P2 glutamine of RQIpS adopted a similar binding mode to PKD2 and RQA_M 
described by Mohammed et al (Mohammed, Cobbold et al. 2008) in that the 
accommodation of the polar glutamine residue in the mainly hydrophobic B-pocket is 
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Figure 3.13 The accommodation of anchor residues in HLA-A2 phosphopeptides 
 
The accommodation of the P2 anchor residue in the B-pocket of the peptide binding groove 
is depicted for HLA-A2-RLQpS (A), HLA-A2-RLSpS (B), HLA-A2-RTFpS (C), HLA-A2-RTLpS (D) 
and HLA-A2-RQIpS (E). The main chain of each peptide is represented by red cylinder, with 
water molecules shown as red spheres. The surrounding MHC residues are represented in 
stick format. 
 
 
Table 3.4 Hydrophobic and van der Waals contacts between peptide P2 anchor residues and HLA-A2 
 HLA-A2-RLQpS HLA-A2-RLSpS HLA-A2-RQIpS HLA-A2-RTFpS HLA-A2-RTLpS 
P2 Anchor Leu Leu Gln Thr Thr 
 Cα (7) Cα (8) Cα (7) Cα (7) Cα (7) 
 Cβ (8) Cβ (7) Cβ (7) Cβ (4) Cβ (6) 
 Cγ (7) Cγ (8) Cγ (7) Oγ1 (7) Oγ1 (8) 
 Cδ1 (12) Cδ1 (12) Cδ (9) Cγ2 (10) Cγ2 (9) 
 Cδ2 (12) Cδ2 (12) Oε1 (12)   
   Nε2 (13)   
Total Contacts 46 47 55 28 30 
 
The number of hydrophobic and van der Waals contacts between the individual atoms of the P2 side chain and the surrounding residues 
of HLA-A2 are shown in parenthesis. 
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 compensated by an unusual set of direct and water mediated interactions with surrounding 
residues (Figure 3.13 E). Moreover, this is accompanied by the re-orientation of His70 (a 
residue which has a highly conserved position in other HLA-A2 structures) due to the 
introduction of ordered water molecules. This conformational adjustment of His70 results in 
a dramatic reshaping of the B-pocket. 
3.9 Phosphate moiety effects on epitope binding affinity 
Having established there is considerable structural plasticity in the binding mode of 
canonical phosphopeptides, involving altered phosphate mediated contacts to the 
surrounding residues of the MHC, an interesting question that arose is what implications do 
these altered phosphate binding modes have upon antigen binding energetics. Previous 
work has highlighted that the phosphate moiety can radically alter peptide-MHC binding 
affinity (Mohammed, Cobbold et al. 2008). However, the degree to which the phosphate 
affects binding affinity was also shown to be epitope dependent. Therefore the HLA-A2 
binding affinities of the phosphopeptides used for this study (RQIpS, RLSpS, RTLpS, RTFpS, 
RLQpS and RQApS_V) were determined in collaboration with Prof. Victor Englehard using 
previously described methods (Mohammed, Cobbold et al. 2008) along with their non-
phosphorylated counterparts. These results were collated with the previously determined 
canonical phosphopeptide epitope affinities (Mohammed, Cobbold et al. 2008) and 
documented in Table 3.5. 
Comparison of the binding affinities of each canonical phosphopeptide with their non-
phosphorylated counterpart for MHC reveals three distinct groups; firstly those with sub-
dominant  anchors (RQA_M) which display the highest phosphate induced increase in 
 
 
Table 3.5 Affinity analysis of HLA-A2 phosphopeptides and their non-phosphorylated counterparts  
Sequence Source Protein 
Peptide length 
(amino acids) 
IC50 (nM) 
Nonphosphorylated 
peptide 
IC50 (nM) 
Phosphorylated 
peptide 
Fold 
increase 
RQApSIELPSMAV Lymphocyte-specific protein 1 12 26 60 -2.3 
RLSpSPLHFV ORF 17, chromosome 2 9 27.0 16.0 1.7 
RLQpSTSERL Mitochondrial escape 1-like 1 9 325.0 122.5 2.7 
KMDpSFLDMQL Nedd4 binding protein 2 10 11.4 3.4 3.4 
RVApSPTSGV Insulin receptor substrate 2 9 731.3 178.5 4.1 
RTYpSGPMNKV Premature ovarian failure, 1B 10 792.8 116.9 6.8 
RQApSLSISV Protein kinase D2 9 284.5 38.5 7.4 
RTLpSHISEA FLJ13725 9 165.0 16.5 10.0 
RTFpSPTYGL β-synemin/Desmuslin 9 408.2 32.5 12.6 
RQIpSQDKVL Adenosine monophosphate deaminase 2 9 1,925.0 25.5 75.5 
RQApSIELPSM Lymphocyte-specific protein 1 10 1,769.0 11.2 158.6 
 
Competitive binding assays were performed as previously described (Mohammed, Cobbold et al. 2008). The peptide concentrations covered a 
100,000 fold range. The concentration at which test peptide displaced 50% of the radiolabeled peptide (IC50) was calculated allowing a 
reasonable approximation of the dissociation constant (Mohammed, Cobbold et al. 2008).   
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binding affinity, secondly those with a sub-dominant  P2 anchor (T and Q) but with a 
dominant  PC anchor (V, L or I) (RVApS, RTYpS, RQApS, RTFpS, RQIpS) and thirdly those that 
possess dominant  P2 (L or M) and PC anchor residues  (RLSpS, RLQpS, KMDpS). These results 
indicate that minimal phosphate enhanced binding effects are observed with epitopes that 
encompass dominant P2 and PC anchor residues. However, in cases where peptides contain 
sub-dominant anchor residues, the phosphate can dramatically enhance epitope binding 
compared to its non-phosphorylated counterpart. These new epitopes (RTFS, RQIS, RLSS and 
RLQS) confirm and extend the results shown by Mohammed et al (Mohammed, Cobbold et 
al. 2008) in that the phosphate can have a dramatic affect on binding affinity in the presence 
of subdominant anchor residues. 
However, two epitopes (RQA_V and RTLpS) do not conform to this pattern. For RTLS this is 
most likely due to interactions mediated by residues other than anchor residues which serve 
to increase epitope binding for non-phosphorylated RTLS (which contains no dominant 
anchor residues). In the case of RQA_V a small decrease in binding affinity upon phosphate 
addition is observed. This may possibly result from a loss of stabilising interactions present in 
the non-phosphorylated version which may be lost upon phosphate addition.     
3.10 Conclusions 
Prior to this study canonical HLA-A2 phosphopeptide antigens were shown to adopt a 
conserved binding mode and that the phosphate moiety could dramatically increase antigen 
binding affinity for some epitopes. However, upon expanding the number of canonical 
phosphopeptide structures solved, this study has demonstrated that the binding mode of 
phosphopeptides is considerably more diverse than previously thought. The plasticity of the 
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phosphate moiety in certain epitopes allows the phosphate to form new or additional 
contacts to surrounding residues of the MHC peptide binding groove. Upon correlation of 
the phosphopeptide structures with their binding affinities it is clear that the plasticity of the 
phosphate seems to have little effect upon the degree of phosphate dependant binding as 
the two epitopes that display phosphate moiety plasticity, RTFpS and RLSpS, show a high  
and low degree of phosphate dependant binding respectively. This demonstrates that the 
plasticity of the phosphate moiety observed in these epitopes is possibly a result of the 
phosphate adopting an altered conformation with optimal energetic potential for the given 
epitope and that factors such as the presence or absence of canonical anchor residues play a 
much more prominent role in determining the overall antigen binding energetics. However, 
although observations in the binding affinities of canonical phosphopeptides can be made, 
such as how different anchor residues or how the plasticity of the phosphate may affect 
affinity, it is extremely difficult to generate predictions of binding affinities based on epitope 
sequence alone (as demonstrated by RQA_Vp and RTLpS).  This may be due to the affinity 
being dependent upon not only P2 and PC anchor residues but also upon other interactions 
including intra-peptide and peptide-MHC interactions along the entire epitope which may 
change upon addition of the phosphate moiety. 
Despite this plasticity in phosphate moiety positioning, the conformation of the main chain 
for each of the canonical phosphopeptide epitopes in this study show a relatively conserved 
raised P4 position consistent with those of Mohammed et al (Mohammed, Cobbold et al. 
2008). However, it is still unclear to what extent the presence of the phosphate moiety has 
upon determining this raised conformation. These effects could conceivably impact upon the 
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overall structure of presented antigen but also upon antigen recognition. The molecular 
mechanisms that govern this will be explored in the following chapters.  
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4 Phosphate induced effects on HLA-A2 
antigen identity 
4.1 Background 
Due to the alteration/dysregulation of the phophoproteome during infection and 
tumourigenesis (Greenman, Stephens et al. 2007), phosphopeptide antigens are emerging as 
potential targets for use in immunotherapeutic approaches. Studies have shown that 
phosphorylated antigens can be presented by MHC class I and II molecules at the cell surface 
and be recognised by phosphopeptide specific T-cells in a phosphate dependent and epitope 
specific manner (Zarling, Ficarro et al. 2000; Zarling, Polefrone et al. 2006; Depontieu, Qian 
et al. 2009). However the molecular basis of how phosphopeptide antigens are presented 
and distinguished from their non-phosphorylated counterpart is poorly understood. To date, 
only a single study  has characterised  the structures of phosphorylated antigen with their 
non-phosphorylated counterparts (Petersen, Wurzbacher et al. 2009). This study examined 
three epitopes, only one of which conformed to the canonical phosphopeptide motif which 
demonstrated no change in overall conformation. However, in a previous study four 
separate canonical phosphopeptide structures were compared with the structures of several 
unrelated non-phosphorylated epitopes obtained from the protein data bank (Mohammed 
et al., 2008). Although this was not a direct comparison of phosphorylated versus non-
phosphorylated antigen pairs, the study demonstrated  a strikingly conserved raised 
conformation of the P4 pSer compared to the other non-related non-phosphopeptide 
antigens, suggesting that the phosphate may have an effect in restricting antigen main chain 
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conformation between P1-P4.  These studies highlighted two possible mechanisms by which 
phosphorylated antigens may be distinguished from their non-phosphorylated counterparts. 
Firstly, in the case of the IRS2 antigen described in the Petersen et al study, the phosphate 
may have no effect on overall antigenic structure and in such cases discrimination is likely to 
involve direct TCR-mediated contact to the phosphate moiety, which is likely going to 
depend on its position within the epitope. Alternatively, the Mohammed et al study 
demonstrated a conserved conformation of canonical phosphopeptides between P1-P4 thus 
highlighting the possibility that for some epitopes phosphorylation may induce a 
conformational change along the length of the epitope due to this apparent restriction in the 
binding mode of the antigen. 
Based on this data it is apparent that the current understanding of how the phosphate 
affects antigen identity remains poorly defined. Having shown that the phosphate can 
dramatically influence antigen binding and that there is considerable plasticity in the binding 
mode of the phosphate moiety within canonical phosphopeptides, this chapter will focus on 
the effects the phosphate moiety has on antigen conformation and its impact on antigen 
recognition will be explored. 
4.2 HLA-A2-nonphosphopeptide complex production 
HLA-A2-non-phosphopeptide complexes were produced in the same manner as HLA-A2-
phosphopeptide complexes as described in Chapter 3. Initially, epitope selection for the non-
phosphopeptides was focused on those with available structural data for their 
phosphorylated equivalents. However, subsequent structural studies led to the inclusion of 
other epitopes that lacked structural data for their phosphorylated counterparts with 
attempts to obtain structural data in both phosphorylated and non-phosphorylated forms 
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conducted in parallel. As with the production of previous HLA-A2-phosphopeptide 
complexes, renaturation of HLA-A2-non-phosphopeptide complexes with in vitro dilution 
refolding strategies provided high yields of protein to a sufficient purity for subsequent 
crystallisation screening studies (Figure 4.1 and 4.2). 
4.3 Crystallisation 
4.3.1 Crystallisation of HLA-A2-non-phosphopeptide complexes using 
commercial screens 
Initial crystallisation screening trials were performed using purified HLA-A2-non-
phosphopeptide at 10-15 mg/ml with a range of sparse matrix based commercial screens 
(including JCSG-plus, PACT, PEG Ion I+II, PEGRx, Wizard I+II, Wizard III+IV, Index and 
Structure screens I+II). Generally, the non-phosphorylated complexes were intransigent to 
crystallisation in these standard trials with the exception of two cases (Table4.1). Firstly, the 
HLA-A2-RQISQDVKL (HLA-A2-RQISnp) complex crystallised in 3 unique conditions obtained 
from the PEG Ion I+II screen and secondly crystals of the HLA-A2-RTLSHISEA (HLA-A2-RTLSnp) 
complex were identified with the Wizard I+II and Proplex screens. In order to obtain crystals 
of sufficient size and quality for X-ray diffraction studies, multiple rounds of optimisation 
were performed. Large crystals of HLA-A2-RQISnp, which were sufficient for X-ray diffraction 
experiments, were manually grown in 0.1M Sodium Tartrate dibasic dehydrate, 0.1M Bis Tris 
propane pH6.5, 19% PEG 3350 using hanging drop vapour diffusion with a drop size of 
1µl+1µl (Table 4.1 and Figure 4.3 A). Unfortunately, despite extensive efforts, it was not 
possible to generate diffraction-grade crystals for the HLA-A2-RTLSnp complex (Table 4.1 
and Figure 4.3 B). 
 
 
Figure 4.1 Size exclusion chromatography purification of a typical HLA-A2-nonphosphopeptide complex 
 
Blue line shows a size exclusion elution profile of the HLA-A2-RLSSnp complex using a Superdex 200 column. Red arrows indicate the 
elution peaks of the HLA-A2-RLSSnp complex (45kDa), and free β2M (11.8kDa) which has not been incorporated into the HLA-A2 complex. 
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Figure 4.2 SDS-PAGE analysis of purified HLA-A2-nonphosphopeptide complex 
used for crystallisation 
 
Typical SDS-PAGE analysis of gel filtration purified HLA-A2-nonphosphopeptide complexes. 
Molecular weight standards are shown in the first lane with masses indicated in kDa. Lane 1 
shows HLA-A2-nonphosphopeptide complex analysed under reducing conditions. The 
samples were of sufficient purity for subsequent crystallisation trials. 
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Table 4.1 Conditions tested for crystallisation of HLA-A2-nonphosphopeptide 
complexes 
Epitope Source Protein 
Protein 
conc. 
(mg/ml) 
Screens Tested Hits 
RQLSSGVSEI Heat shock protein 27 
12.1 PACT 1 
12.1 Index 2 
12.1 Peg Ion I+II 5 
RLSSPLHFV ORF 17, chromosome 2 
12, 11 Peg Ion I+II 0 
12 Index 0 
12 PACT 0 
10 Structure Screen I+II 0 
12 Petersen 0 
RQISQDVKL 
Adenosine monophosphate deaminase 
2 
12 Peg Ion I+II 3 
12 Index 0 
12 PACT 1 
12 Petersen 0 
RLQSTSERL Mitochondrial escape 1-like 1 
12.46 Wizard III+IV 0 
12.46 JCSG-Plus 0 
12.46 Wizard I+II 1 
12.46 PACT 0 
12 Petersen 0 
RTLSHISEA FLJ13725 
10 JCSG-Plus 0 
14, 10 Structure Screen I+II 0 
14, 10 Index 0 
10 Proplex 1 
14 Wizard I+II 1 
13.5 Peg Ion I+II 0 
14 PACT 0 
14 Wizard III+IV 0 
11 Petersen 0 
RTFSPTYGL β-synemin/Desmuslin 
13.2, 11 PACT 0 
10 JCSG-Plus 0 
13.2, 10 Structure Screen I+II 0 
13.2, 10 Index 0 
13.2, 7.73 Wizard III+IV 0 
7.73 Peg Rx 0 
13.2 Wizard I+II 0 
10 Peg Ion I+II 0 
11 Petersen 0 
RLDSYVRSL Trafficking protein particle complex 1 
11.16 Index 0 
11.16 JCSG-Plus 0 
11.16 Peg Ion I+II 0 
11.16 PACT 0 
11.16 Peg Rx 0 
11.16 Wizard I+II 0 
11 Petersen 0 
RLFSKELRC 
TFIID transcription initiation factor 
subunit 13 
12 Peg Ion I+II 0 
12 Wizard I+II 0 
12 PACT 0 
KMDSFLDMQL Nedd4 binding protein 2 8, 9, 10, 11, 12 Petersen 0 
RTYSGPMNKV Premature ovarian failure, 1B 7.7 Petersen 0 
 
Initial crystallisation conditions for each complex were tested with sparse-matrix based 
commercial screens using the hanging drop vapour diffusion method. All hanging drop 
screens were set up using the Mosquito nanolitre crystallisation robot. The success of crystal 
generation in the initial screens and further optimisation to produce diffraction grade 
crystals was very poor. Screens highlighted in red indicate conditions which yielded initial 
crystals but were unable to produce diffraction grade crystals. The screen shown in green 
yielded preliminary hits that enabled further optimisation and ultimately produced crystals 
suitable for X-ray diffraction experiments. 
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Figure 4.3 Crystals of HLA-A2-nonphosphopeptide complexes 
 
 
 
 
 
 
 
 
 
 
 
 
HLA-A2-nonphosphopeptide crystals of the HLA-A2-RQISnp complex which were crystallised 
in 0.1M Sodium Tartrate dibasic dehydrate, 0.1M Bis Tris propane pH6.5, 19% PEG 3350 
using hanging drop vapour diffusion in a drop size of 1µ+1µl (A). These crystals typically took 
2 days to appear at 23°C. The HLA-A2-RTLSnp complex, which was crystallised in 1M Sodium 
citrate, 0.01M Imidazole pH8, 0.1M Sodium Iodide as above, produced microcrystals 
intransigent to optimisation (B). (C) LILRB1-HLA-A2-RLSSnp crystals crystallised in 0.1M Tris 
pH 8.5, 0.2M Ammonium Acetate, 18% PEG 3350 using hanging drop vapour diffusion with a 
drop size of 2µl+2µl. Crystals in this condition typically took 2-3 weeks to appear at 23°C. 
LILRB1-HLA-A2-RTFSnp (D), LILRB1-HLA-A2-RLQSnp (E) and LILRB1-HLA-A2-RLSSnp (F) 
following optimisation with the Additive Screen (Molecular Dimensions). These crystals were 
produced using hanging drop vapour diffusion with a drop size of 1µl+1µl. Crystals typically 
took 2 days to appear. All crystals apart from HLA-A2-RTLSnp crystals were approximately 
100µm x 100µm in size. 
A B 
C D 
E F 
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4.3.2 Crystallisation of HLA-A2-non-phosphopeptide complexes with 
LILRB1 
As mentioned above the majority of HLA-A2-non-phosphopeptide complexes were 
intransigent to crystallisation using conventional approaches, including conditions which 
have previously led to crystallisation of a wide range of HLA-A2-peptide complexes (Table 
4.1) (Petersen, Wurzbacher et al. 2009). In order to circumvent intransigent crystallisation, a 
novel method was explored in which the HLA-A2-non-phosphopeptide complex was co-
crystallised with a previously identified MHC-binding protein. An obvious candidate was 
LILRB1 (Anderson and Allen 2009), a broadly expressed inhibitory receptor that binds  MHC 
class I with low affinity and which has previously been co-crystallised in complex with HLA-
A2 to 3.4Å resolution (Willcox, Thomas et al. 2003). Crucially, the LILRB1 binding site on HLA-
A2 involves the non-polymorphic α3 and β2M domains and does not interfere with  the α1-
α2 peptide-binding platform (Willcox, Thomas et al. 2003). In order to verify that binding of 
LILRB1 to MHC-class I does not alter the peptide binding platform or epitope conformation, 
two identical HLA-A2 structures previously crystallised with and without LILRB1 (Madden, 
Garboczi et al. 1993; Willcox, Thomas et al. 2003) were compared. The α1α2 domains of 
each complex were found to be highly conserved with a root mean square deviation (RMSD) 
of 0.6Å and the epitope also adopted essentially identical conformations within the antigen 
binding groove (Figure 4.4 A/B) highlighted by a low rmsd RMSD of 0.35Å.  This was 
confirmed with a higher resolution structure of the LILRB1-HLA-A2-ILK complex determined 
to 2.4Å resolution, which enabled a more accurate structure of the peptide moiety. Notably, 
the final optimised crystallisation condition that yielded the higher-resolution LILRB1-HLA-
A2-ILK complex structure consisted of 20% PEG 3350, 0.2 M ammonium acetate and 0.1 M 
Tris-HCL pH 8.5 (Index screen; Hampton Research), which is subtly different from the 
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Figure 4.4 Comparison of HLA-A2 structure with and without LILRB1 
 
Comparison of the overall structure of the Garboczi et al HLA-A2-ILK complex (Blue; HLA-A2) 
with the LILRB1-HLA-A2-ILK complex from the Willcox et al study (Green; HLA-A2, Cyan; 
LILRB1) reveals very little difference in α1α2 domain conformation demonstrated by a low 
RMSD of 0.6Å (A).  Analysis of each peptide (Garboczi - Green, Willcox - Blue) also shows that 
binding of LILRB1 does not affect the conformation of the bound epitope highlighted by a 
low RMSD of 0.35Å (B). Following the generation of a higher resolution structure of LILRB1-
HLA-A2-ILK (Red; HLA-A2, Cyan; LILRB1), comparison of this structure with the HLA-A2-ILK 
complex from the Garboczi et al study (Blue; HLA-A2) conclusively demonstrated that 
binding of LILRB1 has no effect upon α1α2 domain and antigen conformation as shown by 
low RMSD values of 0.6Å and 0.24Å respectively.  
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chemical compounds used to determine the corresponding low resolution complex structure 
(Willcox et al., 2003); the precipitant 20% PEG 3350 is substituted with 30% PEG 4K. Despite 
these subtle differences in the LILRB1-HLA-A2-ILK crystallisation condition, the high 
resolution complex crystals adopted an alternate space group of P3221 (rather than P3121 in 
the low resolution structure), with a larger unit cell and twice the number of LILRB1-HLA-A2 
complexes per asymmetric unit. To eliminate the possibility of altered crystal contacts 
affecting epitope conformation, we compared the high resolution ILK epitope with that of 
the same HLA-A2 bound peptide structure determined in the absence of LILRB1. Structural 
overlay comparisons demonstrated that the peptide binding platform in both complexes was 
very similar with an RMSD value of 0.6Å. Most crucially, the peptide itself showed no 
changes in epitope structure upon LILRB1 binding to HLA-A2 (Figure 4.4 C/D) with an RMSD 
of 0.24Å. Hence, the HLA-A2-LILRB1 co-crystallisation strategy was potentially an attractive 
strategy for overcoming intransigent crystallisation of HLA-A2-non-phosphopeptide 
complexes and could be used to explore phosphate mediated effects on antigen identity. 
Initially, co-crystallisation trials for each non-phosphopeptide epitope utilised the same 
condition described above for crystallisation of the high resolution LILRB1-HLA-A2-ILK 
complex which consisted of 20% PEG 3350, 0.2M ammonium acetate and 0.1M Tris-HCL pH 
8.5. For these experiments purified HLA-A2-non-phosphopeptide complexes were mixed 
with LILRB1 in a 1:1 ratio at 13.5mg/ml (Table 4.2).  There was limited success in producing 
diffraction grade crystals for specific epitopes such as LILRB1-HLA-A2-RTFSPTYGL (LILRB1-
HLA-A2-RTFSnp), LILRB1-HLA-A2-KMDSFLDMQL (LILRB1-HLA-A2-KMDSnp) and LILRB1-HLA-
A2-RLQSTSERL (LILRB1-HLA-A2-RLQSnp) (Table 4.2). 
 
 
 
Table 4.2 Crystallisation and optimisation of LILRB1-HLA-A2-nonphosphopeptide complex crystals 
HLA-A2 Epitope 
Protein 
conc. 
(mg/ml) 
Screen Hits Condition/Crystallisation information 
RTFSPTYGL 
12, 11, 
10, 9 
Index Screen, 
Mohammed et al 2012 
n/a 
0.1M HEPES pH 7.4, 0.2M Ammonium Acetate, 18-20 % PEG 3350. Only small 
microcrystals 
 PEG/Ion I+II  
0.2M Potassium Sodium Tartrate, 20% PEG 3350. 1µl+1µl produced a single 
crystal which diffracted to 2.3Å 
KMDSFLDMQL 
12, 11, 
10, 9 
Index Screen, 
Mohammed et al 2012 
n/a 
0.1M HEPES pH 7.4, 0.2M Ammonium Acetate, 18-20 % PEG 3350. Only small 
microcrystals 
RLSSPLHFV 
12, 11, 
10, 9 
Index Screen, 
Mohammed et al 2012 
n/a 
0.1M Tris pH 8.5, 0.2M Ammonium Acetate, 18% PEG 3350. 2µl+2µl yielded 1 
crystal that produced x-ray diffraction data to 3.4Å 
13.5 PEG/Ion I+II 20 
Hits used for further optimisation 
F1 - 4% Tacsimate pH 6, 12% PEG 3350 
G10 – 2% Tacsimate pH 7, 0.1M HEPES pH 7.5, 20% PEG 3350 
13.5 
Molecular Dimensions 
Additive Screen 
6 
Condition B4 (10% DMSO) hit taken for further optimisation/x-ray diffraction. 
Final optimised condition 3% Tacsimate pH 6, 12.8% PEG 3350, 10% DMSO 
13.5 
Homemade metal ion 
screen 
0 Metal Ion screen based on 3% Tacsimate pH 6, 12.8% PEG 3350, 10% DMSO 
RLQSTSERL 
13.5 PEG/Ion I+II 13 
0.2M Potassium Acetate, 20% PEG 3350 taken forward to 1µl+1µl trials which 
produced small crystals. This was taken forward for further optimisation. 
13.5 
Molecular Dimensions 
Additive Screen 
0 Additive screen based on 0.2M Potassium Acetate  
 
Initial screening results of LILRB1-HLA-A2-nonphosphopeptide complexes and subsequent optimisation. 
1
0
1 
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One of the complexes however, HLA-A2-RLSSnp, despite the poor reproducibility of crystal 
generation, did yield a single drop that provided diffraction quality crystals (Figure 4.3 C). 
Despite this, based on the lower levels of crystal reproducibility coupled with higher 
nucleation sites, the previously identified LILRB1-HLA-A2 crystallisation condition was 
deemed insufficient for generating diffraction-grade crystals (data not shown).  
Due to the unreliable nature of this generic HLA-A2-LILRB1 crystallisation condition, a range 
of commercial screens were used in order to identify novel reagents that consistently 
produced crystals of sufficient size and quality for X-ray diffraction experiments. Of the 
several commercial screens tested (PACT, Index, PEG Ion I+II, PEGRx, Structure screen I+II, 
JCSG-Plus, Proplex, Wizard I+II and Wizard III+IV) the PEG Ion screen yielded promising initial 
hits  for each LILRB1-HLA-A2-epitope complex (Table 4.2). Following optimization of the 
preliminary conditions (Table 4.2), diffraction-grade crystals for the LILRB1-HLA-A2-
RLSSPLHFV (RLSSnp) (Figure 4.3C/F), LILRB1-HLA-A2-RTFSnp (Figure 4.3D) and LILRB1-HLA-
A2-RLQSnp (Figure 4.3E) complexes were readily generated for X-ray diffraction studies.  
4.4 X-ray Data collection and Processing 
The HLA-A2-RQISnp crystals were first soaked in reservoir solution supplemented with 
increasing amounts (5, 10, 15 and 20%) of ethylene glycol (as cryoprotectant) before being 
flash-cooled in liquid nitrogen. X-ray data collection was performed as previously described 
in Chapter 3 and the data collected to a resolution of 2.1Å (Figure 4.5). 
The LILRB1-HLA-A2-RLSSnp crystal grown in the previously optimised condition used for the 
crystallisation of the high resolution LILRB1-HLA-A2-ILK complex was also soaked in 
increasing amounts of ethylene glycol as above before being flash-cooled in liquid nitrogen. 
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Figure 4.5 X-ray diffraction patterns of HLA-A2-RQISnp and LILRB1-HLA-A2-
RTFSnp complexes 
 
A 0.5° oscillation image collected from (A) HLA-A2-RQISnp and (B) LILRB1-HLA-A2-RTFSnp 
crystals. Diffraction data for each complex crystal was collected on an in house Micro-Max 
007HF rotating anode X-ray generator (Rigaku) using a Saturn CCD detector (University of 
Birmingham Macromolecular X-ray Facility). The HLA-A2-RQISnp and LILRB1-HLA-A2-RTFSnp 
crystals diffracted X-rays to 2.1Å and 2.3Å respectively. 
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However this crystal only diffracted to a resolution of 3.2Å and the resulting data proved 
extremely difficult to process. Therefore, LILRB1 complex crystals of HLA-A2-RTFSnp, HLA-
A2-RLQSnp and HLA-A2-RLSSnp were initially soaked in reservoir solution containing 
increasing concentrations of ethylene glycol or glycerol (5, 10, 15 and 20 %) before being 
flash-cooled and stored in liquid nitrogen. Data collection was performed as above and 
revealed that the glycerol cryoprotectant was sub-optimal due to the presence of ice-rings in 
the diffraction pattern (data not shown). However, crystals vitrified in ethylene glycol 
cryoprotectant allowed data to be collected to 2.3Å, 2.8Å and 2.9Å for LILRB1-HLA-A2-
RTFSnp, LILRB1-HLA-A2-RLQSnp and LILRB1-HLA-A2-RLSSnp complexes respectively. 
Diffraction data sets for both LILRB1-HLA-A2-peptide and HLA-A2-peptide complexes  were 
integrated, scaled and merged using programs of the XDS suite (Kabsch 1993).  While X-ray 
data for HLA-A2-RQISnp and LILRB1-HLA-A2-RTFSnp complexes produced spherical spots 
with high quality profiles (Figure 4.5) allowing data  to be processed to an acceptable 
standard, the equivalent  data  for LILRB1-HLA-A2-RLQSnp and LILRB1-HLA-A2-RLSSnp 
complexes generated diffraction images  with streaky spots (data not shown). Hence, it was 
extremely difficult to process the latter two data sets with acceptable statistics, which in 
turn prevented subsequent structure solution; these were therefore not included in the 
analysis. The relevant data processing statistics are listed in Table 4.3. 
4.5 HLA-A2-non-phosphopeptide complex structure solution 
Initial phase information for HLA-A2-RQISnp and the LILRB1-HLA-A2-RTFSnp complexes were 
determined by molecular replacement using MOLREP within the CCP4 suite (Murshudov, 
Vagin et al. 1997). The phasing model used for the HLA-A2-RQISnp complex was as described 
in Chapter 3 (PDB ID code 1HHG)(Madden, Garboczi et al. 1993).  
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Table 4.3 Data processing statistics for HLA-A2-RQISnp and LILRB1-HLA-A2-
RTFnp complexes 
 HLA-A2-RQISnp LILRB1-HLA-A2-RTFSnp 
Space Group P21 P3221 
Unit Cell Length (Å) 
Unit Cell Angles (°) 
a=56.4,b=79.3,c=56.8 
α=90, β=115.5, γ=90 
a=116.3,b=116.3,c=192.6 
α=90, β=90, γ=120 
Resolution (Å) 20-2.1 20-2.3 
Observed Reflections 299127 (94287) 758810(41698) 
Unique Reflections 26307 (8581) 66969(7529) 
Multiplicity 11.4 (11.0) 11.3 (5.5) 
Completeness 99.3 (98.8) 99.1(94.0) 
Rmerge (%) 6.5 (14.5) 11.3(67.3) 
I/σ(I) 25.2 (11.4) 23.6(2.8) 
 
X-ray data for all complexes were integrated, scaled and merged using programs of the XDS 
suite. Numbers in parentheses represent data processing statistics in the highest resolution 
shell.  
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In contrast, for the LILRB1-HLA-A2-RTFSnp complex, the phasing model consisted of the  
LILRB1-HLA-A2 complex (PDB ID code 1P7Q) (Willcox, Thomas et al. 2003), with the peptide 
co-ordinated omitted to minimise model bias. 
Molecular replacement calculations for both the HLA-A2-RQISnp and LILRB1-HLA-A2-RTFSnp 
complexes yielded unambiguous rotation (θ1, θ2 and θ3) and translation (translation vectors 
x, y and z) function solutions as demonstrated by peak RF-function and monitor scores, 
respectively (Values for each complex are documented in Appendix F and G) 
4.6 HLA-A2-non-phosphopeptide structure refinement 
The HLA-A2-non-phosphopeptide and LILRB1-HLA-A2-non-phosphopeptide structures were 
refined in the same manner as the HLA-A2-phosphopeptide structures discussed in Chapter 
3. The final refinement statistics for each complex is listed in Table 4.4. As with some of the 
HLA-A2-phosphopeptide complexes both of these complexes display some residues within 
disallowed regions of the Ramachandran plot. For the HLA-A2-RQISnp complex the single 
residue in a disallowed region is within a loop region away from the peptide binding 
platform and is also within clear electron density therefore we can assume that the position 
of this residue is correct. For the LILRB1-HLA-A2-RTFSnp complex the several disallowed 
residues reside in flexible loop regions of the MHC and LILRB1 but also of note is that the 
refinement statistics show that further refinement is required in order to reduce the 
statistics to an acceptable level, however as the peptide and the surrounding residues of the 
peptide binding groove are all within electron density, structural comparisons between the 
non-phosphopeptide and phosphopeptide are able to be performed as the structure of 
these residues will alter very little during further refinement. 
107 
 
Table 4.4 Refinement Statistics for HLA-A2-RQISnp and LILRB1-HLA-A2-RTFnp 
complexes 
 HLA-A2-RQISnp LILRB1-HLA-A2-RTFSnp 
Resolution Range (Å) 20 - 2.1 20 - 2.3 
Ref. in working set 25033 63557 
Ref. in test set 1781 3401 
Rcryst (%) 19.02 26.13 
Rfree (%) 23.67 29.58 
Number of protein atoms 3151 9133 
Average B-factor (Å2) 
Heavy Chain A – 12.55 
Heavy Chain A – 33.80 
Heavy Chain E – 35.62 
Light Chain B – 16.19 
Light Chain B – 26.95 
Light Chain F – 26.71 
 
LILRB1 D – 36.11 
LILRB1 H – 42.10 
Number of water mol. 265 202 
RMS Bond Length (Å) 
RMS Bond Angle (°) 
0.016 
1.46 
0.008 
1.48 
 
Ramachandran Plot 
Allowed (%) 
Generously Allowed (%) 
Disallowed (%) 
 
 
99.4 
0.3 
0.3 
 
 
98.5 
0.9 
0.5 
 
Final refinement statistics for each HLA-A2/phosphopeptide complex were generated 
following several rounds of alternating simulated annealing and positional refinement 
followed by isotropic B factor refinement and model building. Although both complexes 
demonstrate some residues in disallowed regions of the ramachandran plot, the disallowed 
residue in the HLA-A2-RQISnp structure does not form part of the peptide binding groove 
and is well defined in electron density. The LILRB1-HLA-A2-RTFSnp structure demonstrates a 
higher degree of disallowed residues due to their position in flexible loops and requires 
further refinement of these regions. 
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4.7 Overall Structure of HLA-A2-non-phosphopeptide 
complexes 
The structural analysis of each HLA-A2-phosphopeptide complex was performed with COOT 
and the CCP4 software suite (Murshudov, Vagin et al. 1997; Emsley and Cowtan 2004). All 
structural figures were produced using Pymol (Schrodinger 2010). In addition to the two 
non-phosphopeptide structures mentioned above, two additional HLA-A2-peptide 
complexes, HL-A2-RQA_V and HLA-A2-PKD2 (RQAS), were previously solved in their 
phosphorylated and non-phosphorylated forms by Dr Fiyaz Mohammed and will be included 
for the remainder of this chapter. As with the phosphorylated versions of each epitope 
described in Chapter 3 the overall structure of each HLA-A2-non-phosphopeptide complex is 
similar, both to each other and to previously solved structures of HLA-A2 complexes, 
including HLA-A2-RTFS and HLA-A2-RQA_V which were crystallised with LILRB1 co-
crystallisation strategy (Figure 4.6). Analysis of each complex revealed unambiguous electron 
density for each epitope (Figure 4.7). Similar to previous observations, the overall mode of 
binding for each non-phosphopeptide complex is similar to their phosphorylated 
counterpart in that each peptide adopts an extended structure in the antigen binding groove 
formed by the α1-α2 platform. Furthermore, each peptide maintains a conserved network of 
stabilising hydrogen bonding interactions between their N and C terminus and HLA-A2 
residues. In addition to this, the anchor residues at position 2 (P2) and the C-terminus (PC) 
are orientated in a broadly similar orientation to related HLA-A2-phosphopeptide structures 
(Mohammed, Cobbold et al. 2008), in that they protrude  downwards into the B and F 
pockets, respectively (Figure 4.8). 
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Figure 4.6 Overall structure of HLA-A2-nonphosphopeptide and LILRB1-HLA-A2-
nonphosphopeptide complexes 
 
The overall structures of HLA-A2-RQInp (A), HLA-A2-PKD2np (B), LILRB1-HLA-A2-RTFnp (C) 
and LILRB1-HLA-A2-RQA_Vnp (D) are shown as cartoon representations. The heavy chain of 
HLA-A2 consisting of the α1, α2 binding platform and membrane proximal α3 domain are 
shown in grey with the β2M domain shown in blue. LILRB1 molecules bound to HLA-A2 
complexes are highlighted in pink (C and D). The peptide in each complex is shown within 
the peptide binding groove of the HLA-A2 molecule as stick representation. 
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Figure 4.7 Electron density for phosphopeptides epitopes in their non-
phosphorylated state 
 
Individual phosphopeptide epitope structures of RQISnp (A), PKD2np (B), RTFSnp (C) and 
RQA_Vnp (D). The 2Fo-Fc electron density map is contoured to 1σ (grey wire). 
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Figure 4.8 Orthogonal view of non-phosphopeptides in the antigen binding groove 
of HLA-A2  
 
Orthogonal view of HLA-A2-RQISnp (A), HLA-A2-PKD2np (B), HLA-A2-RTFSnp (C) and HLA-A2-
RQA_Vnp (D) complexes. Molecular surfaces of α1α2 peptide binding platforms (grey) 
overlay ribbon representation of the α1α2 regions (dark blue). Phosphopeptides are shown 
in stick representation. 
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4.8 Phosphate induced effects on epitope identity 
To date there has only been a direct structural comparison of a single canonical 
phosphopeptide in its phosphorylated and non-phosphorylated state bound to HLA-A2.  This 
study highlighted extremely limited changes in epitope structure upon addition of the 
phosphate moiety. However, this epitope adopted an unusual conformation relative to 
previous phosphopeptide structures suggesting it is not typical of the canonical 
phosphopeptide repertoire (Figure 4.9). This unusual conformation was hypothesised by 
Peterson et al to be due to the limited flexibility of the P5 Pro restricting the main chain from 
adopting a raised conformation upon phosphorylation of the antigen. Therefore the effect of 
the phosphate moiety on phosphopeptide that adopt a typical main-chain conformation has 
remained unclear. To address this issue the HLA-A2-phosphopeptide complexes of HLA-A2-
PKD2p, HLA-A2-RQApS_V, HLA-A2-RQIpS and HLA-A2-RTFpS were compared to the structure 
of their non-phosphorylated counterparts. 
In each case the phosphorylated epitopes maintain the conserved raised positioning of the 
main chain at position 4 of the peptide (see Chapter 3 for details). The PKD2 epitope exhibits 
phosphate dependent binding for HLA-A2 with a binding affinity of Kd 38.5nm versus Kd 
284.5nm for phosphorylated and non-phosphorylated epitopes respectively (See Chapter 3, 
table 3.1). Although the phosphorylated form of PKD2 had been previously crystallised in 
complex with HLA-A2 (Mohammed, Cobbold et al. 2008), both the HLA-A2 bound 
phosphorylated and non-phosphorylated forms were re-crystallised for this study in a 
previously described condition (Petersen, Wurzbacher et al. 2009). This yielded crystals that 
in each case belong to the orthorhombic space group P212121 with very similar unit cell 
parameters for both phosphorylated and non-phosphorylated complexes and allowed a 
113 
 
Figure 4.9 Comparison of RVApS (IRS2) peptide conformation with other 
phosphopeptide epitopes 
 
 
Comparison of the IRS2 epitope RVApS (red) conformation compared to previously solved 
phosphopeptides and phosphopeptides solved in this study (blue).  The IRS2 epitope adopts 
an unusual conformation compared to other canonical phosphopeptide epitopes. 
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precise comparison of both structures. The overall MHC main chain structure of the 
phosphorylated and non-phosphorylated PKD2 structures was found to be very similar with 
an rmsd of 0.21Å. However the same comparison revealed a striking difference in the 
epitope main chain conformation as demonstrated by the high rmsd value of 1.41Å which is 
much greater than the previous comparisons of phosphorylated/non-phosphorylated 
structures solved by Petersen etal (range 0.09-0.45Å) (Petersen, Wurzbacher et al. 2009) 
(Figure 4.10 A). In the unmodified version of PKD2, the P4 Ser adopts a much lower position 
within the peptide binding groove and forms no contacts with surrounding residues of the 
MHC (Figure 4.10 B). Upon phosphorylation, the P4 pSer adopts a raised conformation, 
enabling the formation of multiple hydrogen-bonding interactions typical of the canonical 
phosphopeptide group (Figure 4.10 C). These additional interactions introduced upon 
addition of the phosphate are likely to contribute to the increased affinity of the 
phosphorylated PKD2p antigen binding to the MHC. The raising of the main chain at position 
4 in PKD2p results in an altered main chain conformation within the central region of the 
epitope and re-orientation of the side chains at position 5, 6 and 7 (Figure 4.11 A). These 
residues are frequently involved in TCR binding and this alteration in antigen structure 
within the central region of the epitope causes a dramatic change in the molecular surface 
(Figure 4.11 B/C) and may therefore significantly impact upon antigen recognition and 
discrimination by phosphopeptide specific TCRs. 
The RQApS_V peptide is a canonical phosphopeptide epitope composed of 12 residues, an 
unusual length for HLA-A2 binding. Also, peptide-MHC binding studies have highlighted that 
the binding affinities are highly similar with Kds of 60.0nM and 26nM for phosphorylated 
and non-phosphorylated epitopes, respectively (See Chapter 3 Table 3.1). 
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 Figure 4.10 Comparison of phosphorylated and non-phosphorylated PKD2 
epitope conformation 
 
Phosphorylation of the PKD2 epitope causes substantial conformational change in the 
antigen main-chain (A), with the phosphopeptide depicted in blue and the non-
phosphorylated epitope in red. The interactions mediated by P4 Ser (B)/pSer (C) to HLA-A2 
are compared. Hydrogen bonding interactions are shown in red dashed lines. Solvent 
molecule is represented as a red sphere. 
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Figure 4.11 Comparison of phosphorylated and non-phosphorylated PKD2 epitope 
side chain orientation and surface electrostatics 
 
The side chains of P5, P6 and P7 are re-orientated upon phosphorylation of PKD2 (A).   The 
phosphopeptide is shown in blue whereas the non-phosphopeptide counterpart is 
highlighted in red (A). The surface representation of PKD2np (B) and PKD2p (C) epitopes 
highlight not only significant charge related differences  on the epitope surface(blue, 
positive; grey, neutral; red, negative), but also substantially different conformation over the 
central region of the epitope. 
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An initial hypothesis that suggested the unusual length of the epitope may disrupt the 
canonical phosphate binding mode observed for other phosphopeptides was proposed. 
However upon solving the structure of HLA-A2-RQApS_V to 2.1Å, despite exhibiting a novel 
helical segment towards the C-terminus of the peptide, the phosphate adopted a position 
and interactions similar to other canonical phosphopeptides which have been shown to 
contribute to increased antigen affinity (Chapter 3) (Mohammed, Cobbold et al. 2008).  A 
second hypothesis envisaged that conformational rearrangement of the epitope upon 
addition of the phosphate moiety may potentially disrupt stabilising interactions which are 
present in the non-phosphorylated epitope. Therefore the structure of HLA-A2-RQAS_Vnp 
was solved to 2.7Å in complex with LILRB1. Once again following comparison of the two 
MHC structures very little difference in overall MHC main chain structure was observed, with 
an rmsd of 0.75Å. However comparison of the peptide main chains of phosphorylated and 
non-phosphorylated RQAS_V revealed a dramatic alteration in the conformation of the 
antigen highlighted by an rmsd of 2.1Å (Figure 4.12 A). In the non-phosphorylated epitope 
the P4 serine adopts a low position within the antigen binding groove and forms no contacts 
with surrounding residues (Figure 4.12 B). As with PKD2, when phosphorylated, the P4 pSer 
raises and permits interactions with surrounding residues (Figure 4.12 C). Also like PKD2 the 
conformational change is focused on the central region of the epitope with substantial 
differences in main chain position and side chain orientations at Positions 4, 5, and 7 (Figure 
4.13 A), thereby altering the molecular surface of the epitope (Figure 4.13 B/C). These 
results may also explain the relatively similar binding affinities for the phosphorylated and 
non-phosphorylated epitopes (See Chapter 3, table 3.1) in that, when in the non-
phosphorylated form, the low main chain position adopted by P4 serine and surrounding 
peptide main-chain allows additional side chain and intra-peptide contacts along the length 
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Figure 4.12 Comparison of RQA_Vp and RQA_Vnp epitope structure and P4 binding 
 
Phosphorylation of the RQA_V epitope causes substantial conformational change in the 
antigen main-chain (A) with the phosphopeptide depicted in blue and the non-
phosphorylated epitope in red. The interactions mediated by P4 Ser (B)/pSer (C) to HLA-A2 
are compared. Hydrogen bonding interactions are shown in red dashed lines. Solvent 
molecule is represented as a red sphere. 
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Figure 4.13 Comparison of RQA_Vp and RQA_Vnp epitope side chain orientation 
and surface electrostatics 
 
Repositioning of the side chains of P4, P5 and P7 upon phosphorylation of RQA_V with the 
phosphopeptide highlighted in blue and non-phosphopeptide in red. The surface 
representation of RQA_Vnp (B) and RQA_Vp (C) epitopes highlight not only significant 
charge related differences on the epitope surface (blue, positive; grey, neutral; red, 
negative), but also substantial differences in conformation over the central region of the 
epitope. 
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of the epitope which help stabilise the complex. These are lost upon phosphorylation due to 
elevation of P4 serine which results in a more extended conformation compared to the non-
phosphorylated epitope. Most striking is the dramatic difference in the orientation and 
position of Ile5 in RQA_Vnp relative to RQApS_V, allowing numerous hydrophobic 
interactions with the side-chains of Arg97, His70 and Tyr99 (Table 4.5 and Figure 4.14 A). 
Also, Tyr159 is positioned closer to the epitope in RQA_Vnp and makes an additional 
hydrogen-bonding interaction to the backbone carbonyl group of Gln2 (Figure 4.14 B). 
Finally, although the 3/10 helix is maintained in both phosphorylated and non-
phosphorylated epitopes, the intra-peptide hydrophobic interactions between Ile5 and 
Met10 are present in RQAS_Vnp but absent upon phosphorylation (Table 4.5 and Figure 4.14 
C). Therefore, whilst phosphorylation introduces novel contacts between the phosphate 
moiety and surrounding residues the resulting conformational change leads to a loss of 
interactions present in the non-phosphorylated form, the net effect of which results in 
similar overall binding affinities. 
Comparison of the RQIS epitope in phosphorylated and non-phosphorylated forms as 
expected revealed very little difference in overall MHC structure with an rmsd of 0.62Å. 
However, unlike PKD2 and RQAS_V, phosphorylation of the epitope resulted in very little 
change in epitope conformation highlighted by a low rmsd of 0.39Å (Figure 4.15 A) despite 
the phosphopeptide epitope conforming to the canonical binding motif and forming 
phosphate mediated contacts similar to those described previously (Mohammed, Cobbold et 
al. 2008). This may explain why the RQIS epitope has a dramatic 75-fold increase (Chapter 3, 
Table 3.5) in binding affinity upon addition of a phosphate moiety; due to retention of 
contacts present in the non-phosphorylated epitope coupled with the additional contacts 
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Table 4.5 Comparison of Hydrogen and Hydrophobic contacts in RQA_Vnp and 
RQA_Vp binding 
Residue Atom RQA_V phos RQA_V np  Residue Atom RQA_V phos RQA_V np 
P1 Arg 
C 7 (6) 7 (6)  
P7 Leu 
C 2 (12) 0 (10) 
O 8 (5) 7 (5)  O 3 (19) 0 (12) 
N 11 (1) 13 (1)  N 0 (10) 1 (8) 
C
α 
9 (3) 7 (3)  C
α 
1 (11) 1 (13) 
C
β 
9 (2) 7 (1)  C
β 
4 (5) 1 (8) 
C
γ 
5 (2) 4 (2)  C
γ 
5 (1) 2 (6) 
C
δ 
10 (1) 5 (0)  C
δ1 
11 (1) 5 (7) 
N
ε 
2 (1) 10 (0)  C
δ2 
15 (0) 7 (1) 
C
ζ 
1 (1) 4 (0)  
P8 Pro 
C 0 (11) 0 (15) 
NH
1 
4 (0) 1 (0)  O 0 (10) 0 (13) 
NH
2 
0 (3) 6 (0)  N 1 (9) 0 (8) 
P2 Gln 
C 6 (7) 6 (6)  C
α 
1 (10) 0 (10) 
O 5 (12) 9 (7)  C
β 
0 (3) 0 (6) 
N 8 (5) 7 (5)  C
γ 
0 (5) 0 (3) 
C
α 
7 (6) 6 (6)  C
δ 
0 (10) 0 (5) 
C
β 
6 (5) 3 (5)  
P9 Ser 
C 2 (12) 0 (9) 
C
γ 
7 (2) 6 (2)  O 4 (8) 3 (9) 
C
δ 
8 (0) 8 (0)  N 0 (14) 0 (11) 
O
ε1 
11 (0) 9 (0)  C
α 
0 (10) 0 (7) 
N
ε2 
12 (0) 11 (0)  C
β 
1 (6) 1 (3) 
P3 Ala 
C 1 (8) 3 (9)  O
γ 
1 (5) 0 (4) 
O 3 (9) 5 (7)  
P10 Met 
C 4 (8) 4 (8) 
N 7 (7) 3 (7)  O 8 (7) 6 (8) 
C
α 
8 (7) 5 (6)  N 1 (13) 0 (10) 
C
β 
10 (3) 10 (5)  C
α 
4 (10) 1 (10) 
P4 
Ser/pSer 
C 0 (8) 0 (10)  C
β 
5 (4) 2 (5) 
O 0 (6) 1 (11)  C
γ 
1 (6) 1 (3) 
N 0 (7) 1 (5)  S
δ 
1 (1) 1 (0) 
C
α 
1 (5) 1 (8)  C
ε 
8 (0) 3 (3) 
C
β 
0 (3) 0 (5)  
P11 Ala 
C 3 (10) 4 (10) 
O
γ 
3 (3) 0 (2)  O 6 (9) 4 (10) 
P 3 (1) N/A  N 2 (12) 2 (11) 
O
1 
4 (3) N/A  C
α 
4 (11) 2 (10) 
O
2 
4 (0) N/A  C
β 
2 (6) 1 (7) 
O
3 
0 (1) N/A  
P12 Val 
C 9 (2) 11 (2) 
P5 Ile 
C 0 (9) 6 (9)  O 11 (2) 11 (2) 
0 0 (12) 10 (5)  N 4 (5) 5 (5) 
N 0 (7) 0 (9)  C
α 
5 (3) 6 (3) 
C
α 
0 (7) 0 (8)  C
β
 7 (2) 6 (2) 
C
β
 1 (3) 5 (3)  C
γ1 
13 (1) 11 (3) 
C
γ1 
4 (2) 8 (3)  C
γ2 
12 (1) 10 (1) 
C
γ2 
3 (5) 15 (1)  OXT 7 (4) 9 (4) 
C
δ1 
9 (0) 2 (6)  
Total 365 (260) 345 (248) 
P6 Glu 
C 0 (13) 2 (7)  
O 0 (18) 3 (7)  
HLA-A2-peptide contacts and intra-
peptide contacts (in brackets) between 
2.3Å and 4.5Å in distance were 
calculated using CONTACT.  
N 0 (7) 2 (8)  
C
α 
0 (8) 5 (10)  
C
β 
0 (5) 1 (5)  
C
γ 
0 (1) 0 (5)  
C
δ 
0 (0) 0 (1)  
O
ε1 
0 (1) 0 (0)  
O
ε2 
0 (0) 0 (0)  
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Figure 4.14 Differences in RQA_Vnp epitope interactions compared to RQA_Vp 
 
The altered conformation of the RQA_Vnp epitope permits novel contacts to HLA-A2 that 
are absent in the phosphorylated counterpart. A, the P5 Ile side chain of RQA_Vnp forms 
multiple hydrophobic contacts with residues His70, Arg97 and Tyr99 of HLA-A2. B, The side 
chain of Tyr159 is positioned closer to the RQA_Vnp epitope and mediates a hydrogen 
bonding interaction with the backbone carbonyl group of P2 Gln. C, demonstrates the close 
proximity of P5 Ile and P10 Met therefore allowing intra-peptide hydrophobic interactions 
between the two residues.  
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Figure 4.15 Comparison of RQIpS and RQISnp epitope structure and surface 
electrostatics 
 
Comparison of the RQISnp (red) and RQIpS (blue) epitope structure reveals very little 
difference in antigen conformation (A). This results in the RQISnp epitope (B) possessing a 
similar molecular surface structure to the RQIpS epitope (C), the only difference being the 
presence of the phosphate, therefore altering surface electrostatics (blue, positive; grey, 
neutral; red, negative).  
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provided by the phosphate moiety. The molecular surfaces available for TCR binding of both 
phosphorylated and non-phosphorylated epitopes are therefore very similar (Figure 4.15 
B/C), with the only difference being the presence or absence of the phosphate moiety. Two 
reasons underlie these observations: Firstly, in the RQISnp epitope, Glu63 and Lys66 interact 
with one another to form a hydrogen bond network with the backbone amide and carbonyl 
of Gln2 (Figure 4.16), thus forming a ‘molecular clamp’ which may act to stabilise and restrict 
the conformation within this region of the epitope. These interactions are conserved in 
canonical phosphopeptide structures but unlike in RQISnp they are disrupted in the non-
phosphorylated versions of PKD2 and RQA_V which undergo altered antigen conformation. 
Secondly, in the majority of canonical phosphopeptides the phosphate contacts restrain the 
main chain conformation between position 4 and 5 (as shown in Chapter 3). In the non-
phosphorylated forms of PKD2 and RQA_V these contacts are lost and the position of P4 
serine lowers into the antigen binding groove, however for RQISnp the elevation in the main 
chain is maintained by His70, which can adopt two conformations one of which protrudes 
from the base of the α1 helix binding platform and re-orientates relative to its position 
adopted in the phosphorylated structure (Figure 4.17). This enables stabilising interactions 
with the backbone carbonyl of P3 and P5 (Figure 4.17) and allows RQISnp to naturally mimic 
the main chain conformation of the phosphorylated peptide. 
 The RTFS epitope also revealed overall similarity of the MHC main chain upon comparison of 
the phosphorylated and non-phosphorylated structures and also showed very little 
difference in antigen main chain conformation, as demonstrated by a very low rmsd value of 
0.07Å (Figure 4.18 A). As with RQIS the molecular surface of both the phosphorylated and 
non-phosphorylated epitopes are very similar (Figure 4.18 B/C). 
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Figure 4.16 RQISnp interactions with Glu63 and Lys66 
 
The P2 Carbonyl and amide groups of the RQISnp epitope form a network of hydrogen 
bonding interactions with the HLA-A2 side chains of Lys66 and Glu63. These interactions are 
commonly found in canonical phosphopeptide antigens and are absent in the non-
phosphorylated forms of the PKD2 epitope and RQA_V epitope. In the RQISnp epitope these 
interactions act as a “mechanical clamp”, restricting the conformation of this region of the 
peptide. 
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Figure 4.17 RQISnp elevation of main chain by His70 
 
The side chain of His70 in the RQISnp complex (A) is able to adopt an additional raised 
orientation in comparison to the RQIpS complex (B) thereby contributing to the maintenance 
of a raised conformation in the non-phosphorylated RQIS epitope. HLA-A2 heavy chain 
shown in grey with the side chain of His 70 depicted in stick representation. The main chain 
of RQISnp and RQIpS epitopes are shown in red and blue cartoon representation 
respectively. 
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Figure 4.18 Comparison of RTFSnp and RTFpS antigen structure and surface 
electrostatics 
 
Comparison of RTFpS (blue) and RTFSnp (red) epitope conformation (A) reveals very little 
difference. This results in very similar surface structures for the RTFSnp (B) and RTFpS (C) 
epitopes with the only difference being the presence of the phosphate moiety which 
introduces differences in surface electrostatics (blue, positive; grey, neutral; red, negative). 
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The maintenance of main chain elevation in RTFSnp may be due to several factors. Firstly, 
RTFS contains a proline residue  at position 5 of the epitope, which has been shown in other 
epitopes to restrict epitope conformation in this region (Petersen, Wurzbacher et al. 2009) 
due to its limited flexibility. However comparison of the RTFpS epitope structure with that of 
the P5 Pro containing epitope, RVApS demonstrated by Petersen etal to have limited 
flexibility, shows that while the RVApS epitope adopts an altered lower conformation 
compared to other canonical phosphopeptides the RTFpS epitope does not and adopts a 
position similar to other canonical phosphopeptides (as demonstrated in Figure 4.9), 
including those without P5 proline. Secondly, similar to RQISnp, the RTFSnp epitope 
maintains interactions with Glu63 and Lys66 through a hydrogen bond network with the 
backbone amide and carbonyl of Gln2 (as seen in Figure 4.16 for RQISnp) and also 
demonstrates a raised positioning of His70 which may contribute to the maintained raised 
position of the non-phosphorylated epitope (Figure 4.19). Finally, the presence of a relatively 
large Phe side chain at position 3 of the RTF epitope causes a restriction in the ability of the 
P3-P5 main chain region to adopt a lower conformation upon removal of the phosphate but 
also most notably forms hydrophobic contacts with P5 Pro further restraining the 
conformation around the P3-P5 region of the epitope (Figure 4.19).  
These results may also explain the 12.6-fold increase in binding affinity upon 
phosphorylation of the RTFS epitope (See Chapter 3, Table 3.5) as unlike RQApS_V, which 
loses several interactions upon antigen phosphorylation due to conformational change, 
RTFpS maintains interactions observed in RTFSnp but also gains additional phosphate 
mediated interactions with surrounding residues (See Chapter 3, Figure 3.12B). In addition, 
an alteration in P1 Arg side chain orientation upon phosphorylation allows direct hydrogen 
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  Figure 4.19 Maintenance of the raised conformation in RTFnp by P3 Phe 
 
His70 of the MHC α1 helix is able to adopt a raised conformation which contributes to the 
elevation of the RTFSnp epitope main chain. The presence of the bulky side chain of Phe at 
P3 inhibits the lowering of the main chain and can adopt a conformation that allows 
hydrophobic interaction with the P5 Pro residue which acts to further restrict the 
conformation of the peptide in the P3-P5 region of the RTFnp epitope, thus enabling the 
RTFnp epitope to maintain the raised conformation observed in the RTFpS epitope. The 
α1α2 domains of HLA-A2 are shown in grey. The RTFnp epitope and His70,  Arg97, Tyr99 and 
Tyr159 side chains of the HLA-A2 peptide binding groove are shown in stick representation.   
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bonding between the P1 Arg side chain and the carboxyl group of Glu63 (Figure 4.20). RTFpS 
also forms novel direct interactions between the hydroxyl group of P7 Tyr and the carboxyl 
group of Gln155, along with indirect water mediated contacts between the hydroxyl group 
of Tyr116 and the main chain carbonyl of P7 Tyr (Figure 4.20). These additional peptide-MHC 
contacts observed in RTFpS account for the substantial increase in epitope affinity compared 
to RTFSnp. 
4.9 Conclusions 
These results show that antigen phosphorylation can radically alter antigen conformation 
and epitope identity and demonstrate the molecular mechanisms which govern this. The 
epitopes PKD2 and RQAS_V which both undergo conformational rearrangement upon 
phosphorylation do so by a similar structural mechanism, whereby the P4 pSer induces the 
elevation of the surrounding main chain relative to the non-phosphorylated state, thereby 
allowing the phosphate moiety to satiate its bonding requirements and participate in 
stabilising interactions with surrounding residues of the peptide and MHC. Despite this 
similarity in phosphate binding and phosphate induced conformational rearrangement, the 
consequences of antigen phosphorylation on peptide-MHC affinity is clearly highly epitope 
dependent, and highlights the benefit of parallel structural and peptide-MHC affinity analysis 
to fully understand the effects of phosphorylation for individual epitopes. For PKD2 the 
conformational rearrangement resulted in the formation of additional phosphate mediated 
contacts without significant loss of contacts observed in the non-phosphorylated epitope 
and thus resulted in a net increase in epitope binding affinity upon phosphorylation. 
Conversely the conformational rearrangement of RQApS_V upon phosphorylation causes a 
loss of interactions in the central region of the epitope which act to balance out the 
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Figure 4.20 RTFpS peptide MHC contacts 
 
Additional contacts between RTFpS epitope and HLA-A2, other than phosphate mediated 
contacts, which are not found in RTFnp. The main chain of the RTFpS epitope is shown in 
blue ribbon representation with side chains of P1 Arg, P4 pSer and P7 Tyr shown in line 
representation with Carbon (green), Oxygen (red) and Nitrogen (blue). The HLA-A2 heavy 
chain residues Glu63, Tyr116 and Gln155 are shown in stick representation with Carbon 
(green), Oxygen (red), Nitrogen (blue) and the main chain in grey. Red sphere represents a 
water molecule and relevant hydrogen bonds are indicated by red dashed line.  
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 additional contacts introduced by the phosphate which results in no net gain in antigen 
binding. The effect of the conformational change both these epitopes undergo upon 
phosphorylation also highlights that the most drastic conformational rearrangement occurs 
within the central region of the epitope, which has been highlighted as a key region for 
antigen recognition and discrimination by TCRs.  
However, the study also highlights two antigens (RQIS and RTFS) which do not alter in 
conformation upon phosphorylation and are consistent with a previously described 
canonical phosphopeptide RVAS which did not undergo conformational rearrangement upon 
phosphorylation (Petersen, Wurzbacher et al. 2009). This study has demonstrated that this 
can occur through a combination of mechanisms on an epitope specific basis and allow the 
non-phosphorylated epitopes to naturally mimic the conformation of the phosphorylated 
forms. 
It can therefore be concluded that there exists two types of phosphopeptide antigen; those 
which undergo conformational change upon phosphate addition and therefore represent 
completely novel antigens for T-cell discrimination and those which do not undergo 
conformational rearrangement and consequently discrimination between 
phosphopeptide/non-phosphopeptide counterparts would be to a large extent based upon 
direct TCR engagement of the phosphate moiety. This knowledge of how particular epitopes 
are presented upon phosphorylation may lead to informed decisions on optimal therapeutic 
strategies targeting phosphopeptide antigens, with the antigens exhibiting a more 
dramatically altered structure upon phosphorylation being the less likely to display cross-
reactivity upon use in vaccination strategies. However, the molecular mechanisms which 
govern phosphopeptide recognition by phosphopeptide specific T-cell receptors have never 
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been directly studied. Therefore, knowledge of how these T-cell receptors discriminate 
between phosphorylated and non-phosphorylated epitopes is lacking and so these questions 
will form the basis of the following chapter. 
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5 Phosphopeptide antigen recognition by 
phosphopeptide specific T-cell receptors 
5.1 Background 
Having demonstrated  in  Chapter 4 that phosphorylation can affect antigen identity through 
two distinct mechanisms; either conformational change or phosphate presence alone, this 
chapter will focus on defining the molecular mechanisms that govern phosphopeptide 
recognition and discrimination by phosphopeptide specific T-cells. Interestingly, although 
epitopes which undergo conformational change may be more antigenically distinct than 
those which do not, previous studies have highlighted that antigens that exhibit minimal  
structural rearrangement  (Petersen, Wurzbacher et al. 2009) can also be discriminated  and 
targeted by phosphopeptide specific T-cell clones (Zarling, Ficarro et al. 2000; Zarling, 
Polefrone et al. 2006). These T-cell clones, which have been highlighted  to target and 
eliminate phosphopeptide-expressing tumour cells in a phosphopeptide-specific manner, 
were obtained from Dr Angela Zarling (University of Viriginia) and used to study the 
molecular basis of TCR phosphopeptide recognition and discrimination.  
5.2 Production of soluble T-cell receptors 
5.2.1 Expression vector cloning 
Plasmids containing either the α or β chain genes from the three separate phosphopeptide 
specific T-cell clones; IRS2 (specific for the IRS2 epitope RVApS), IRS2BK which is also specific 
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for the IRS2 epitope RVApS but showed higher avidity than the previous clone in T-cell killing 
assays (Zarling et al unpublished data) and CDC25B (specific for the CDC25B epitope GLLGpS) 
were kindly donated by Dr Angela Zarling. Each chain was amplified from the plasmids using 
a pair of chain specific primers (Table 5.1 and Figure 5.1) which incorporated the restriction 
enzyme sites BglII and XbaI for subsequent cloning into pMTBipV5-His expression vectors, 
enabling expression in the Drosophila expression system. The sequence for each cloned T-
cell receptor (TCR) chain was verified by plasmid sequencing performed by the Functional 
Genomics facility (University of Birmingham) and verification of correct sequence was 
performed using Sequencher® (Sequencher v.4.5, Genecodes) (See Appendix H-N for 
individual sequences). 
5.2.2 Soluble T-cell receptor expression 
Following successful cloning of each TCR α and β chain into pMTBipV5-His expression vectors 
containing acid and base zipper constructs respectively (Chang, Bao et al. 1994; Adams, 
Chien et al. 2005; Willcox, Pitard et al. 2012), these constructs were used for co-transfection 
into insect S2 cells along with a plasmid conferring Hygromycin resistance. Transfected S2 
cells were cultured in media containing Hygromycin as a selection agent. Following several 
weeks of selection the transfected S2 cells were induced with 500µM CuSO4 and the 
expression of soluble TCR assessed by Western blot (Figure 5.2) of the S2 supernatant. Each 
TCR showed good levels of expression by day 5 induction of both the α-acid zipper chain and 
β-base zipper chain, however each seems to exhibit a higher molecular weight than the 
predicted 31KDa and 33KDa respectively, this is most likely due to glycosylation of the TCR 
chains in the Drosophilla expression system. Correct hetrodimer conformation was verified 
for each clone by dot blot analysis with an acid/base zipper 
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Table 5.1 TCR Specific primers 
TCR Chain Primer Sequence 
Tm 
(°C) 
IRS2 
α 
Forward 
Reverse 
5’-GGA AGA TCT GCT CAG TCA GTG ACA CAG CC-3’ 
5’-GGA TCT AGA ACA GGG AAC GTC TGA ACT GGG-3’ 
64 
66 
β 
Forward 
Reverse 
5’-GGA AGA TCT GAA GCT GGA GTC ACC CAG TC-3’ 
5’-GGA TCT AGA ACA GTC TGC TCG GCC CCA G-3’ 
64 
64 
IRS2BK 
α 
Forward 
Reverse 
5’-GGA AGA TCT GCT CAG TCA GTG ACA CAG CCC GAT G-3’ 
5’-GGA TCT AGA ACA GGG AAC GTC TGA ACT GGG G-3’ 
78 
70 
β 
Forward 
Reverse 
5’-GGA AGA TCT GAG GCT GCA GTC ACC CAA AGT C-3’ 
5’-GGA TCT AGA ACA GTC TGC TCG GCC CCA GGC-3’ 
66 
72 
CDC25B 
α 
Forward 
Reverse 
5’-GGA AGA TCT GGC GAG CAG GTG GAG CAG-3’ 
5’-GGA TCT AGA ACA GGG AAC GTC TGA ACT GG-3’ 
62 
62 
β 
Forward 
Reverse 
5’-GGA AGA TCT GCA GTC ACC CAA AGC CCA AG-3’ 
5’-GGA TCT AGA ACA GTC TGC TCG GCC CCA G-3’ 
64 
64 
 
This table documents the primer sequences used for the cloning of phosphopeptide specific 
TCR α/β chain sequences into pMTBipV5-His expression vectors. Letters in italics represent 
positions within the primer which introduce BglII and XbaI restriction sites into the PCR 
product to enable ligation into pMTBipV5-His expression vectors. 
 
 
 
Figure 5.1 PCR amplification of α and β TCR chains  
 
TCR chains (α and β) for IRS2 (A) CDC25B (B) and IRS2BK (C) phosphopeptide-specific T-cells were amplified using chain-specific primers 
which introduced a BglII and XbaI restriction site, enabling ligation into pMTBipV5-His expression vectors.  1
3
7 
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Figure 5.2 Western Blot analysis of soluble TCR expression in transfected S2 insect 
cell supernatant following induction 
 
Western blot analysis of transfected S2 cell IRS2 TCR (A), IRS2BK TCR (B), CDC25B TCR (C) and 
CDC25BBirA (D) production following 5 days of expression with an anti-His antibody, reveals 
suitable production of both α (lower band) and β (upper band) chains for each TCR when 
assessed in reducing conditions (Lane R) and that these form a dimer when assessed under 
non-reducing conditions (Lane NR).   
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specific antibody (2H11) (Chang, Bao et al. 1994) (Figure 5.3). Following confirmation of TCR 
expression, large scale inductions of 1-2L were performed. His-tagged TCR-zippers were 
isolated from the resulting supernatant by binding to a Ni-NTA bead column followed by 
washing in PBS 10mM imidazole and elution of the bound TCR with PBS 250mM imidazole. 
The yield of each TCR varied somewhat between preparations but typically reached levels of 
4-6mg/Litre of S2 supernatant. The purity of each TCR following Ni-NTA purification was 
assessed by SDS-PAGE (Figure 5.4 A-C). Both α and β chains were visualised for each TCR 
clone under reducing conditions. However, as noted in western blot analysis, the bands for 
each TCR chain were slightly higher than the sequence derived molecular weight of the α (31 
kDa including the acid zipper) and β chains (33 kDa including the base zipper).  As mentioned 
above the most likely explanation for the mobility shift on the SDS-PAGE is that the 
Drosophila derived TCRs are glycosylated to a significant extent (Figure 5.4 A-C). This was 
also the case for the heterodimer TCR observed under non-reducing conditions, which 
migrated higher than the expected sequenced-derived molecular weight (64 kDa with 
acid/base zipper moieties) for each clone (Figure 5.4 A-C). SDS-PAGE analysis also reveals 
that the different TCR clones obtained different levels of purity following Ni-NTA bead 
purification, with IRS2 exhibiting the highest purity (Figure 5.4A) and IRS2BK the lowest 
(Figure 5.4C). Following Ni-NTA bead purification each TCR was used in further studies which 
will now be discussed on a TCR by TCR basis.  
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Figure 5.3 Heterodimer dot blot analysis of TCR complexes 
 
Heterodimer dot blot analysis using an acid/base zipper specific antibody (2H11) confirms 
the presence of TCR heterodimer in IRS2 TCR (3), IRS2BK TCR (4), CDC25B TCR (5) and 
CDC25B BirA TCR (6). Lane 1 and 2 are negative controls consisting of pure IRS2 α (1) and β 
(2) chains which are not detected by the heterodimer-specific antibody. 
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Figure 5.4 SDS-PAGE analysis of Ni-NTA bead purified TCRs 
 
Following Ni-NTA bead purification soluble IRS2 (A), CDC25B (B) and IRS2BK (C) were 
assessed by 12.5% SDS-PAGE analysis under reducing (Lane R) or non-reducing (Lane NR) 
conditions. All samples were compared to a molecular weight marker (Lane M) so as to 
assess purity of each TCR preparation. The α and β bands were assigned based on single 
chain transfectants.  
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5.3 IRS2 TCR binding studies  
The IRS2 TCR clone which recognises the RVApS epitope of insulin receptor substrate 2 was 
produced in high quantity with reasonable purity following Ni-NTA bead purification (Figure 
5.4 A). This was used for a preliminary surface plasmon resonance (SPR) binding study in 
which 5118 Response units (RU) IRS2 TCR was immobilised onto a flow cell of an Ni-NTA chip 
with 2668RU of a negative control αβ TCR (LDN5) immobilised onto a separate flow cell. To 
assess specific binding purified soluble HLA-A2-RVApS complexes were injected over each 
flow cell. The resulting sensogram showed very similar increases in response for IRS2 TCR 
relative to the negative control LDN5 TCR even at very high concentrations of HLA-A2-
phosphopeptide complex (Figure 5.5). This result was extremely surprising given that T-cells 
which express this TCR are known to target and kill cells expressing HLA-A2-RVApS 
complexes. There are several explanations as to why the TCR did not display any binding. 
Firstly, the strength of TCR binding to the Ni-NTA chip is poor as demonstrated by the 
significant reduction in levels of protein immobilised over-time, suggesting on-going TCR 
dissociation from the surface. Secondly, the purity of the TCR sample used for 
immobilisation is likely to play a significant role in the quality of binding observed. This may 
also have a greater impact in the Ni-NTA chip setting as the impurities eluted from the Ni-
NTA purification step are proteins which are also likely to exhibit a degree of (non-specific) 
binding to Ni-NTA chip and therefore the observed levels of protein binding to the Ni-NTA 
chip may result in a gross overestimation of the levels of bound TCR. To address these issues, 
a second series of SPR experiments were performed using a CM5 chip with either 
 
 
Figure 5.5 Surface Plasmon resonance sensogram of Ni-NTA purified IRS2 TCR using a Ni-NTA chip 
 
 
Following immobilisation of 5118RU NI-NTA purified IRS2 TCR (blue) or 2668RU LDN5 TCR (red) to separate flow cells of an Ni-NTA sensor 
chip via His tag-Ni coupling, 10µl of HLA-A2-RVApS, in solution at a concentration of 41.8µM, was injected over each flow cell using a flow 
rate of 10µl/min. The sensogram suggests a high degree of aggregate sticking in both flow cells with no credible increase in specific 
binding to the IRS2 TCR relative to the LDN5 negative control. 1
4
3 
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biotinylated HLA-A2-RVApS (5436RU) or an unrelated HLA-A2-WT1 (Willms tumour 1 
antigen) epitope complex (5352RU) coupled with streptavidin to individual flow cells. Prior 
to injection, the IRS2 TCR was further purified by size exclusion chromatography using a 
Sephaadex HR-200 column (Figure 5.6). Despite improved purity of the IRS2-TCR, there was 
still no detectable specific binding of the IRS2 TCR above negative controls (Figure 5.7). 
These results indicate that the IRS2 TCR clone may recognise HLA-A2-RVApS with an affinity 
that is below the limit of detection by SPR. Furthermore, due to this low affinity, attempts to 
generate TCR/HLA-A2 complexes for X-ray crystallography would be extremely difficult.   
5.4 IRS2BK T-cell binding studies 
A second clone which recognises HLA-A2-RVApS with greater affinity in cellular assays than 
the previous IRS2 clone (Personal communication from Angela Zarling) was generated as 
described above. A preliminary SPR binding study was performed in which either 
biotinylated HLA-A2-RVApS (8780RU), HLA-A2-RVASnp (5539RU) or an unrelated HLA-A2-
WT1 epitope control (6325RU) were coupled to individual flow cells of a CM5 sensor chip 
using streptavidin. Following MHC immobilisation, soluble IRS2BK TCR was concentrated to 
7mg/ml, diluted to 4mg/ml in HBS-EP buffer and injected over the surface of each flow cell. 
The responses measured were marginally higher over HLA-A2-RVApS/HLA-A2-RVASnp than 
over the HLA-A2-WT1 negative control, however the signal for the non-phosphorylated 
version of RVAS was higher than that of the phosphopeptide, albeit by only a small amount 
(Figure 5.8). This is despite the fact that there was 8000 RU of HLA-A2-RVApS immobilised. 
These results were surprising as at the high concentration of TCR (62.5µM) specific binding 
to the phosphopeptide would be expected. 
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Figure 5.6 HR-200 gel filtration purification of IRS2 TCR 
 
Purification of IRS2 TCR by HR200 gel filtration results in an elution profile with multiple 
peaks, including those indicated by red and green asterisk (A). Further analysis of these 
peaks by SDS-PAGE (B) reveals that although the first peak (red asterisk) contains some TCR 
α and β chains, the non-reduced analysis indicates the second peak (green asterisk) contains 
the majority of the TCR. This SDS-PAGE analysis also reveals that there are still small 
amounts of residual contaminants following HR-200 gel filtration. 
 
 
Figure 5.7 Surface Plasmon resonance sensogram of HR-200 purified IRS2TCR using a CM5 chip 
  
Following immobilisation of 5436RU HLA-A2-RVApS (blue) and 5352RU HLA-A2-WT1 negative control (red), to separate flow cells of a 
CM5 sensor chip via amine coupling, 10µl of HR200 purified IRS2 TCR, in solution at a concentration of 42.2µM, was injected over each 
flow cell (including one which contained no MHC complex, sown in green) using a flow rate of 10µl/min. The sensogram demonstrates 
essentially no difference in response between HLA-A2-RVApS and HLA-A2-WT negative control, consistent with no binding under these 
conditions. 14
6 
 
 
Figure 5.8 Surface Plasmon resonance sensogram of HR-200 purified IRS2BK TCR using a CM5 chip 
 
Following immobilisation of 8780RU HLA-A2-RVApS (blue), 5500RU HLA-A2-RVASnp  (red) or 6300RU HLA-A2-WT1 negative control 
(green) to separate flow cells of a CM5 sensor chip via streptavidin coupling, 10µl of HR200 purified IRSBK TCR at a concentration of 
62.5µM was injected over each flow cell at a flow rate of 10µl/min. Although there is an observable increase in binding over HLA-A2-WT1 
the IRS2BK TCR does not have increased binding above the HLA-A2-RVASnp control.  14
7 
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This raises the question of whether these are genuine binding responses and alternatively of 
whether this receptor also exhibits a low binding affinity.    
5.5 CDC25B T-cell clone binding studies 
A third TCR which recognises HLA-A2-GLLGpS, an epitope of CDC25B, was produced as 
previously described and purified by Ni-NTA bead purification alone or by Ni-NTA bead 
purification followed by HR200 gel filtration (Figure 5.9). A preliminary SPR binding study 
was performed by coupling either 5898RU HR-200 gel filtrated CDC25B TCR, 7889RU Ni-NTA 
bead purified CDC25B TCR or 3969RU of an Ni-NTA bead purified negative control αβ TCR 
(LDN5) to separate flow cells using His-Ni binding. Following immobilisation of TCR to each 
flow cell S200 gel filtrated HLA-A2-GLLGpS complex in HBS-EP buffer was injected over each 
flow cell at a concentration of 1.3mg/ml. The resulting sensogram (Figure 5.10) showed 
increased levels of binding to the HR-200 purified CDC25B TCR relative to the negative 
control and also to the non-HR-200 purified CDC25B TCR. This result provided the first 
evidence that there was detectable specific binding of the HR200 purified CDC25B TCR to the 
HLA-A2-GLLGpS complex. However there are a number of caveats about this result which 
must be noted. Firstly, the sensogram shows that there was a high degree of sticking over 
the HR-200 CDC25B flow cell surface compared to control as indicated by the bi-phasic 
dissociation phase of the HLA-A2-GLLGpS ligand. As a result, the sensogram for this flow cell 
fails to return to pre-injection levels, which is typical of samples containing protein 
aggregates (van der Merwe, Barclay et al. 1994). This may be accounted for by the poor 
resolution of the TCR by HR-200 gel filtration prior to injection (Figure 5.9), or by an innate 
propensity to aggregate. The gel filtration profile also suggests plenty of opportunity for 
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Figure 5.9 Purification of CDC25B TCR by HR-200 gel filtration 
 
Purification of the CDC25B TCR by HR-200 gel filtration shows a poorly refined elution profile 
(A) which contains multiple unresolved peaks (asterisks). Fractions corresponding to these 
peaks were analysed by SDS-PAGE (B). Each peak is denoted by green, red, blue and orange 
asterisks. The left hand panel represents samples loaded under reducing conditions and the 
right hand panel under non-reducing conditions. The analysis indicates that the majority of 
CDC25B TCR is contained in the peak denoted by the blue asterisk although multiple 
contaminants still exist. 
 
 
Figure 5.10 Surface plasmon resonance sensogram of HLA-A2-GLLGpS binding to CDC25B TCR using an Ni-NTA chip  
 
Following immobilisation of 5898RU HR200 purified CDC25B TCR (Blue), 7889RU Ni-NTA purified CDC25B TCR (Red) or 3969RU negative 
control LDN5 TCR (Green) to separate flow cells of an Ni-NTA via His tag-Ni coupling, HLA-A2-GLLGpS in solution at a concentration of 
28.7µM was injected over each flow cell. The trace indicates a clear specific binding of HLA-A2-GLLGpS to the HR200 purified CDC25B 
TCR. 
1
5
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inactive (but His-containing) protein in pre-HR200 post-NiNTA samples which because of the 
poor resolution of gel filtration may not be fully removed from the HR-200 purified sample.  
This lack of purity may also account for the lack of binding seen in the non-HR200-purified 
sample as the presence of inactive His-containing proteins within the sample would also bind 
to the flow cell resulting in a gross overestimation of the levels of bound TCR.  Secondly, the 
base level on all flow cells seems to be continually falling at a steady rate prior to and 
following the injection. This is indicative of on-going dissociation of immobilised TCR from 
the flow cell surface during the experiment, making accurate determination of relative 
amounts bound to each flow cell surface difficult. Finally, these results did not ascertain 
whether the CDC25B phosphopeptide specific TCR is phosphate and epitope specific. 
In order to address some of these issues a second SPR binding study was performed. Rather 
than coupling TCR to the surface of the sensor chip using His-Ni binding which proved to be 
suboptimal in the experiments above. A CM5 chip coated with streptavidin via amine 
coupling was used to immobilise biotinylated MHC molecules consisting of 2982RU HLA-A2-
GLLGpS, 2768RU HLA-A2-GLLGnp and 2821RU of a negative control HLA-A2-WT1. CDC25B 
TCR which had been previously purified by HR-200 gel filtration was thawed and 
concentrated to 7.1mg/ml before dilution to 3.5mg/ml (55µM) in HBS-EP buffer. Initial test 
injections at this concentration revealed increases in signal which were much greater over 
the flow cell presenting HLA-A2-GLLGpS than over either of the two control flow cells, thus 
indicating specific binding (Figure 5.11). Therefore a series of TCR dilutions (ranging from 4 - 
0.06mg/ml) were injected over each flow cell (Figure 5.12). The dilution series indicated that 
specific binding of CDC25B TCR to the phosphorylated epitope could be seen over the entire 
range of injected TCR concentrations. However, although specific binding to the  
 
 
Figure 5.11 Surface plasmon resonance sensorgram of CDC25B TCR binding to HLA-A2-GLLGpS using a CM5 sensor chip 
 
Following immobilisation of 2982RU HLA-A2-GLLGpS (blue), 2768RU HLA-A2-GLLGSnp (red) and 2821RU HLA-A2-WT1 negative control via 
streptavidin coupling to separate flow cells of a CM5 sensor chip, 5µl of CDC25B TCR was injected at a concentration of 55.5µM with a 
flow rate of 10µl/min. These results demonstrate clear specific binding of the CDC25B TCR to the HLA-A2-GLLGpS complex with no 
binding observed for the other HLA-A2 complexes. 
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Figure 5.12 Surface plasmon resonance sensorgram of CDC25B TCR dilution series binding to immobilised HLA-A2 
complexes 
 
Following immobilisation of 2982RU HLA-A2-GLLGpS (blue), 2768RU HLA-A2-GLLGSnp (red) and 2821RU HLA-A2-WT1 negative control via 
streptavidin coupling to separate flow cells of a CM5 sensor chip, 10µl of CDC25B TCR was injected in a dilution series of 0.9µM, 1.7µM, 
3.5µM, 6.9µM, 13.9µM, 27.7µM and 55.5µM at a flow rate of 10µl/min. The sensogram indicates specific binding of CDC25B TCR to HLA-
A2-GLLGpS at all concentrations. 1
5
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phosphorylated epitope was observed, there was still significant levels of TCR sticking to the 
HLA-A2-GLLGpS flow cell compared to the non-phosphorylated-MHC complex and negative 
control flow cells as evident by the bi-phasic dissociation phase of the profile. This problem 
is exacerbated at the higher protein concentration injections consistent with protein 
aggregation effects (van der Merwe, Barclay et al. 1994), thus limiting the accuracy of any 
specific binding readings. Due to these effects it is problematic to calculate an accurate 
affinity for the TCR-MHC interaction based on this data. The sticking effect observed in these 
experiments is likely due to protein aggregate formation within the injected solution, 
possibly due to freeze/thawing of the sample or following concentration. 
Due to the inability to obtain pure CDC25B TCR samples at high concentrations without 
aggregation a third SPR binding study was designed in which biotinylated CDC25B TCRs were 
immobilised to the surface of a streptavidin-coated CM5 chip and MHC-peptide complexes 
injected over in solution. It was hypothesised that this method would reduce the sticking 
phenomenon observed in previous experiments because the HR-200 gel filtrated MHC 
complexes were highly purified and can be concentrated to  high  concentrations with 
minimal aggregate formation. However in order to immobilise the CDC25B TCR to the 
surface of a CM5 chip, the α chain of the CDC25B TCR needed to be cloned into the 
pMTBipV5-BirA/His vector to incorporate a C-terminal BirA tag, enabling biotinylation of the 
TCR protein. The CDC25B TCR containing a BirA biotinylation site was expressed as described 
above. 2995RU of Biotinylated CDC25B TCR was then immobilised on to streptavidin-coated 
flow cells of a CM5 sensor chip with 2985RU of LDN5 αβ TCR immobilised to a separate flow 
cell as a negative control. As well as reducing the amount of sticking observed in previous 
attempts this experiment also sought to determine the specificity of CDC25B TCR binding, 
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not only between phosphorylated and non-phosphorylated GLLGS epitope, but in 
comparison to other phosphorylated epitopes with a P5 pSer. Therefore complexes of HLA-
A2-GLLGpS, HLA-A2-GLLGSnp and HLA-A2-SLLTpS were purified by HR-200 gel filtration 
immediately prior to concentration and injection over each flow cell.  The resulting binding 
curves demonstrated unequivocal binding of HLA-A2-GLLGpS complex to the immobilised 
CDC25B TCR but not to the LDN5 TCR or blank flow cell (Figure 5.13A) and displayed minimal 
levels of sticking. Crucially, upon injection of HLA-A2-GLLGnp and HLA-A2-SLLTpS, no binding 
was observed over any of the flow cells indicating the CDC25B TCR binds in a phosphate-
dependent and epitope specific manner (Figure 5.13 B/C). Subsequent affinity analysis using 
an HLA-A2-GLLGpS dilution range of 88.9µM – 0.7µM was performed by subtracting the 
control response (LDN5 flow cell) from the response measured in the CDC25B TCR flow cell 
at equilibrium for each dilution of injected HLA-A2-GLLGpS. The specific responses were then 
plotted vs free analyte concentration (HLA-A2-GLLGpS), or as a Scatchard plot (ie. specific 
binding vs specific binding/free ligand concentration) (Figure 5.14). This revealed the 
CDC25B TCR/HLA-A2-GLLGpS interaction to have an affinity of 41.2µM and 40.1µM by direct 
non-linear curve fitting and Scatchard analysis respectively (Figure 5.14). 
To verify this interaction and obtain accurate binding data in both orientations the CDC25B 
TCR was purified by HR200 gel filtration immediately prior to concentration and injection 
over 3024RU HLA-A2-GLLGpS, 3100RU HLA-A2-GLLGSnp and 3165RU HLA-A2-SLLTpS 
complex immobilised to separate flow cells of a CM5 chip. The top concentration was also 
reduced (to 2mg/ml rather than 7mg/ml) so as to minimise the level of aggregate formation 
during this step. A second alteration to previous experiments in this orientation was to 
increase the flow rate and decrease the volume of each injection, therefore reducing the  
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Figure 5.13 Surface plasmon resonance binding of CDC25B TCR with MHC in 
solution 
 
Following immobilisation of CDC25B TCR (blue) or the negative control LDN5 TCR (red) onto 
separate flow cells of a CM5 sensor chip, 5µl of 22.2µM HLA-A2-GLLGpS (A), 22.2µM HLA-A2-
GLLGSnp or 44.4µM HLA-A2-SLLTpS was injected over each flow cell using a flow rate of 
10µl/min. 
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Figure 5.14 Equilibrium affinity measurement of CDC25B TCR-HLA-A2-GLGGpS 
interaction with MHC in solution 
 
Equilibrium affinity analysis of CDC25B TCR with HLA-A2-GLLGpS complex using a CM5 
sensor chip with TCR bound to the surface and HLA-A2 in solution at 22.2µM, 11.1µM, 
5.6µM, 2.8µM and 1.3µM, demonstrates a specific binding affinity of 41.2µM and 40.1µM by 
direct non-linear curve and Scatchard plot analysis respectively.  
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time injected protein was in contact with the flow cell surface and the ability of aggregates 
to stick. Although there was still evidence of some sticking at the higher concentrations, the 
resulting injected dilution series (31.3µM – 0.5µM) revealed a considerably improved 
binding profile compared to previous experiments in this orientation and more importantly 
confirmed specific binding of the CDC25B TCR to HLA-A2-GLLGpS (Figure 5.15). Due to the 
improved quality of these results further affinity analysis in this alternate orientation was 
carried out. The measurement of specific binding response at each concentration revealed a 
similar affinity to that of the previous experiment in the opposite orientation (35µM and 
38µM) as demonstrated by direct non-linear curve and Scatchard analysis respectively 
(Figure 5.16). 
In order to determine how the phosphate moiety may influence TCR discrimination of 
GLLGpS, three unrelated TCR-HLA-A2 structures; 1AO7, 1BD2 and 1OGA were used to model 
the CDC25B TCR interaction with HLA-A2-GLLGpS complex. The HLA-A2 regions of the three 
TCR-HLA-A2 complex structures were superimposed onto the HLA-A2-GLLGpS complex, 
3FQU, from the Petersen et al study using lsqman (Figure 5.17). The three resulting TCR-HLA-
A2-GLLGpS models confirmed that the raised solvent exposed position of the phosphate 
would allow direct contacts to the TCR. In particular it highlighted the possibility of multiple 
direct contacts to α and β chain CDR3 loop regions. While direct TCR-phosphopeptide-MHC 
crystal structures will be required to validate these findings, they strongly suggest that even 
when phosphopeptide and non-phosphopeptide antigens are closely matched, the 
phosphate moiety is likely to be able to mediate direct contacts with appropriate 
phosphopeptide specific TCRs (Figure 5.17) thus ensuring TCR discrimination of the 
phosphopeptide from its non-phosphorylated counterpart.  
 
 
Figure 5.15 Optimised surface plasmon resonance sensogram of CDC25B TCR dilution series binding to immobilised HLA-
A2 complexes 
 
Following immobilisation of 3024RU HLA-A2-GLLGpS (blue), 3100RU HLA-A2-GLLGSnp (red) and 3165RU HLA-A2-WT1 negative control via 
streptavidin coupling to separate flow cells of a CM5 sensor chip, 5µl of CDC25B TCR was injected in a dilution series of 0.5µM, 0.9µM, 
1.9µM, 3.9µM, 7.8µM, 15.6µM and 31.3µM at a flow rate of 20µl/min. The trace indicates specific binding of CDC25B TCR to HLA-A2-
GLLGpS at all concentrations.  
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Figure 5.16 Equilibrium affinity measurement of CDC25B TCR, TCR in solution 
 
Equilibrium affinity analysis of CDC25B TCR with HLA-A2-GLLGpS complex using a CM5 
sensor chip with HLA-A2 bound to the surface and CDC25B TCR in solution demonstrates a 
specific binding affinity of 35.1µM and 38µM by direct non-linear curve and Scatchard plot 
analysis respectively.  
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Figure 5.17 Models of potential TCR interactions with GLLGpS phosphate moiety 
 
TCR-HLA-A2 complex structures; 1AO7 (A), 1BD2 (B) and 1OGA (C) were used to model 
potential interactions between TCRs and the phosphate moiety of GLLGpS. This was 
performed by superimposing the HLA-A2 onto the HLA-A2-GLLGpS complex structure (PDB 
code 3FQU; (Petersen, Wurzbacher et al. 2009). Visualisation of the interactions and figure 
production was performed using Pymol. TCR α and β chains are highlighted in yellow and 
purple cartoon, respectively. HLA-A2 α1α2 regions are shown in blue cartoon with the 
surface depicted in grey. The GLLGpS epitope is shown in stick representation with carbons 
(green), oxygen (red), nitrogen (blue) and phosphate (orange).  
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5.6 Conclusions 
Previous studies have shown that phosphopeptide specific T-cells are able to recognise and 
kill cells which present HLA-A2-phosphopeptide complexes and this can occur in a 
phosphate-dependent and epitope-specific manner, however the mechanism in which this 
occurs and the extent of any cross reactivity in TCR binding between matched 
phosphorylated and non-phosphorylated epitopes is poorly understood. These issues could 
potentially have profound implications in selection of phosphopeptide epitopes as targets in 
immunotherapy strategies. Conceivably if the non-phosphorylated epitope could induce 
cross-reactivity of phosphopeptide specific T-cells and was presented within the thymus or 
upon normal tissue this may result in impaired phosphopeptide specific T-cell responses due 
to central tolerance mechanisms or result in autoimmunity respectively. This study therefore 
sought to determine the evidence for direct phosphopeptide-specific TCR recognition of 
HLA-A2-phophopeptide complexes by examining the binding properties of several TCRs with 
their phosphorylated and non-phosphorylated epitope as well as to different epitopes with 
similar phosphate positioning. Overall the results revealed that the analysis of the TCR-HLA-
A2-GLLGpS complex affinity by SPR was highly dependent upon the purity of TCR used. In 
each experiment, sticking was observed as a bi-phasic dissociation phase along with other 
features such as not reaching equilibrium  which is indicative of aggregate binding (van der 
Merwe, Barclay et al. 1994). In the case of CDC25B TCR, the aggregate binding still 
demonstrated specificity for the HLA-A2-GLLGpS complex indicating that aggregated TCR still 
retains specific binding properties. Even following purification by HR-200 gel filtration, the 
subsequent concentration of the TCR preparation often resulted in aggregate formation 
which could potentially be exacerbated by residual impurities due to the poor resolution of 
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the HR-200 gel filtration purification (observed as multiple merged peaks on the elution 
profile). Although limiting the amount of TCR concentration prior to injection and decreasing 
the length of injection slightly alleviated some of the observed sticking, the employment of 
additional   purification steps such as increased imidazole concentration during washing of 
the Ni-NTA bead column or anion/cation exchange may help to improve the initial TCR purity 
and reduce aggregate formation. However, the fact that the aggregate effects are only 
observed on specific flow cells suggests that they are aggregated TCR rather than non-
specific impurities. This raises the question as to whether further buffer optimisation is 
required to alleviate this propensity for the TCR to aggregate following gel filtration 
purification. 
The IRS2 and IRS2BK TCRs, whilst known to enable T-cell recognition and killing of HLA-A2-
RVApS presenting cells (Zarling, Polefrone et al. 2006), demonstrated no binding by SPR 
analysis. One conclusion could again be the purity of these receptors used in SPR analysis 
affecting the quality of binding observed, however this is unlikely as the purity of the IRS2 
TCR was much greater than that of the CDC25B TCR which displayed specific binding in SPR 
experiments. One possible explanation for these findings is that the IRS2 and IRS2BK TCRs 
may interact with HLA-A2-RVApS with a very low affinity that is below the detection limit for 
SPR methods. This has been noted before for immune-receptor complexes (such as CD4 
binding to MHC-class II) which are known to bind but due to their low affinity are not 
observable by SPR. In these situations other methodologies, such as Alpha-screen, which 
relies on chemiluminecence-based detection of multimeric bead-bead interactions, could be 
used to detect if these TCRs can recognise HLA-A2-RVApS complexes. 
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However, despite no observable binding of the two HLA-A2-RVApS-specific TCRs the CDC25B 
TCR demonstrated specific binding to the HLA-A2-GLLGpS complex upon analysis using an Ni-
NTA chip and CM5 in ether orientation (bound to surface or in solution). Further analysis 
revealed that the TCR has an affinity within the region of other TCRs specific for non-
phosphorylated epitopes such as certain viral epitopes (1-100µM) (Davis, Boniface et al. 
1998). The CDC25B TCR was also shown to be able to discriminate between epitopes in a 
phosphate-dependent but also an epitope-specific manner. This is further supported by data 
from Petersen et al (Petersen, Wurzbacher et al. 2009) which shows that the phosphate 
moiety of the GLLGpS epitope adopts a raised solvent exposed position within the central 
region of the epitope. Further to this, modelling of 3 unrelated TCR receptors onto the HLA-
A2-GLLGpS complex structure revealed that the phosphate is situated in an optimal position 
close to the CDR loop regions of the TCR α and β chains. This may result in direct contact of 
the TCR with the phosphate moiety and other residues of the GLLGpS epitope. 
As mentioned above, the ability and mechanism of phospho-antigen discrimination by 
phosphopeptide specific T-cells are important considerations in any potential vaccine design. 
Clearly phosphate induced conformational change is not a prerequisite for productive 
phosphopeptide-TCR interactions as demonstrated by CDC25B TCR-HLA-A2-GLLGpS. 
However, while some epitopes which do not undergo conformational change may be 
specifically recognised by phosphopeptide specific TCRs with an affinity which allows 
measurement by SPR, such as GLLGpS, others, such as RVApS may not. This difference in 
recognition of the two antigens by each of the TCR clones studied hear, which have been 
previously reported to exhibit activation of T-cells (both native CD8+ T-cells and TCR 
transfected Jurkat cells) upon binding to specific HLA-A2-phosphopeptide complex  (Zarling, 
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Polefrone et al. 2006), may be due to the fact that in the GLLGpS epitope, the pSer is in the 
P5 position rather than the P4 position in RVApS. This may result in the P5 phosphate 
mediating more contacts with the TCR as it is positioned centrally relative to the TCR binding 
footprint compared to the P4 positioning in RVApS, which adopts a more remote position 
closer to the N-terminus of the peptide, and may therefore only allow minimal contacts to 
the TCR. This conceivably provides an explanation for the lower affinity observed for the 
HLA-A2-RVApS specific TCRs. Also the HLA-A2-RVApS complex reported by Petersen et al 
(Petersen, Wurzbacher et al. 2009) demonstrated that the RVApS epitope adopts a low 
conformation in the binding groove resulting in flexibility of the phosphate moiety compared 
to that of other canonical phosphopeptides reported by Mohammed et al (Mohammed, 
Cobbold et al. 2008) and those from this study. This may therefore contribute to reducing 
the availability of the phosphate moiety to form stable contacts with RVApS specific TCRs 
thus reducing the overall stability and affinity of the HLA-A2-RVApS-TCR interaction. 
Unfortunately, due to the lack of detectable interaction observed for the RVApS specific 
TCRs used in this study, examining the structure of the HLA-A2-RVApS-TCR complex by X-ray 
crystallography methods proved unfeasible, although future analysis of the HLA-A2-GLLGpS 
in complex with CDC25B TCR may help to shed light on these issues.  
Due to the discrepancies in TCR recognition of phosphopeptides which undergo little 
conformational change, it is therefore conceivable that the most optimal approach for future 
vaccination strategies would be to target antigens such as PKD2 and RQAS_V which were 
shown in chapter 4 to undergo dramatic conformational change upon phosphorylation. 
Although responses to the RQApS_V epitope have been raised in human T-cells, obtaining a 
clonal population has proved elusive (personal communication from Dr Mark Cobbold). 
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Further work to isolate a clonal population of HLA-A2-RQApS_V specific T-cells and isolate 
the TCR into expression systems for further structural and biophysical analysis would greatly 
aid in determining how conformational change as well as phosphate presence affects TCR 
binding.  
These results show for the first time that certain phosphopeptide specific T-cells are able to 
discriminate in a phosphate-dependent and epitope-specific manner at the level of TCR 
binding. Due to the fact that phosphorylation is highly altered in tumour tissue, it is 
conceivable that if the phosphopeptide were inherently linked to the tumourigenesis 
process and, like GLLGpS, was able to be discriminated by T-cells from its non-
phosphorylated counterpart, this would provide a highly suitable target for tumour 
immunotherapy strategies. 
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6 Discussion 
This thesis has focused on the molecular basis of phosphopeptide antigen presentation and 
recognition of phosphopeptide antigens by specific TCR’s. In chapter 3 I demonstrated that 
the phosphate moiety of canonical phosphopeptides displays a previously unidentified 
epitope specific plasticity in its orientation and the interactions formed with surrounding 
residues, with implications for the role the phosphate moiety plays in contributing to the 
binding energetics for certain epitopes. This was followed in chapter 4 by analysis of the 
overall structure of several epitopes in both their phosphorylated and non-phosphorylated 
states. This comparison revealed that for some epitopes, addition of a phosphate moiety had 
very little impact upon the overall main chain structure of the epitope. However for other 
epitopes, introduction of a phosphate moiety had a profound effect upon the overall antigen 
main chain conformation which, when compared to their non-phosphorylated counterparts, 
represent structurally distinct antigens and may therefore be more likely to be discriminated 
from their non-phosphorylated counterparts by phosphopeptide specific T-cells. Finally, in 
chapter 5, the molecular basis of phosphopeptide discrimination by phosphopeptide specific 
TCR’s was studied. This demonstrated that one of these TCRs was able to specifically bind to 
HLA-A2-GLLGpS in a phosphate-dependent and epitope-specific manner, with an affinity 
comparable to that of previously documented TCR-MHC-antigen interactions (Davis, 
Boniface et al. 1998). 
Previously, Mohammed et al demonstrated that inclusion of a phosphate moiety can 
increase the antigen affinity for HLA-A2 (Mohammed, Cobbold et al. 2008). By studying the 
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binding affinity of a greater number of antigens, this study has shown that the majority of 
HLA-A2 phosphopeptides possessing a canonical motif can fit into three categories 
depending upon the type of P2 and PC anchor residues they possess. Phosphopeptide 
antigens with canonical P2 and PC anchors display the least increase in binding upon 
phsophorylation, followed by antigens with non-canonical P2 but canonical PC, and finally 
those with non-canonical anchors at P2 and PC which demonstrate the greatest increase in 
binding upon addition of the phosphate moiety. However, two antigens in this study (RTLpS 
and RQApS_V) did not fit this classification. RQA_V showed a similar binding affinity upon 
phosphate addition compared to its non-phosphorylated form. This was surprising, as the 
epitope possess the canonical motif and also displays a conserved canonical binding mode as 
demonstrated in chapter 3. However, the structure of both the phosphorylated and non-
phosphorylated forms of RQA_V may provide an explanation for the lack of phosphate 
induced increase in epitope binding by the fact that this epitope undergoes significant 
conformational rearrangement upon addition of the phosphate. Although addition of the 
phosphate results in additional phosphate mediated contacts the change in epitope 
conformation leads to the loss of several interactions between the peptide and the MHC 
leading to a net reduction in peptide MHC contacts. Therefore one hypothesis generated by 
this study is that this lack of phosphate-induced increase in binding affinity due to 
conformational rearrangement may also be true for other epitopes, such as RTLpS, however 
further comparison of the phosphorylated and non-phosphorylated forms of these epitopes 
would need to be performed to fully understand these effects for individual epitopes. 
Comparison of the canonical phosphopeptide structures have also revealed plasticity in the 
phosphate moiety orientation and the stabilising contacts the phosphate moiety forms for 
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each individual epitope. However, further correlation with antigen affinity data revealed no 
significant impact upon overall antigen affinity when the phosphate moiety adopted altered 
orientations to those seen in the majority of canonical phosphopeptides studied to date. 
This subtle re-orientation of the phosphate moiety for certain epitopes (RTFpS, RLSpS) may 
therefore highlight that the phosphate adopts altered confirmations in order to obtain the 
most optimal energetic potential for the given epitope. These results may also provide a 
model for the effects seen in mutational studies of RQA_M (Mohammed, Cobbold et al. 
2008), which demonstrated that loss of both P1 Arg and Arg65 was required to significantly 
reduce phosphopeptide affinity, upon loss of only one of these interactions it is highly likely 
that the phosphate may adopt an alternate conformation in order to obtain the highest 
binding potential and complex stability. 
Another point that this study has highlighted is that it is problematic to predict the overall 
binding properties of a phosphopeptide epitope based upon its sequence alone. Epitopes 
such as RTLpS and RQA_V not only demonstrate this point, but also the extent to which the 
phosphate moiety can influence the overall epitope structure. In some cases addition of a 
phosphate moiety can result in substantial rearrangement of the epitope main chain (RQA_V 
and PKD2); however, other epitopes (RQIpS and RTFpS) are able to naturally adopt the 
raised P4 positioning commonly observed in the canonical phosphopeptide group but 
without the presence of the phosphate moiety. This maintenance of the main chain 
conformation seems to be due to several factors which are epitope specific such as the 
presence of a proline at P5, which has been suggested to restrict the antigen main chain in 
this region due to its limited flexibility (Petersen, Wurzbacher et al. 2009). The positioning of 
His 70 may also adopt a raised position, thus contributing to the elevation of the main chain 
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around the P4-P5 region of the epitope. Also, the presence of interactions between P2 and 
residues of the MHC to form a “molecular clamp”, which are present in the canonical 
phosphopeptides but are lost upon removal of the phosphate in antigens that undergo main 
chain rearrangement, can help to restrict the conformation within this region of the epitope 
main chain. Finally, it is also conceivable that residues at P3 and P5 may also impact upon 
the ability of the antigen to maintain a raised position through interactions with surrounding 
residues of the MHC. This may be true for RQIpS in that although the side chain of Glu155 
displayed only partial electron density, indicating a degree of flexibility, the residue is 
located in a position which may allow interactions with the P5 Glu side chain of RQIpS, thus 
potentially contributing to the maintained elevation of the main chain within this region. It is 
therefore clear that detailed structural analysis of individual epitopes in their 
phosphorylated and non-phosphorylated forms is required for determining the impact of 
phosphorylation upon not only antigen binding but also overall antigen conformation. 
The ability of the phosphate moiety to influence epitope binding and epitope conformation 
are both important considerations for the design of any future vaccination strategies 
targeting phosphopeptide antigens. One major factor influencing the success of any 
potential vaccination strategy is the relative expression and presentation of the target 
antigen on various tissue types, including thymus and normal tissue. 
As this study has shown, phosphopeptide epitopes can either undergo conformational 
change or maintain the overall epitope structure upon addition of the phosphate moiety. If 
the epitope undergoes substantial conformational change upon addition of the phosphate, 
these epitopes represent structurally distinct antigens compared to their non-
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phosphorylated counterparts. It is therefore conceivable that even in the event of the non-
phosphorylated form being presented within the thymus, due to the unique structural 
identity of these phosphorylated epitopes, phosphopeptide specific T-cells may not be 
deleted. This putative escape of T-cells specific for phosphopeptides which undergo 
conformational change is further supported by the fact that in order for the phosphopeptide 
epitope to be present within the thymus requires not only the expression of the parent 
protein but also the activity of the relevant kinase to form the specific phosphorylation 
event. Due to these factors, epitopes which undergo conformational change upon 
phosphorylation represent prime candidates for vaccination strategies using multiple 
approaches such as peptide vaccination, TCR gene transfer, antigen primed DC vaccination.  
The second group of phosphopeptide antigens, those which do not undergo conformational 
change, may be more susceptible to central tolerance mechanisms due to the structural 
similarities between the phosphorylated and non-phosphorylated forms, with the only 
structural difference between the two being the presence or absence of the phosphate 
moiety. Therefore the position of the phosphate within these epitopes may play an 
important role in determining the degree to which they are able to induce epitope cross-
reactivity of phosphopeptide and non-phosphopeptide specific T-cells. For example, the non-
canonical epitope GLLGpS (which exhibits no conformational change upon addition of the 
phosphate), the p5 positioning of the phosphate lies within a region of the epitope that 
would allow direct phosphate mediated contacts to both the α and β chains of the TCR, most 
notably to the CDR3 regions. The presence or absence of the phosphate would therefore be 
likely to represent a significant structural difference in terms of TCR discrimination, meaning 
that if the non-phosphorylated epitope was present within the thymus it may not induce 
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cross-reactivity of phosphopeptide specific T-cells. I was able to address discrimination of 
phosphorylated and non-phosphorylated forms of GLLG by a phosphopeptide specific TCR in 
chapter 5 and demonstrated that this TCR was able to recognise HLA-A2-GLLGpS complex in 
a phosphate-dependent and epitope-specific manner with an affinity comparable to that of 
anti-viral responses. 
However in the event of no conformational change to an epitope upon phosphate moiety 
addition to a residue, such as P1, may result in increased cross reactivity between the 
phosphorylated and non-phosphorylated epitopes due to the fact that P1 is a residue 
commonly ignored by the TCR. This could potentially lead to increased central tolerance of 
the T-cell repertoire not only in the event of the phosphorylated form being present within 
the thymus but also if the non-phosphorylated form were to be present. This hypothesis 
may explain why the two RVApS specific TCRs (IRS2 and IRS2BK) demonstrated no 
observable phosphopeptide specific binding by SPR. The fact that the RVApS epitope 
demonstrates no conformational change upon addition of the phosphate moiety (Petersen, 
Wurzbacher et al. 2009), and that the P4 positioning of the phosphate lies within a region 
which potentially would allow only minimal contacts to the TCR, may lead to an increased 
potential for TCR cross reactivity between the phosphorylated and non-phosphorylated 
epitopes. Therefore, if the non-phosphorylated RVAS epitope is expressed within the thymus 
this potential for cross reactivity could potentially lead to functional deletion or tolerisation 
of the T-cell repertoire with only the T-cells possessing low affinity phosphopeptide specific 
TCRs escaping negative selection. These factors would therefore impact upon the success of 
any vaccination strategy. 
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This also raises the therapeutic importance of some fundamental aspects of phosphopeptide 
presentation and recognition. Firstly, a major question is whether phosphopeptide antigens 
are presented within the thymus. For an immunotherapy approach to be effective there 
must be a pool of T-cells that can bind the antigen/MHC complex with high enough avidity to 
invoke a positive proliferative and activatory response. If the antigen is presented within the 
thymus upon medullary thymic epithelial cells (mTEC) then negative selection of antigen 
specific high avidity T-cells will occur and result in a pool of low avidity T-cells. However 
certain phosphopeptides may not be presented in the thymus due to lack of other 
components involved in the initial phosphorylation of the antigen. This means that although 
T-cells reactive with non-phosphorylated antigens could well be deleted in the thymus due 
to promiscuous expression of tissue specific antigen (TSA) by AIRE (Cheng, Shum et al. 2007; 
Mathis and Benoist 2009), T-cells specifically recognising the phosphorylation in the context 
of a certain antigen might not be deleted and so form a pool of high/moderate avidity T-cells 
able to target and kill cells presenting this antigen. This would be an attractive therapy in a 
cancer setting as the up-regulation of phosphorylation events coupled with the over-
expression of many proteins provides an extra level of selectivity in targeting tumours.  In 
relation to these points, on-going studies have shown that a broad range of HLA-A and HLA-B 
phosphopeptide specific T-cells are able to be obtained from healthy donor as well as  
cancer patient PBMC and that these are functionally active, producing high levels of IFN-γ 
upon phosphopeptide recognition (personal communication from Dr Mark Cobbold). This 
clearly demonstrates that certain phosphopeptide epitopes are able to escape central 
tolerance mechanisms. In addition, these phosphopeptide specific T-cells also seem to be of 
clinical relevance as cancer patients who do not posses phosphopeptide reactive T-cells have 
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a worse prognosis than patients who do mount a broad phosphopeptide specific response 
(personal communication from Dr Mark Cobbold).  
A second question is how efficiently phosphopeptides are cross-presented, since this could 
significantly affect natural phosphopeptide-specific responses in cancer patients, as well as 
DC vaccination approaches. For a vaccine to elicit a CTL response it must be able to undergo 
cross-presentation. Early evidence in mouse models by Zarling et al (Zarling, Ficarro et al. 
2000; Zarling, Polefrone et al. 2006) have shown generation of CTL by phosphopeptide 
pulsing of bone marrow derived DC and T-cell stimulation in vivo suggesting that the 
phosphate can survive cross-presentation. This however is still yet to be proven in a human 
setting. 
In addition it is currently unclear how specific phosphopeptides are for expression on 
tumours verses normal tissue. Clearly HLA-B class I molecules, such as HLA-B7 and HLA-B27, 
represent a promising avenue for future vaccination strategies due to the HLA-B molecules 
presenting a far greater amount of phosphopeptide antigens than HLA-A molecules, and the 
fact that associated phosphopeptides are from source proteins that have been strongly 
linked to tumourigenisis, such as altered kinases (Michelotti, Price et al. 2000; Krivtsov and 
Armstrong 2007). The molecular basis for this increase in epitope presentation by HLA-B 
molecules is currently unknown, however they do possess a similar canonical motif to that 
seen in HLA-A2 binding phosphopeptides in that P1 is typically a charged residue and the 
phosphate is a P4 pSer. Therefore it is conceivable that the binding mode may be similar to 
that of HLA-A2 canonical phosphopeptides. During this study attempts were made to try to 
elucidate the molecular mechanisms governing the high degree of phosphopeptide 
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presentation in the context of HLA-B7 through analysis of the binding affinities for several 
epitopes in their phosphorylated and non-phosphorylated forms and also by determining 
the crystal structure of these epitopes. Although methods I developed for refolding and 
purification of HLA-B7-phosphopeptide complexes was successful (documented in Appendix 
section 6) the low yield of complex obtained rendered crystallisation challenging. 
Surprisingly, analysis of the binding affinities of HLA-B7 epitopes (performed by Clara 
Cummings and Victor Engelhard) revealed that upon addition of a phosphate moiety the 
affinity of the epitope was actually reduced compared to its non-phosphorylated 
counterpart rather than increasing like many of the HLA-A2 epitopes, suggesting the 
molecular ground rules governing HLA-B7-phosphopeptide binding may be different. 
Therefore if phosphorylation actually reduces epitope affinity we are left with the question 
as to why there is such a high prevalence of phosphopeptide antigens associated with HLA-B 
alleles. This could be due to factors other than antigen-MHC binding interactions. One 
possibility for the increased prevalence of phosphopeptides associated with HLAB molecules 
is that the non-phosphorylated HLA-B-restricted epitopes naturally possess a higher degree 
of similarity to Kinase motifs and therefore the pool of phosphopeptides able to bind to HLA-
B molecules is also increased. A second possibility could be that these epitopes are 
preferentially selected for because the phosphorylation results in altered antigen processing 
such as increased or altered proteasome cleavage. Alternatively or in addition, 
phosphorylation may play an important role in HLA-B7 epitope presentation through 
alteration of TAP transport, possibly resulting in increased epitope transfer into the ER upon 
epitope phosphorylation. Finally, it is still unclear what effect phosphorylation of an epitope 
has upon antigen processing within the ER and how phosphorylation may affect antigen 
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processing by the peptide loading complex. Due to the fact that the effects of 
phosphorylation upon antigen processing pathways have to date not been investigated, it is 
currently difficult to determine the reasons behind the increased prevalence of 
phosphopeptide antigens in the context of HLA-B. Future work should therefore aim to study 
not only the structural aspects of HLA-B-phosphopeptide presentation but should also focus 
upon the impact of phosphorylation on events during antigen processing. 
It is clear from this and other studies that phosphopeptide antigens are emerging as a novel 
set of targets for use in tumour immunotherapy strategies. This study has demonstrated that 
phosphorylation has a profound effect on the antigenic identity of class I MHC peptides and 
how they are recognised by the TCR.  This information suggests that phosphopeptides are 
highly distinct antigens and raises hope that they are suitable candidates for cancer 
immunotherapy.
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Appendix A: HLA-A2-RLQpS complex structure solution rotation and translation 
 
Initial phase information was determined by molecular replacement using MOLREP 
(Murshudov, Vagin et al. 1997) with the HLA-A2 structure (PDB code; 1HHG) as the phasing 
model. The top five results for the rotation and translation functions are shown and the 
correct solution for each is highlighted in red. This is determined by a peak in the RF-function 
and TFcnt/Score values for the rotation and translation functions respectively.  
Rotation Function 
Peak 
Number 
θ (°) φ(°) X (°) RF-function 
 
1 173.50 -111.60 173.73 20.37 
2 168.98 -138.61 177.19 5.48 
3 6.18 27.04 176.73 5.41 
4 14.00 68.42 134.34 5.18 
5 104.82 -86.78 80.70 4.83 
Translation Function 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.404 0.000 0.227 49.83 0.509 0.558 
2 0.899 0.000 0.200 1.97 0.615 0.308 
3 0.258 0.000 0.349 2.81 0.618 0.304 
4 0.542 0.000 0.222 1.86 0.620 0.302 
5 0.300 0.000 0.321 1.96 0.620 0.300 
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Appendix B: HLA-A2-RLSpS complex structure solution rotation and translation 
values 
Rotation Function 
Peak 
Number 
θ (°) φ(°) X (°) RF-function 
 
1 173.29 -116.98 171.40 20.02 
2 7.70 25.23 176.89 6.26 
3 168.88 -142.20 176.28 6.05 
4 105.18 -86.78 79.13 5.27 
5 114.52 -87.65 78.44 4.97 
Translation Function 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.401 0.000 0.227 48.26 0.539 0.541 
2 0.481 0.000 0.212 2.14 0.623 0.340 
3 0.093 0.000 0.265 3.55 0.617 0.336 
4 0.093 0.000 0.264 3.64 0.620 0.334 
5 0.375 0.000 0.232 2.80 0.623 0.332 
 
Initial phase information was determined by molecular replacement using MOLREP 
(Murshudov, Vagin et al. 1997) with the HLA-A2 structure (PDB code; 1HHG) as the phasing 
model. The top five results for the rotation and translation functions are shown and the 
correct solution for each is highlighted in red. This is determined by a peak in the RF-function 
and TFcnt/Score values for the rotation and translation functions respectively.   
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Appendix C: HLA-A2-RTFpS complex structure solution rotation and translation 
values 
Rotation Function 
Peak 
Number 
θ (°) φ(°) X (°) RF-function 
 
1 40.28 -159.21 135.23 15.16 
2 47.28 -159.95 134.81 4.92 
3 47.31 -164.67 132.66 4.81 
4 63.09 -166.16 49.92 4.67 
5 140.18 -61.48 169.38 4.25 
Translation Function 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.336 0.045 0.224 30.98 0.535 0.493 
2 0.850 0.060 0.091 3.22 0.624 0.278 
3 0.235 0.311 0.234 1.88 0.627 0.277 
4 0.155 0.398 0.083 2.96 0.624 0.277 
5 0.240 0.268 0.362 1.92 0.624 0.276 
 
Initial phase information was determined by molecular replacement using MOLREP 
(Murshudov, Vagin et al. 1997) with the HLA-A2 structure (PDB code; 1HHG) as the phasing 
model. The top five results for the rotation and translation functions are shown and the 
correct solution for each is highlighted in red. This is determined by a peak in the RF-function 
and TFcnt/Score values for the rotation and translation functions respectively. 
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Appendix D: HLA-A2-RQIpS complex structure solution rotation and translation 
values 
Rotation Function 
Peak 
Number 
θ (°) φ(°) X (°) RF-function 
 
1 173.25 -115.21 172.24 20.76 
2 7.18 23.40 175.93 5.90 
3 168.83 -140.41 176.00 5.50 
4 11.27 54.05 122.06 4.87 
5 104.71 -86.67 79.73 4.82 
Translation Function 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.401 0.000 0.227 54.16 0.529 0.552 
2 0.390 0.000 0.296 2.81 0.621 0.335 
3 0.278 0.000 0.274 2.57 0.622 0.331 
4 0.472 0.000 0.208 2.88 0.626 0.329 
5 0.026 0.000 0.240 1.99 0.623 0.329 
 
Initial phase information was determined by molecular replacement using MOLREP 
(Murshudov, Vagin et al. 1997) with the HLA-A2 structure (PDB code; 1HHG) as the phasing 
model. The top five results for the rotation and translation functions are shown and the 
correct solution for each is highlighted in red. This is determined by a peak in the RF-function 
and TFcnt/Score values for the rotation and translation functions respectively.  
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Appendix E: HLA-A2-RTLpS complex structure solution rotation and translation 
values 
Rotation Function 
Peak 
Number 
θ (°) φ(°) X (°) RF-function 
 
1 173.58 -114.32 173.03 19.63 
2 14.30 66.67 134.54 5.68 
3 103.99 -86.76 81.08 5.45 
4 169.39 -140.42 175.90 5.43 
5 0.94 5.41 179.99 5.12 
Translation Function 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.892 0.000 0.223 52.44 0.477 0.617 
2 0.020 0.000 0.365 3.02 0.580 0.388 
3 0.063 0.000 0.338 3.14 0.581 0.386 
4 0.216 0.000 0.298 1.72 0.584 0.380 
5 0.549 0.000 0.321 1.68 0.583 0.378 
 
Initial phase information was determined by molecular replacement using MOLREP 
(Murshudov, Vagin et al. 1997) with the HLA-A2 structure (PDB code; 1HHG) as the phasing 
model. The top five results for the rotation and translation functions are shown and the 
correct solution for each is highlighted in red. This is determined by a peak in the RF-function 
and TFcnt/Score values for the rotation and translation functions respectively. 
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Appendix F: HLA-A2-RQInp complex structure solution rotation and translation 
values  
Rotation Function 
Peak Number θ (°) φ(°) X (°) RF-function 
 
1 162.51 90.88 55.07 21.06 
2 149.41 -167.57 69.20 4.57 
3 36.04 155.98 140.37 4.48 
4 86.41 52.14 33.96 4.47 
5 143.11 53.20 45.36 4.43 
Translation Function 
Peak Number  TX TY TZ TFcnt R-fac Score 
1 0.189 0.000 0.137 31.57 0.499 0.533 
2 0.272 0.000 0.420 2.27 0.603 0.277 
3 0.799 0.000 0.486 2.32 0.604 0.275 
4 0.054 0.000 0.167 1.66 0.604 0.275 
5 0.339 0.000 0.411 1.70 0.605 0.274 
 
Initial phase information was determined by molecular replacement with MOLREP using the 
HLA-A2 structure (PDB ID code; 1HHG) as the phasing model. The top five results for the 
rotation and translation functions are shown and the correct solution for each is highlighted 
in red. This is determined by a peak in the RF-function and TFcnt/Score values for the 
rotation and translation functions respectively. 
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Appendix G: LILRB1-HLA-A2-RTFnp structure solution rotation and translation 
values 
Rotation Function 
Peak 
Number 
θ (°) φ(°) X (°) RF-function 
 
1 90.00 -89.97 180.00 14.13 
2 95.63 -84.96 175.98 3.35 
3 94.44 -86.77 176.28 3.34 
4 45.40 54.84 136.08 3.34 
5 14.32 -179.15 49.67 3.26 
Translation Function 1 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.734 0.228 0.019 10.84 0.507 0.360 
2 0.489 0.109 0.432 3.55 0.607 0.087 
3 0.833 0.406 0.057 2.91 0.605 0.087 
4 0.878 0.361 0.158 4.51 0.606 0.087 
5 0.761 0.649 0.214 2.53 0.609 0.083 
Translation Function 2 
Peak 
Number  
TX TY TZ TFcnt R-fac Score 
1 0.785 0.533 0.175 8.31 0.540 0.279 
2 0.733 0.238 0.524 4.49 0.561 0.222 
3 0.740 0.244 0.518 3.58 0.566 0.220 
4 0.261 0.480 0.143 2.32 0.564 0.219 
5 0.238 0.459 0.151 2.13 0.563 0.212 
 
Initial phase information was determined by molecular replacement with MOLREP using the 
LILRB1-HLA-A2 structure (PDB ID code; 1P7Q) as the phasing model. The top five results for 
the rotation and translation functions are shown and the correct solution for each is 
highlighted in red. This is determined by a peak in the RF-function and TFcnt/Score values for 
the rotation and translation functions respectively. For the LILRB1-HLA-A2-RTFnp complex 
two translation functions were determined due to the presence of two molecules occupying 
the unit cell. 
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Appendix H: IRS2 TCR α chain gene sequence 
 
Gene sequence of IRS2α chain with Variable, Joining and Constant domains highlighted 
(kindly provided by Dr Angela Zarling).  
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Appendix I: IRS2 TCR β chain gene sequence 
 
Gene sequence of IRS2β chain with Variable, Joining and Constant regions highlighted (kindly 
provided by Dr Angela Zarling). 
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Appendix J: IRS2BK TCR α chain sequence 
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Gene sequence of IRS2BK α chain with Variable (Blue), Joining (Dark Green) and Constant 
(Light Green) regions highlighted (kindly provided by Dr Angela Zarling). 
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Appendix K: IRSBK TCR β chain sequence 
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Gene sequence of IRS2BK β chain with Variable, Joining and Constant regions highlighted 
(kindly provided by Dr Angela Zarling).  
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Appendix L: CDC25B TCR α chain sequence 
 
Gene sequence of CDC25B α chain with Variable (Blue), Joining (Grey) and Constant (Yellow) 
regions highlighted (kindly provided by Dr Angela Zarling).  
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Appendix N: CDC25B TCR β chain sequence 
 
Gene sequence of CDC25B β chain with Variable (Dark Blue), Joining (Red) and Constant 
(Grey) regions highlighted (kindly provided by Dr Angela Zarling).  
193 
 
Appendix O 
HLA-B7-phosphoeptide complex production 
In order to generate soluble HLA-B7-phosphoeptide complexes use in this study two 
separate pet23a vectors incorporating either the HLA-B7 heavy chain or the β2M - domain 
were generated prior to this study. Full expression was performed in E. coli BL21 (DE3) cells 
and inclusion bodies purified then solubilised in 8M urea as documented in chapter 3. For 
this study epitopes which were able to generate immune responses in ELISPOT assays of 
healthy human PBMC (personal communication from Dr Mark Cobbold) were selected. Initial 
attempts utilised standard dilution refolding (Garboczi, Hung et al. 1992) as used for the 
generation of HLA-A2 molecules documented in chapter 2, 3 and 4. However, purification by 
S200 gel filtration yielded a peak which, upon SDS-PAGE analysis, contained multiple 
contaminant bands and lacked stoichiometric levels of β2M, indicating the presence of HLA-
B7 heavy chain which was not in complex with β2M (Apendix O Figure 1).  
Previous studies of non-phosphorylated epitope presentation by HLA-B molecules have used 
various alterations to the levels of heavy-chain: β2M: peptide ratio added to the refold mix 
as well as the length of time the refold mix was left before purification, indicating that the 
efficiency of complex refolding for HLA-B molecules may not be as high as HLA-A molecules 
(Macdonald, Williams et al. 2002). Attempts were therefore made to improve upon the 
refold efficiency but without increasing the levels of phosphopeptide too much in order to 
keep the cost of refolding low. Initial tests seemed to improve the refold efficiency, however 
when further purified by Resource-Q anion exchange this revealed multiple peaks due to 
194 
 
contaminating proteins such as free β2M and free HLA-B7 heavy chain (Appendix Figure 6.2). 
Following several rounds of refinement the most optimal refold protocol for generating HLA-
B7-phosphopeptide complexes is documented in chapter 2. However although this method 
resulted in increased yields of stoichiometric HLA-B7-phosphoeptide complex (Appendix O 
Figure 3) due to the continued need for Resource-Q purification the yields were still too low 
for efficient use in crystallisation trials. Therefore further work is needed to improve upon 
this refold technique in order to provide enough soluble HLA-B7-phosphoeptide complex for 
use in crystallisation studies.  
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Appendix O Figure 1 
 
SDS-PAGE analysis of 2 HLA-B7-phosphoeptide complexes (Lane 1 HLA-B7-RPFpSPREAL, Lane 
2 HLA-B7-RPApSAGAML) following standard dilution refolding and S200 gel filtration 
purification revealed that the complexes lacked stiochemetric β2m.  
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Appendix O Figure 2 
 
Purification by Resource-Q anion exchange reveals that the single peak obtained from 
previous S200 gel filtration does not contain single HLA-B7 complex but also contains free 
β2M and HLA-B7 heavy chain only complex when assessed by SDS-PAGE under reducing 
conditions. 
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Appendix O Figure 3 Improved purity of HLA-B7-phosphoeptide complex 
 
 
Optimisation of HLA-B7-phosphoeptide refolding yields significantly improved purity of HLA-
B7 complex (Lane1) following Resource-Q anion exchange purification when assessed by 
SDS-PAGE under reducing conditions. 
 
 
Appendix O Table 1 Affinity analysis of HLA-B7 phosphopeptides and their non-phosphorylated counterparts 
Sequence Source Protein 
Peptide length 
(amino acids) 
IC50 (nM) 
Nonphosphorylated 
peptide 
IC50 (nM) 
Phosphorylated 
peptide 
Fold 
increase 
RPTpSRLNRL Nuclear receptor co-activator 1 9 1.15 5.55 4.8 
RPFpSPREAL Leucine zipper protein 1 9 1.9 4.5 2.4 
RPHpSPEKAF ELG protein 9 1.75 17.5 10 
KPRpSPVVEL Beta adrenergic receptor kinase 1 variant 9 2.25 20 8.9 
RPApSAGAML Myocyte enhancer factor 2D 9 1.05 10 9.5 
EPRpSPSHSM Mixed-lineage leukemia 9 2.05 8.5 4.1 
RVRpSPTRSP Mixed-lineage leukemia 9 3.2 21 6.7 
 
Competitive binding assays were performed as previously described (Mohammed, Cobbold et al. 2008). The peptide concentrations 
covered a 100,000 fold range. The concentration at which test peptide displaced 50% of the radiolabeled peptide (IC50) was calculated 
allowing a reasonable approximation of the dissociation constant (Mohammed, Cobbold et al. 2008). 
 
 
 
 
 
 
 
1
9
8 
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